Nodal marginal zone lymphoma. An emerging entity by Brand, M. van den
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/178917
 
 
 
Please be advised that this information was generated on 2018-07-08 and may be subject to
change.
NODAL MARGINAL 
ZONE LYMPHOMA
AN EMERGING ENTITY
N
O
D
A
L M
A
R
G
IN
A
L ZO
N
E LYM
P
H
O
M
A
    AN
 EM
ER
G
IN
G
 EN
TITY
M
ichiel van den B
rand
Michiel van den Brand
NODAL MARGINAL ZONE LYMPHOMA
AN EMERGING ENTITY
Michiel van den Brand
ISBN 
978-94-92380-85-2
Design/lay-out 
Bregje Jaspers, ProefschriftOntwerp.nl, Nijmegen 
Cover Design/Artwork
Anuli Croon, www.anulicroon.nl
De kleurrijke, strak vormgegeven schilderijen van Anuli Croon activeren als vanzelf het 
reservoir aan associaties van de beschouwer; beelden en indrukken van raadselachtigheid, 
dubbelzinnigheid, verwijzingen naar volkskunstuitingen, stripfiguren en reclamebeelden, 
alledaagse gebruiksvoorwerpen, stofpatronen en universele symbooltekens voor menselijke 
gebaren en lichaamstaal vormen slechts enkele elementen van haar beeldtaal.
Anuli Croon’s colourful, severely structured paintings automatically activate the beholder’s 
reservoir of associations: images and impressions of mysteriousness, ambiguity, references 
to primitive art, comic characters and commercials, everyday household items, fabric patterns 
and universal symbols for human gestures and body language are just a few of the elements 
of her imagery.
Print 
Ipskamp printing 
© Michiel van den Brand , 2017 
All rights are reserved. No part of this book may be reproduced, distributed, stored in a retrieval 
system, or transmitted in any form or by any means, without prior written permission of the 
author.
NODAL MARGINAL ZONE LYMPHOMA
AN EMERGING ENTITY
Proefschrift 
ter verkrijging van de graad van doctor 
aan de Radboud Universiteit Nijmegen 
op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken, 
volgens besluit van het college van decanen 
in het openbaar te verdedigen 
op vrijdag 22 december 2017 om 12.30 uur precies
door
Michiel van den Brand
geboren op 1 februari 1984
te Eindhoven
Promotor:
Prof. dr. J.H.J.M. van Krieken
Copromotor:
Dr. P.J.T.A. Groenen
Manuscriptcommissie:
Prof. dr. N.M.A. Blijlevens
Prof. dr. A.H.M. Geurts van Kessel
Prof. dr. D. de Jong (VU Medisch centrum)


TABLE OF CONTENTS
Chapter 1 General introduction 
Chapter 2  Recognizing nodal marginal zone lymphoma: recent 
advances and pitfalls 
Chapter 3  A subset of low-grade B-cell lymphomas with a follicular 
growth pattern but without a BCL2 translocation shows 
features suggestive of nodal marginal zone lymphoma 
Chapter 4  Clinical features of patients with nodal marginal zone 
lymphoma compared to follicular lymphoma: similar 
presentation, but differences in prognostic factors and rate 
of transformation 
Chapter 5  Immunohistochemical differentiation between follicular 
lymphoma and nodal marginal zone lymphoma – combined 
performance of multiple markers 
Chapter 6  Sequential immunohistochemistry: a promising new tool 
for the pathology laboratory 
Chapter 7  Protein expression in nodal marginal zone lymphoma 
differs between lymph node compartments 
Chapter 8  Recurrent mutations in genes involved in nuclear factor 
kappa B signaling in nodal marginal zone lymphoma 
Chapter 9  General discussion 
Chapter 10  Summary
  Nederlandse samenvatting
  References
  Dankwoord
  Curriculum Vitae 
  Publicatielijst
9
29
49
61
77
91
103
115 
133
149
153
158
179
185
187
Part of this general introduction was published as:
Michiel van den Brand1, Blanca Scheijen1, Corine J Hess2, J Han JM van Krieken1,  
Patricia JTA Groenen1
1Department of Pathology, Radboud university medical center, Nijmegen, the Netherlands
2Department of Hematology, Radboud university medical center, Nijmegen, the Netherlands
Blood Reviews. 2017; Epub ahead of print.
1
General introduction
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This general introduction describes the normal development of B-cells and the classification 
of B-cell lymphomas with particular attention to the classification of nodal marginal zone 
lymphoma (NMZL) and follicular lymphoma (FL). In addition, current concepts in the etiology 
and molecular pathogenesis of B-cell lymphomas are discussed.
 Lymphomas are neoplastic proliferations of lymphocytes. Lymphocytes are an 
essential part of the immune system and mostly function within the adaptive immune system. 
Different types of lymphocytes have very different functions and appearances and accordingly, 
lymphomas represent a very diverse group with large differences between the prognosis and 
treatment of the different types of lymphoma. 
 Lymphomas are broadly divided into Hodgkin lymphoma and non-Hodgkin lymphoma 
and the non-Hodgkin lymphomas are further subdivided into B-cell and T/NK-cell non-Hodgkin 
lymphomas (Figure 1.1). The group of B-cell lymphomas is further subdivided into different 
types of lymphomas with a strong correspondence between normal B-cell development and 
the different types of lymphoma.
Figure 1.1. Subgroups of lymphoma
NORMAL B-CELL DEVELOPMENT
B-cells are part of the adaptive immune system and their ultimate objective is to produce 
antibodies against unwanted antigens such as viral and bacterial proteins. To recognize these 
antigens, each B-cell has a unique B-cell receptor (BCR) on the cell surface. Because the 
antigen-BCR reaction is very specific, a large repertoire of different B-cells with different 
BCRs are necessary to allow a response to the very diverse array of antigens that might be 
encountered. 
 To form this large repertoire of different B-cells, unique BCRs are formed during 
B-cell development by recombination of the different genes that encode for the BCR. The BCR 
consists of two identical heavy chains and two identical light chains (Figure 1.2). The tips of 
both the heavy chain and the light chain together form the antigen binding site.
non-HodgkinHodgkin
B-cell T/NK-cell
Lymphoma
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Figure 1.2. Immunoglobulin structure. The heavy chains are indicated in green, the light chains are 
indicated in blue. The antigen binding sites are marked by the arrows.
The immunoglobulin heavy chain locus (IGH) located at chromosome 14q32 encodes for 
the BCR heavy chain. It consists of approximately 44 V (variable) segments, 27 D (diversity) 
segments and 6 J (joining) segments.1 To generate a functional heavy chain, a specific VDJ 
combination is formed. This occurs in a stepwise fashion starting with recombination between 
D and J followed by recombination between V and DJ (Figure 1.3). In addition to the diversity 
generated by the many different types of V, D, and J segments, nucleotides are randomly 
added and removed at the junctions between V-DJ and D-J, further adding to the diversity. 
This recombination process generates either a functional heavy chain, in which the precursor 
B-cell can proceed to the next stage, or a non-functional heavy chain, in which case the cell 
has another chance on the second allele. If recombination on both alleles does not result in a 
functional heavy chain, the cell goes into apoptosis.
 If IGH recombination is successful, the cell continues with recombination of the light 
chains in a similar fashion. The cell first can have two attempts on the immunoglobulin kappa 
locus (IGK) at chromosome 2p12 and then, in case kappa rearrangement has not resulted 
in a functional gene, another two attempts at the immunoglobulin lambda locus (IGL) at 
chromosome 22q11. The process of recombination for the light chains is similar to that for the 
heavy chain, but there is no D segment and there are different numbers of V and J segments. 
Importantly, if recombination on IGK is successful, the B-cell and its progeny will express 
only kappa light chains. If recombination on IGK is unsuccessful, but IGL recombination is 
successful, only lambda light chains will be expressed on the B-cell and all daughter cells. 
With this process of recombination and junctional diversity, an estimated number of over 1012 
possible combinations is generated.2
 Successful immunoglobulin gene rearrangement will result in a mature naïve B-cell 
that expresses functional immunoglobulin on the cell surface, ready to engage with an antigen. 
CHAPTER 1
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If an antigen is encountered and the right stimulatory signals are present, this will result in 
activation of that B-cell, typically resulting in the so-called germinal center reaction.
Figure 1.3. Immunoglobulin heavy chain gene rearrangement. Rearrangement starts with recombination 
between D and J, followed by recombination between V and DJ. The intervening DNA is excised as circular 
fragments.
The germinal center is a specialized compartment in secondary lymphoid organs which aims 
to generate B-cells with an even higher affinity for the antigen they recognize. In the germinal 
center, antigen is being presented by follicular dendritic cells to the B-cells. At the same time, 
the B-cells are dividing and generating mutations in the immunoglobulin genes, mainly at the 
sites that encode for the antigen binding site. This process, called somatic hypermutation, 
will generate either an increased or a decreased affinity for the antigen. The B-cells with 
mutations that cause higher affinity for the target antigen will bind stronger to the antigen on 
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 1dendritic cells and will receive signals allowing them to survive and be selected. In contrast, 
the cells with a lower affinity will go into apoptosis. The result is survival of B-cells with high-
affinity immunoglobulin. These cells will then progress to the next stage to become either 
immunoglobulin secreting plasma cells or memory B-cells. Consistent with its functions, the 
normal germinal center has very high proliferative activity and a very high level of apoptosis. 
The high proliferative rate is evidenced by the frequent mitoses and high expression of Ki67. 
The high rate of apoptosis is evidenced by frequent apoptotic cells, frequent tingible body 
macrophages that have phagocytized apoptotic cells, and lack of expression of BCL2, which is 
an anti-apoptotic protein. 
 In addition to the germinal center reaction, plasma cells and memory B-cell can also 
form in a germinal center independent fashion which is evidenced by the fact that patients who 
are unable to form germinal centers do have B-cells with evidence of somatic hypermutation.3, 
4
The classification of B-cell lymphomas is based on normal B-cell development (Figure 1.4). 
For example, follicular lymphomas are related to the normal germinal center and B-cell 
lymphoblastic leukemia/ lymphoma resembles normal precursor B-cells. NMZL mostly 
resembles post-germinal center B-cells, which is discussed in more detail in chapter 2.
Figure 1.4. Normal B-cell development and its correspondence to different types of B-cell lymphoma. 
Abbreviations: CLL/SLL: chronic lymphocytic leukemia/ small lymphocytic lymphoma; CLP: common 
lymphoid precursor; DLBCL: diffuse large B-cell lymphoma; MCL: mantle cell lymphoma; MZL: marginal 
zone lymphoma.
CHAPTER 1
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CLASSIFICATION OF LYMPHOMAS – WHY AND HOW?
Why is it important to classify a lymphoma? First of all, it is important for the patient. The 
different types of lymphoma require different types of treatment and are associated with a 
different prognosis. In addition, the recognition of groups of lymphomas with similar features 
has proved to be an important basis for the development of new treatments and refinement of 
prognosis.
 Lymphomas are currently classified according to the World Health Organization 
(WHO) classification of 2008 (with an expected update in 2016).5 This classification uses an 
entity-based approach in which features from different domains (i.e. clinical, morphological, 
immunophenotypic, genetic) are used to make a diagnosis of a specific subtype of lymphoma. 
The features in these different domains together make up an entity and the different domains 
may be more or less important depending on the specific differential diagnosis that is being 
assessed. For example, to differentiate between FL and NMZL the most important criteria will 
be in the morphologic, immunophenotypic, and genetic domains. In contrast, to differentiate 
between the different types of marginal zone lymphoma, the clinical domain is the crucial 
one. This multi-dimensional WHO approach to lymphoma classification requires excellent 
communication between the hematologist, molecular biologist, and pathologist to arrive at the 
right diagnosis.
 The ideal classification would consist of sharply defined and non-overlapping entities 
that encompass the entire spectrum of disease. In practice however, many gray areas remain 
between the different entities. In this thesis, the gray area between NMZL and FL is explored 
with the aim to find criteria that can better separate these entities from each other.
NODAL MARGINAL ZONE LYMPHOMA – CLASSIFICATION BY EXCLUSION
NMZL is currently classified as “a primary nodal B-cell lymphoma that resembles lymph nodes 
involved by marginal zone lymphoma of extranodal or splenic type, but without evidence of 
extranodal or splenic disease”.5 although morphological and immunophenotypic findings are 
described in the chapter on NMZL, these are not specific and shared with many other types of 
indolent B-cell lymphoma. Accordingly, NMZL is often a diagnosis of exclusion; if a particular 
small B-cell lymphoma does not fulfill the criteria for another lymphoma, it is classified as 
NMZL. This is problematic and in contrast with the principles of the WHO classification. The 
WHO classification is aiming to define entities; ‘real’ diseases with specific features in different 
domains. For a disease that is diagnosed mostly by exclusion, as is the case for NMZL, it 
is difficult to be considered an entity. Accordingly, NMZL is a disease with a heterogeneous 
clinical presentation, morphology, and genetic profile. This heterogeneity hampers studies 
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 1into better treatment and prognostication of NMZL. Accordingly, novel immunophenotypic or 
molecular markers are highly needed to better define the group of NMZL.
THE ETIOLOGY OF INDOLENT B-CELL LYMPHOMAS
Normal B-cells are stimulated by antigens and not surprisingly, different types of antigens have 
been implicated in the development of B-cell lymphoma. Evidence for the role of antigens in 
B-cell lymphomas comes from both the direct detection of micro-organisms and the detection 
of stereotyped B-cell receptors.
Micro-organisms
Both a role for viruses and bacteria has been recorded in the oncogenesis of indolent B-cell 
lymphomas.
 Viruses are a well-recognized cause of aggressive lymphomas. Epstein-Barr virus 
(EBV) and human herpes virus 8/ Kaposi sarcoma herpes virus (HHV8/KSHV) are the viruses 
most commonly involved in the development of B-cell lymphomas, particularly in situations 
of immune deficiency. Of these, EBV is the most important. It is present in the large majority 
of lymphomas arising in HIV/AIDS or in the post-transplant setting and it is also positive in a 
subset of aggressive B-cell lymphomas without a known background of immune deficiency, 
including Hodgkin lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, and some 
T/NK-cell lymphomas.6, 7 In indolent B-cell lymphomas however, EBV has been reported only 
rarely. Reported cases include EBV positive subcutaneous marginal zone lymphomas arising in 
the post-transplant setting or in patients with genetic or congenital diseases.8-10 Other reports 
detected EBV in marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT 
lymphomas) outside of the transplant setting, but because PCR was used to detect EBV, the 
positivity could be arising from background cells rather than true EBV positive tumor cells.11
 Co-occurrence of Hepatitis C virus (HCV) infection and lymphoma has been reported 
in multiple types of non-Hodgkin lymphoma, including indolent B-cell lymphomas. In fact, HCV 
is both hepatotropic and lymphotropic, forming a possible starting point for a role for HCV in 
lymphomagenesis. However, the association between B-cell lymphoma and HCV has varied 
significantly between studies, with stronger associations in those areas with a higher HCV 
prevalence. In systematic reviews, 13%-18% of B-cell lymphomas were HCV-associated.12-14 In 
NMZL, the picture is similar with only some studies reporting an association between HCV and 
NMZL, depending on the geographical population studied.12, 15, 16
 In addition to a association between HCV and lymphoma, a causative role is suggested 
by lymphoma regression in response to antiretroviral therapy.17-19 The mechanisms by which 
HCV induces lymphoma are not well understood, but possibilities include chronic antigenic 
stimulation and/or a direct oncogenic effect of the virus.14
CHAPTER 1
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KSHV is detected in lymphomas almost exclusively in patients with immunodeficiency and these 
are aggressive subtypes of lymphoma including primary effusion lymphoma and plasmablastic 
lymphoma. The rare patients with KSHV-associated lymphomas but without obvious immune 
deficiency were patients of old age suspected to have an impaired immune response related to 
age.20 KSHV has not been implicated in the development of indolent B-cell lymphomas, except 
maybe for the very rarely reported germinotropic lymphoproliferative disorder, which appears 
to have a good prognosis in the majority of patients.21-24
With respect to bacteria, multiple different species have been implicated in the development of 
MALT lymphoma with Helicobacter pylori being the best studied and most convincing example. 
H. pylori can be detected in up to 92% of MALT lymphomas and eradication of the bacterium 
by antibiotic treatment results in complete and long-lasting remissions of lymphoma in 
three quarters of patients with early-stage disease.25-29 Factors associated with the lack of a 
response to H. pylori eradication include a higher disease stage and the presence of specific 
translocations involving the API2, MALT1, or BCL10 gene.30-32 In both instances, it is suspected 
that the lymphoma cells have already become independent of the antigenic stimulus. Even 
in diffuse large B-cell lymphomas (DLBCLs) of the stomach, H. pylori eradication has been 
reported to result in long-term remission in up to two-thirds of patients.33, 34 
 In ocular adnexal MALT lymphoma, Chlamydophila psittaci can be detected in 
more than half of patients and this bacterium has been suggested as a target for antibiotic 
treatment.35-40 Although C. psittaci has also been detected in other MALT lymphomas, mainly of 
extra-gastrointestinal types, it is most frequently detected in ocular adnexal MALT lymphoma.41 
In a review from 2013, most studies showed partial or complete responses in approximately 
45% of patients with ocular adnexal MALT lymphoma treated with antibiotics.35 However, only 
in two out of three studies this response was better in C. psittaci-positive cases. In those two 
studies, the response rates were 66% vs. 50% and 64% vs. 38% for C. psittaci positive vs. 
negative patients.37, 40 These results suggest that although C. psittaci may have a role in the 
development of ocular adnexal MALT lymphoma and is amenable to antibiotic treatment, other 
bacteria or direct anti-tumor effects of the antibiotics used may also have a role. 
In MALT lymphomas of both the stomach and the ocular adnexa, the micro-organisms involved 
have similar roles. They do not stimulate the neoplastic B-cells directly, but rather cause 
an inflammatory milieu that contains activated helper T-cells that stimulate the neoplastic 
B-cells. The neoplastic B-cells often show B-cell receptors that are directed to self-antigens 
rather than exogenous antigens.41
In cutaneous MALT lymphoma, Borrelia burgdorferi has been suggested as a causative 
agent, with varying frequencies depending on the region where the studies were performed. 
In endemic areas, up to 40% of cutaneous MALT lymphomas showed evidence of Borrelia 
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 1infection.42-44 Although patient numbers are very limited, a subset of patients appears to 
respond to antibiotic therapy against Borrelia.35
 In immunoproliferative small intestinal disease (IPSID), Campylobacter jejuni has 
been reported as a possible causative micro-organism.45, 46 However, the evidence for this 
association is limited to anecdotal reports and no clinical studies have been performed. In 
pulmonary MALT lymphoma, Achromobacter xylosidans has been detected with increased 
frequency in lymphomas in comparison to controls, but these results are limited to a single 
study and have not been validated clinically.47 In primary intraocular B-cell lymphoma, the 
presence of Toxoplasma gondii has been reported.45
 In NMZL, no causative organism has been identified, but there are also no published 
reports that have addressed this issue.
Auto-immune diseases
Auto-immune diseases are associated with an increased risk of lymphoma.48 In different 
auto-immune diseases, different types of lymphomas are most frequent; lymphomas that 
develop in the context of rheumatoid arthritis are mostly aggressive B-cell lymphomas, 
whereas lymphomas developing in patients with Sjögren’s syndrome are predominantly 
extranodal marginal zone lymphomas.49, 50 With respect to the pathophysiology of lymphoma 
development in Sjögren’s syndrome, it has been suggested that the B-cell clone often has a 
B-cell receptor with rheumatoid factor (RF) activity, being directed against the Fc portion of 
IgG.51-54 The hypothesis is then that polyclonal B-cells which are activated in the auto-immune 
inflammatory environment acquire additional mutations and eventually grow out to become a 
B-cell lymphoma.53
Stereotyped B-cell receptors
Although micro-organisms have been implicated in the development of B-cell lymphomas, 
the neoplastic B-cell do not appear to have BCRs that recognize antigens belonging to these 
micro-organisms. Therefore, infections appear to contribute by forming a pro-inflammatory 
environment rather than directly stimulating the neoplastic cells. The questions then arises 
to what extent antigen stimulation is necessary for B-cell lymphoma development and which 
antigens are involved. With respect to the first part of this question, several lines of evidence 
argue for a role of antigens in lymphomagenesis.
 First, the BCR is retained in the majority of B-cell lymphomas and most lymphoma cells 
cannot survive autonomously ex vivo. This suggests a dependence on the micro-environment 
and on signaling through the BCR.55 Second, studies into the structure of the B-cell receptor 
have revealed stereotyped B-cell receptors in different types of B-cell lymphoma. 
In chronic lymphocytic leukemia (CLL), multiple subsets with specific stereotyped receptors 
have been recognized, with approximately one third of CLLs having a stereotypic BCR.56 Part of 
these stereotypes are associated with a specific clinical presentation or prognosis. In splenic 
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MZL (SMZL), about one third of lymphomas express the same immunoglobulin heavy chain 
variable gene. The fact that the BCRs in different lymphomas show a similar IGH structure 
suggests selection of tumor cells by specific antigens or superantigens.57
 If B-cell cell lymphomas are dependent on antigens for their survival, then which 
antigens are responsible? In both SMZL and CLL, it has been shown that the BCRs of the 
neoplastic cells are often reactive to self-antigens, including antigens which are expressed 
during cell death.58-62 In addition, reactivity to viral bacterial and fungal antigens has also been 
suggested, but the bacteria implicated are different from those previously discussed in the 
context of MALT lymphoma.
MOLECULAR PATHWAYS IN THE ONCOGENESIS OF INDOLENT B-CELL 
LYMPHOMAS
B-cell receptor/ Toll-like receptor/ NF-kappaB signaling
The nuclear factor kappa B (NF-kappaB) family consists of five proteins:
• RELA, also known as p65
• RELB
• REL, also known as c-Rel
• NFKB2, also known as p100/p52
• NFKB1, also known as p105/p50
These proteins share an N-terminal REL homology domain which facilitates homo- and 
heterodimerization and DNA binding. In the absence of NF-kappaB stimulation, NF-kappaB-
dimers are retained in the cytoplasm due to attachment of an inhibitor (NF-kappaB inhibitors - 
NFKBIs) or because they are present as inactive precursor proteins (p100 and p105). The three 
typical NFKBIs (NFKBIA, NFKBIB, NFKBIE) are constitutively expressed, whereas atypical 
NFKBIs (BCL3 and NFKBIE) are expressed inducibly.
 A canonical and a non-canonical NF-kappaB-pathway are distinguished. The 
canonical pathway is activated by signaling from the B- or T-cell receptor, Toll-like receptor 
(TLR), interleukin-1 receptor (IL1R) or tumor necrosis factor receptor (TNFR). Through multiple 
steps, these signals converge on the inhibitor of kappa-B kinase (IKK) complex. This complex 
consists of two catalytic subunits (CHUK – conserved helix-loop-helix kinase, also known 
as IKBKA, and IKBKB) and a regulatory subunit IKBKG (also known as NEMO – NF-kappaB 
essential modulator). Upstream signals activate the IKK-complex, which allows members 
of this complex to phosphorylate NFKBIs. Phosphorylation induces ubiquitination with 
subsequent proteasomal degradation. Degradation of NFKBIs exposes nuclear localization 
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 1signals on NF-kappaB dimers resulting in sustained nuclear localization and binding of DNA 
for transcriptional regulation.
 The non-canonical pathway is activated by signaling from the lymphotoxin B receptor, 
B-cell activating factor receptor (BAFFR), and CD40. This activates NF-kappaB inducible kinase 
(NIK, also known as MAP3K14) and CHUK, resulting in phosphorylation of NFKB2/p100, which 
is usually dimerized to RELB.63-65  Phosphorylation of NFKB2/p100 causes proteolytic removal 
of its C-terminal NFKBI-like domain, which is followed by nuclear translocation of p52-RELB 
dimers (p52 being the remaining N-terminal half of p100). 
 RELA, RELB, and REL are able to stimulate gene expression via their C-terminal 
transcription activation domain (TAD). Because NFKB1 and NFKB2 lack such a TAD, dimers 
consisting only of these proteins can repress transcription. Heterodimers of NFKB1 or NFKB2 
and a TAD-containing NF-kappaB-member are able to stimulate gene expression.
Diverse signaling cascades in the canonical NF-kappaB pathway converge on the IKK complex 
(Figure 1.5):
 Signaling through both the T-cell receptor and B-cell receptor can result in NF-
kappaB activation. Here, we will focus on the BCR.  The BCR is situated in the cell membrane 
together with CD79A and CD79B, forming the BCR complex. BCR stimulation by binding of 
antigen results in phosphorylation of CD79A and CD79B which causes a signaling cascade 
involving multiple proteins including Bruton’s tyrosine kinase (BTK) and protein kinase C Beta 
(PRKCB). This results in phosphorylation of CARD1166, 67, which then associates with BCL10 
which in turn binds MALT1.68-73 The CARD11-BCL10-MALT1-complex then interacts with TRAF2 
and TRAF6 which induces IKK complex activation.68
 Upon binding their antigens, the IL1R and TLRs signal via receptor-bound MYD88, 
IRAK, and TRAF6, resulting in activation of the TAK1-TAB2-complex which results in IKK 
complex activation.74, 75
 After binding of TNF to the TNFR (not shown in the figure), intracellular receptor-
associated proteins (including TRADD and TRAF2/5) recruit the E2/E3 ligase complex which 
ubiquitinates RIP1.76, 77 RIP1 activates TAK1 which is bound to TAB2.78 The TAK1-TAB2-complex then 
activates the IKK complex. Especially for TNFR signaling, the protein complex LUBAC has been 
shown to add linear polyubiquitin chains to NEMO and RIP1 which facilitates activation of IKKs.79
NF-kappaB signaling is negatively regulated by deubiquitinases. CYLD (cylindromatosis) and 
TNFAIP3 (also known as A20) are well characterized examples of deubiquitinases involved in 
the NF-kappaB pathway. CYLD is able to remove K63-linked ubiquitin from TRAF2, TRAF6, 
TRAF7, RIP1, TAK, and BCL3.80 TNFAIP3 is able to remove K63-linked ubiquitin from TRAF6, 
RIP1, RIP2, and NEMO.81-84 In addition, it could stimulate K48-linked ubiquitination of RIP1, 
targeting if for the proteasome.84 CYLD is a constitutively activated deubiquitinase, whereas 
TNFAIP3 is expressed inducibly.
CHAPTER 1
20
 With respect to the different types of ubiquitination, K48-linked ubiquitination, in 
which polyubiquitin chains are formed through lysine 48 (K48) of ubiquitin, directs proteasomal 
degradation. In contrast, polyubiquitin chains linked through lysine 63 of ubiquitin (K63) 
facilitates low-affinity binding of proteins, supporting formation of protein complexes and 
interactions.85
Figure 1.5. Overview of B-cell receptor/ Toll-like receptor/ NF-kappaB signaling. Canonical NF-kappaB 
signaling is indicated on the left, with stimulation of the BCR or IL1R/TLR ultimately resulting in 
translocation of NF-kappaB to the nucleus. Non-canonical signaling via LTR/CD40/BAFFR is indicated on 
the right.
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 1TLR/BCR/NF-kappaB signaling in lymphomagenesis
Extranodal marginal zone lymphoma. Extranodal marginal zone lymphomas of mucosa-
associated lymphoid tissue (MALT lymphomas) are associated with multiple translocations 
that share their ability to induce NF-kappaB activation. The most common translocations are:
 •  t(11;18)(q21;q21), mostly observed in MALT lymphomas in the lung and 
gastrointestinal tract, causes fusion of BIRC3 (also known as API2) and MALT1.86 
The product of this fused gene is a chimeric protein that is able to activate the 
canonical NF-kappaB pathway.72
 •  t(1;14)(p22;q32) causes overexpression of BCL10 by bringing the BCL10 gene under 
the control of the immunoglobulin heavy chain enhancer.87, 88 BCL10 overexpression 
causes activation of the canonical NF-kappaB pathway.89 In addition, BCL10 has 
been shown to activate the non-canonical NF-kappaB pathway.90
 •  t(14;18)(q32;q21) causes overexpression of MALT1 by bringing it under the control of 
the immunoglobulin heavy chain enhancer. MALT1 is an activator of the canonical 
NF-kappaB pathway, although expression of MALT1 alone does not activate NF-
kappaB.72 In addition, MALT1 is able to cleave TNFAIP3, thereby abrogating its 
inhibitory effect.91, 92
 •  t(3;14)(p13;q32) deregulates FOXP1, which plays a role in B-cell development.93, 94 
FOXP1 may regulate NF-kappaB activation.90
Deletions and mutations in TNFAIP3 have also been shown in MALT lymphomas.95 Interestingly, 
variants of TNFAIP3 are associated with systemic lupus erythematosus and rheumatoid 
arthritis, both conditions also associated with an increased lymphoma risk.85, 96-99
Nodal marginal zone lymphoma. TNFAIP3 inactivation has been described in a subset of 
NMZLs.100 Also, in a comparative genomic hybridization study, Rinaldi and colleagues showed 
recurrent numerical abnormalities in chromosomal regions holding genes involved (NFKBIZ, 
TNFAIP3) and possibly involved (FOXP1, BCL6) in NF-kappaB signaling.101 However, half of 
these changes would cause NF-kappaB inhibition rather than activation (i.e. gains of NFKBIZ 
and BCL6 would repress NF-kappaB activity).
Splenic marginal zone lymphoma (SMZL). In SMZL, recurrent mutations have been reported 
in IKBKB, TNFAIP3, CARD11, MYD88, BIRC3, MAP3K14, and TRAF3.102-106
Lymphoplasmacytic lymphoma (LPL). MYD88 mutations are present in the large majority of 
LPLs and in smaller subsets of SMZL and CLL.103, 107-109 Almost all mutations affect the TIR 
domain with NF-kappaB activation as a result.
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Chronic lymphocytic leukemia/ small lymphocytic lymphoma. Mutations in BIRC3 are present 
in a subset of CLL/SLLs with enrichment in fludarabine-refractory cases.110 MYD88 mutations 
have been found in a small subset of CLL/SLLs, mainly in cases with mutated IGHV.109 
Follicular lymphoma. Mutations in genes involved in BCR/NF-kappaB signaling are relatively 
frequent in FL, with mutations in CARD11, TNFAIP3, CD79A/B, and/or PRKCB being present in 
a third of FLs.111 Interestingly, mutations in NF-kappaB genes were gained at transformation.111 
Mutations in TNFRSF14 are also frequently present in FL, being reported in approximately one 
third of cases.111-113 TNFRSF14 is a putative tumor suppressor which can signal through the 
NF-kappaB pathway after binding of one of its ligands which include LIGHT, BTLA or CD160.114 
However, as loss-of-function mutations in TNFRSF14 are observed in FL, these mutations 
would cause a decrease rather than an increase of NF-kappaB activation. The tumor 
suppressor effect of TNFRSF14 can be explained by the fact that in the unmutated situation, 
triggering of TNFRSF14 by its ligand LIGHT increases the sensitivity to FAS-induced apoptosis. 
Disruption of TNFRSF14 would then make cells less sensitive to apoptosis, contributing to 
lymphomagenesis.115, 116 
BCL2
BCL2 is an anti-apoptotic protein which was initially discovered as the oncogene involved in the 
t(14;18) translocation in FL.117 In the physiological situation, it is part of the balance between 
pro-apoptotic and anti-apoptotic proteins in the intrinsic/ mitochondrial apoptotic pathway. 
In the large majority of FLs and in a significant subset of DLBCLs, overexpression of BCL2 
can be explained by the t(14;18) translocation which puts BCL2 under the control of the IGH 
enhancer. More rarely, translocations between BCL2 and the immunoglobulin light chain loci 
are encountered. However, the large majority of small B-cell lymphomas and many DLBCLs 
express BCL2 without evidence of a BCL2 rearrangement. This can be explained by other 
mechanisms of BCL2 overexpression, including physiological expression, BCL2 amplification, 
hypomethylation, or deletion of microRNAs that downregulate  BCL2.118-121
BCL6
BCL6 is a master regulator of the germinal center B-cell phenotype. It is essential for 
formation of germinal centers, as mice lacking BCL6 are unable to form germinal centers.122 
In the normal germinal center, high proliferation occurs together with genomic instability due 
to somatic hypermutation. In this context, BCL6 functions as a repressor of normal control 
mechanisms of the cell cycle, DNA damage response, and cell death. Although this action 
is necessary to generate B-cells with high-affinity antibodies, it is also dangerous because 
it may lead to deregulated growth and therefore BCL6 expression is tightly regulated in 
the normal situation. However, deregulated BCL6 expression is a common event in B-cell 
lymphomas and multiple mechanisms can cause this. Translocations which put BCL6 under 
the control of a strong promoter such as IGH are a frequent event in DLBCL and are also 
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 1present in a subset of FLs.123-125 Alternative mechanisms include mutations in binding sites for 
repressive transcription factors,126 mutations in MEF2B which is a transcriptional activator of 
BCL6,127 hypermethylation of intron 1 preventing silencing by CTCF,128 and posttranscriptional 
regulation.122  
NOTCH signaling
Mammals possess 4 different NOTCH genes that encode for receptors involved in self-renewal 
and differentiation.129 Upon binding of their ligands, a cleavage step causes release of the 
intracellular part of NOTCH which then translocates to the nucleus where it forms a protein 
complex with other proteins including MAML and histone acetyltransferases (e.g. EP300).130 
This complex then stimulates transcription of a number of genes, resulting in increased 
expression of MYC and activation of the PI3K/AKT, mTOR, and NF-kappaB pathway.129-131 
NOTCH1 is essential for normal T-cell development, but is also frequently mutated in T-cell 
acute lymphoblastic leukemia.132 These mutations occur in the heterodimerization and/or 
PEST domain. The PEST domain is the target for the FBXW7 ubiquitin protein ligase which 
targets NOTCH1 for the proteasome. Mutations in the PEST domain prevent ubiquitination 
and downregulation of NOTCH.  Mutations in the heterodimerization domain cause enhanced 
cleavage of membranous NOTCH.132 In indolent B-cell lymphomas, NOTCH1 mutations have 
been reported in a subset of CLL, SMZL, and FL.103, 109, 133-135 NOTCH2 is the master regulator 
of marginal zone differentiation and NOTCH2 mutations are detected in up to one quarter of 
SMZLs.103, 105, 106, 134
Epigenetic deregulation
Recent large-scale sequencing efforts have identified frequent mutations in genes involved 
in chromatin modulation in B-cell lymphomas.111, 136-138 These have been most extensively 
studied in DLBCL and FL in which mutations in MLL2 (KMT2D), CREBBP, EP300, MEF2B, and 
EZH2 were most frequently observed. Most of these mutations are loss-of-function mutations, 
except for mutations in EZH2 which are gain-of-function. These mutations result in epigenetic 
silencing of specific genetic loci involved in cell cycle progression and regulation of the germinal 
center reaction, contributing to lymphomagenesis.139
Mitogen activated protein kinase (MAPK) signaling
In hairy cell leukemia, the BRAF V600E mutation has been identified by next-generation 
sequencing as a disease-defining genetic event.140 BRAF is downstream from KRAS and 
upstream from MEK and ERK in the MAPK pathway. The BRAF V600E mutation causes 
constitutive activation of BRAF, resulting in cell survival.130
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B-CELL LYMPHOMA IN THE NETHERLANDS
Although hematologic malignancies represent a diverse group with many rare diseases, 
hematologic malignancies as a group are common and represent the sixth most frequent type 
of cancer in the Netherlands. B-cell non-Hodgkin lymphomas represent the largest group, 
with 44% of hematologic malignancies belonging to this category (Figure 1.6A).
Within the group of B-cell non-Hodgkin lymphomas, about half are indolent (including chronic 
lymphocytic leukemia/ small lymphocytic lymphoma; CLL/SLL) and half are aggressive.  When 
looking closer at the group of indolent B-cell lymphomas, most represent CLL/SLL, followed 
by follicular lymphoma (FL) and the group of ‘other indolent B-cell lymphomas’ (Figure 1.6B). 
This latter group contains mostly marginal zone lymphomas, including nodal marginal zone 
lymphoma (NMZL), and indolent small B-cell lymphomas that cannot be classified more 
specifically. Unfortunately, NMZL is not recorded specifically in the Dutch cancer registration.
 In the last 20 years, the cancer incidence in the Netherlands has shown a steady 
rise with an approximately proportional rise in the incidence of hematologic malignancies 
(Figure 1.7A). During this same period, the incidence of ‘other indolent B-cell lymphomas’ 
showed a more marked increase than the incidence of FL (Figure 1.7B). This might be due to 
a true change in the incidence of these lymphomas, but it might also represent a change in 
classification practice. 
A B
Figure 1.6. Subgroups of hematological malignancies (A) and subgroups of indolent B-cell non-Hodgkin 
lymphomas (B) in the Netherlands in 2014. Source: The Netherlands Cancer Registry; http://www.
cijfersoverkanker.nl/?language=en.
GENERAL INTRODUCTION
25
C
ha
pt
er
 1
A
B
Figure 1.7. A: total cancer (light gray, left y axis) vs. hematological cancer incidence (dark gray, right 
axis), showing a roughly proportional increase in total cancer and hematological cancer. B: incidence 
of follicular lymphoma (dark gray) and ‘other indolent B-cell lymphomas’, showing a more pronounced 
increase in ‘other indolent B-cell lymphomas’. Source: The Netherlands Cancer Registry; http://www.
cijfersoverkanker.nl/?language=en.
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RESEARCH OBJECTIVES AND OUTLINE OF THIS THESIS
The incidence of MZLs appears to be increasing yet our knowledge on these lymphomas 
remains limited, especially on NMZL. NMZL is often treated similarly to FL, but it is not sure 
that this is the right approach as NMZL and FL are likely to have a different pathogenesis. 
It can therefore also be expected that they will respond differently to treatment, especially 
to targeted treatment. If we are to compare NMZL with FL, it is very important to be able to 
distinguish between the two entities reliably. A central theme of this thesis is the question how 
to distinguish between NMZL and FL. 
In chapter 2 we describe a systematic review of the literature on NMZL which forms the starting 
point for this thesis. In analogy to the WHO classification, the remaining chapters describe 
investigations into the different domains that make up the diagnosis of NMZL, including the 
clinical, morphological, immunohistochemical, and molecular domain.
 Chapter 3 explores the morphological and immunohistochemical features which 
are traditionally used for a diagnosis of NMZL. We show that specific morphological and 
immunohistochemical features cluster in indolent B-cell lymphomas without a BCL2 
translocation. Some of these were initially diagnosed as FL and some as NMZL. The fact that 
the specific morphological features recognized are those traditionally considered to fit with 
NMZL raises the hypothesis that a subset of low-grade B-cell lymphomas with a follicular 
growth pattern but without a BCL2 translocation actually represents NMZL rather than FL. 
This chapter emphasizes the often difficult and sometimes controversial distinction between 
NMZL and FL.
 In chapter 4, the clinical features of NMZL and FL are compared. NMZL and FL showed 
a largely similar clinical presentation, but some differences were observed. Notably, FLs more 
often transformed to DLBCL during the course of the disease and the factors associated with 
worse survival differed between NMZL and FL.
 Chapter 5 describes the use of an extended immunohistochemical panel to help 
distinguish between NMZL and FL. This panel includes both traditional markers, but also 
newer putative marginal zone markers (MNDA and IRTA1). An immunohistochemical algorithm 
was constructed after testing of an initial series of NMZLs and FLs and this was validated in a 
second group of lymphomas.
Chapter 6 describes a technique to perform multiple rounds of immunohistochemistry on a 
single tissue section. This was initially set up to allow the study of cyclin D1 expression on the 
tumor cells of nodular lymphocyte-predominant Hodgkin lymphoma and T-cell and histiocyte-
rich large B-cell lymphoma.
 In chapter 7, we used the technique described in chapter 6 to study follicular 
colonization in NMZL. We show that in a subset of NMZLs, protein expression of BCL6, BCL2, 
and Ki67 changes depending on the micro-anatomical compartment the tumor cells are in. This 
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because changes in protein expression occurring in NMZL cause an immunohistochemical 
profile with a stronger resemblance to FL.
 In chapter 8, we study the molecular pathogenesis of NMZL in comparison to FL with 
a particular focus on the NF-kappa B pathway. We show that both NMZL and FL often have 
mutations in genes involved in NF-kappaB signaling, but the mutations are partially different. 
The addition of the immunohistochemical algorithm from chapter 5 to the initial diagnosis 
resulted in a strong clustering of TNFRSF14 mutations with FL, but not NMZL.
 In Chapter 9, the key findings of this thesis are discussed in relation to the literature, 
thereby summarizing the current approach to the diagnosis and differential diagnosis of 
NMZL. This is followed by a more broad discussion on the classification of indolent B-cell 
lymphomas and remaining problems in classification with possible solutions. This is followed 
by a summary of the thesis in chapter 10.
Michiel van den Brand, J Han JM van Krieken
Department of Pathology, Radboud university medical center, Nijmegen, the Netherlands
Haematologica. 2013;98(7):1003-1013.
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Recognizing nodal marginal zone lymphoma: 
recent advances and pitfalls
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ABSTRACT
The diagnosis of nodal marginal zone lymphoma is one of the remaining problem areas in 
hematopathology. Because no established positive markers exist for this lymphoma, it is 
frequently a diagnosis of exclusion, making distinction from other low-grade B-cell lymphomas 
difficult or even impossible. This systematic review summarizes and discusses the current 
knowledge on nodal marginal zone lymphoma, including clinical features, epidemiology and 
etiology, histology, and cytogenetic and molecular features. In particular, recent advances 
in diagnostics and pathogenesis are discussed. New immunohistochemical markers have 
become available that could be used as positive markers for nodal marginal zone lymphoma. 
These markers could be used to ensure more homogeneous study groups in future research. 
Also, recent gene expression studies and studies describing specific gene mutations have 
provided clues to the pathogenesis of nodal marginal zone lymphoma, suggesting deregulation 
of the nuclear factor kappa B pathway. Nevertheless, nodal marginal zone lymphoma remains 
an enigmatic entity, requiring further study to define its pathogenesis to allow an accurate 
diagnosis and tailored treatment. However, recent data indicate that it is not related to splenic 
or extranodal lymphoma and also not to lymphoplasmacytic lymphoma. Thus, even though the 
diagnosis is not always easy, it is clearly a separate entity.
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INTRODUCTION
The current World Health Organization (WHO) classification for hematopoietic neoplasms 
enables the accurate diagnosis of most lymphoma types. Some problem areas remain 
however, one of which is the diagnosis of nodal marginal zone lymphoma (NMZL). The 
identification of NMZL has been difficult because of the rarity of this disease and the lack of 
positive immunohistochemical or molecular markers. As a result, epidemiology, prognosis, 
and therapeutic options have not been firmly established. In this review, we provide an 
overview of the current knowledge on NMZL with special emphasis on diagnostic criteria and 
pathogenesis, based on a systematic review of the literature.
We performed a PubMed search in October 2012 with the keywords “nodal marginal zone 
lymphoma”,  “monocytoid B cell lymphoma”, “nodal MZL”, and “nodal MZLs”, and filtered for 
publications in English, which retrieved 167 hits after removal of duplicates, including articles 
from 1986 until 2012. Only articles published after 1994 were included, coinciding with the 
adoption of the REAL classification, after which NMZL and extranodal MZL (EMZL) became 
more clearly separated in literature. From the remaining 116 articles, the abstracts of all 
articles were read by one of the authors (MvdB). Twenty-five papers were excluded because they 
dealt with EMZL or other entities and four papers were excluded because NMZLs represented 
only a very minor part of a larger series (i.e. only 1 or 2 cases of NMZL, comprising less than 
10% of cases). The remaining 87 papers were read entirely, and included if deemed relevant for 
this review. Additional papers were included from bibliographies.
CLASSIFICATION OF NMZL
According to the current (2008) WHO classification, NMZL is “a primary nodal B-cell neoplasm 
that morphologically resembles lymph nodes involved by MZL of extranodal or splenic types, 
but without evidence of extranodal or splenic disease”.19 This means that for a diagnosis of 
NMZL, integration of clinical and pathological data is required and it also implies that NMZL is 
a diagnosis of exclusion. Also, this definition has resulted in lumping the three categories into 
one larger group obscuring the important differences between them.
Marginal zone lymphomas were initially classified as ‘monocytoid B-cell lymphomas’. This 
term was put forward by Sheibani et al. in 1986, in a paper describing lymphomas consisting of 
cells that resemble the monocytoid B-cells observed in reactive conditions like lymphadenitis 
in toxoplasmosis and HIV lymphadenopathy.153 At this time, there was no strict separation 
between nodal and extranodal MZLs. The revised Kiel classification from 1990 introduced 
the separation between nodal and extranodal marginal zone lymphoma (EMZL).154 Shortly 
thereafter, multiple papers emphasized the morphological similarities between EMZL (at that 
time referred to as MALT lymphoma, i.e. lymphoma of the mucosa associated lymphoid tissue) 
CHAPTER 2
32
and NMZL.155, 156 In the REAL classification of 1994, and in the 2001 WHO classification, NMZL 
was adopted as a provisional entity.157, 158 In the current 2008 WHO classification, NMZL has 
become a definitive entity and a pediatric variant has been included.
It has not been firmly established whether MZL of Waldeyers ring should be considered NMZL 
or EMZL. A recent Korean study suggests that, because of the overlap in prognosis, MZL of 
Waldeyers ring resembles NMZL rather than EMZL.159
EPIDEMIOLOGY AND ETIOLOGY
NMZL is a rare lymphoma, accounting for 1,5-1,8% of lymphoid neoplasms.160, 161 The incidence 
of NMZL appears to be increasing, which is most likely due to a ‘real’ increase, rather than 
better recognition.162 Most studies report a median age around 60 years with a wide age 
distribution ranging from adolescence to patients over 90 years old.1, 3, 29, 160-168 Both sexes are 
affected with approximately equal frequency.
Morphologically, NMZL resembles EMZL. EMZL is well known for its association with conditions 
that provide a chronic stimulation to the immune system, including chronic infections (e.g. 
Helicobacter pylori infection in gastric EMZL) and autoimmune conditions (e.g. salivary gland 
EMZL in Sjögren’s syndrome). From this, one could hypothesize that NMZL, or a subset of 
NMZLs, might also be caused by specific chronic inflammatory conditions. Indeed, infections 
and auto-immune disorders have been reported in association with NMZL, but this evidence 
remains far from sufficient to establish a definitive role for these stimuli in lymphomagenesis. 
Recently, we encountered a case of what we had referred to as NMZL lymphoma in an axillary 
lymph node. However, we detected H. pylori by PCR analysis and a gastric biopsy revealed 
EMZL. This case implicates that without extensive work-up, including gastric biopsies, one 
cannot be sure that a case of NMZL really represents this entity.
Hepatitis C virus (HCV) has been reported in a subset of NMZL patients. In an early but small 
study, monocytoid B-cell lymphoma had the highest prevalence of HCV in comparison with 
other lymphoma types.169 In a larger study by Arcaini et al., 9 of 38 (24%) patients with NMZL 
had positive serology for HCV, in one patient combined with positive hepatitis B virus (HBV) 
serology.29 Some other studies confirmed an association with HCV in a smaller proportion of 
patients (Camacho et al. and Oh et al. in 20 and 5% respectively)163, 164, but other studies did 
not.1 The study by Camacho et al. also showed HBV infection in 30% of patients. The difference 
in HCV prevalence in NMZL between studies might be caused by geographical variation, which 
also appears to hold true for HCV prevalence in lymphoplasmacytic lymphoma, an entity closely 
related to NMZL.170-173
NMZL has also rarely been described in human immunodeficiency virus-infected patients, and 
complete regression of transformed NMZL has been reported in one such patient after anti-
retroviral therapy.174, 175
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The composition and use of the different variable families on the immunoglobulin heavy chain 
locus have been connected to certain diseases in specific lymphoma types. In NMZL, multiple 
studies have shown biased use of immunoglobulin heavy chain VH families VH3 and VH4, in 
particular VH4-34.
1, 163, 176-179 Preferential use of VH3-34 is associated with Epstein-Barr- and 
cytomegalovirus in patients with chronic lymphocytic leukemia.180 In NMZL, an association with 
these viruses has not been established.163, 181, 182 In NMZL patients with HCV, VH1-69 was used 
preferentially, which is in line with other studies that describe the preferential use of VH1-69 in 
response to the E2 antigen of HCV.179, 183
Autoimmune diseases have been reported in association with NMZL in multiple studies and 
include rheumatoid arthritis, vitiligo, systemic lupus erythematosus, autoimmune hemolytic 
anemia, chronic thyroiditis, and Sjögren’s syndrome.2, 29, 165, 166, 184 In these studies, 6-19% of 
patients had an autoimmune disease.
In conclusion, there are indications that NMZL is associated with chronic inflammation, but the 
precise mechanisms remain unknown.
CLINICAL AND LABORATORY FEATURES OF PATIENTS WITH NMZL
The clinical features at presentation are summarized in Table 2.1.1, 29, 160-167 Most patients with 
NMZL present with peripheral lymphadenopathy; a very small minority of patients has only 
central lymphadenopathy at presentation. The head and neck lymph nodes are most frequently 
involved. Bulky tumors (larger than 5 cm) are observed in 11-31% of patients. Across studies, 
roughly half of patients present with stage III or IV disease. 10-20% of patients experience 
B-symptoms. Anemia is present with varying frequency (11-36%).1, 29, 160, 164, 166 If these studies 
are taken together, approximately one quarter of patients is anemic. Thrombocytopenia has 
been described in one study in one tenth of patients.1 Involvement of the peripheral blood 
is reported in 10-24% of patients.1, 29, 160, 163 The incidence of bone marrow involvement varies 
greatly between studies (from 0-62%), but if taken together, the bone marrow is involved in 
approximately a third of patients.1, 29, 160, 161, 163-166, 185
Positron Emission Tomography (PET) using (18)F-fluorodeoxyglucose appears to be a good 
way to study disease extent in NMZL, considering PET-positivity in the large majority of cases 
reported thus far (in 92% of 14 cases).186, 187
Serum lactate dehydrogenase (LDH) is elevated in 12-48% of patients,β2-microglobulin is 
increased in 29-45%.1, 29, 160, 161, 163-167 An M-component is present in 6-33% of patients.1, 29, 160, 165 
Cryoglobulins were rarely present in one study (in 2 out of 14 patients).1 Hypoalbuminemia was 
reported in 7-10% in two studies.1, 160
In conclusion, the clinical presentation of NMZL is non-specific and highly variable but this 
may be due to the difficulty of the diagnosis and the variable rigor by which other entities have 
been excluded.
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CELL OF ORIGIN
Marginal zone lymphoma receives its name from the resemblance to the physiological marginal 
zone. The marginal zone surrounds the mantle zone of the germinal center and is usually not 
recognized morphologically in lymph nodes. However, the spleen and some mesenteric lymph 
nodes do show a marginal zone in the normal situation, and occasionally, other lymph nodes 
also have marginal zone development.188
NMZL arises from mature B-cells that have rearranged immunoglobulin genes, enabling 
detection in clonality studies. However, the precise B-cell of origin of NMZL remains poorly 
defined and it has been suggested that NMZL can arise from different subsets of mature 
B-cells, not necessarily being marginal zone B-cells. Multiple small studies have examined the 
presence of somatic hypermutation (SHM), which was detected in the large majority of cases 
(in approximately 85%)1, 163, 176-179, 189, suggesting a (post-)germinal center B-cell. However, less 
than half of cases showed evidence of antigen selection. The study by Conconi and colleagues 
showed on-going mutations in 4 out of 6 hypermutated cases, suggesting derivation from 
germinal center B-cells.178 Although the presence of SHM suggests post-germinal center 
derivation, there is accumulating evidence for germinal center-independent SHM. This 
evidence comes from patients with hyper-IgM syndrome and X-linked lymphoproliferative 
disorder, who lack functional germinal centers, but do show some SHM.17, 18 Multiple other 
studies have also shown germinal center-independent SHM.190, 191 Very recently, Warsame and 
associates showed evidence of on-going mutations in microdissected monocytoid B-cells.192 
In addition, these cells expressed activation-induced cytidine deaminase, which is required for 
SHM.
The name NMZL suggests derivation from marginal zone cells, and the expression of MNDA 
and IRTA1 in many cases (see below) supports this notion; the data so far are however still 
conflicting.
HISTOPATHOLOGY
NMZL has great variability in growth pattern and cellular morphology and is therefore almost 
never a ‘spot diagnosis’. Rather, a diagnosis of NMZL requires careful integration of morphology, 
immunohistochemistry, molecular studies, and clinical features (Figure 2.1).
On low power, multiple growth patterns can be recognized, as was nicely illustrated by Salama 
and colleagues.193 In their study, a diffuse pattern of infiltration was most frequent (in 31 out of 51 
cases), followed by interfollicular and nodular patterns of infiltration in 14 and 10%, respectively. 
Perifollicular growth was reported in only one case. In a study by Traverse-Glehen et al., 
containing 21 patients, nodular and interfollicular growth was most frequently observed, both in 
one third of patients.1 Five cases showed diffuse growth, two showed an inverse follicular pattern.
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Figure 2.1. NMZL histology A-C:Hematoxylin and eosin stain, showing a nodular architecture on low power 
(A), with recognizable remnant follicles at higher power (arrow) (B). In this case, the lymphoma cells consist 
of small cells with scant cytoplasm and round to indented nuclei with fine chromatin structure (lymphocytic/ 
centrocytic) (C). D-G: Immunohistochemistry shows BCL2-negative remnant follicles surrounded by BCL2-
positive lymphoma cells (D). BCL6 highlights the remnant follicles (E). CD23 shows dendritic networks 
that have been partially destructed (F). The tumor cells show strong expression of MNDA (G). H: Strong 
expression of IRTA-1 in another case of NMZL. I-K: Another case of NMZL with prominent plasma cell 
differentiation, with Russell bodies (arrow) (I). Immunohistochemistry against immunoglobulin light chains 
kappa and lambda reveals light chain restriction for lambda light chains (J-K).
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On high power, NMZL cells show heterogeneous morphology, varying from centrocyte-like 
cells to monocytoid cells to plasmacytoid cells and plasma cells with varying numbers of 
interspersed centroblasts and immunoblasts. Monocytoid cells have a central nucleus with 
condensed chromatin and indistinct nucleoli, surrounded by ample pale cytoplasm. Centrocyte-
like cells, resembling the centrocytes of the germinal center, have nuclei with slightly irregular 
nuclear membranes and a coarser chromatin structure. Lymphoplasmacytoid cells have some, 
but not all features of plasma cells; in comparison to plasma cells they have less cytoplasm 
which is basophilic. They are smaller than typical ‘Marschalko-type’ plasma cells and have a 
finer chromatin structure. Monocytoid cells were reported in one third of cases in one study1, 
but predominance of monocytoid cells is rare and should prompt consideration of secondary 
lymph node involvement by MALT lymphoma.194 Plasmacytic differentiation has been reported 
in 22-47%1, 163, 193, 195 and can be extensive (Figure 2.1G-I). Dutcher bodies are rarely observed, 
but can be numerous.1, 195 One case of NMZL with Auer-rod-like inclusions has been reported.196
Campo et al. classified growth patterns in NMZL into splenic and MALT type, which has 
subsequently become the subject of debate.197, 198 The splenic type, being present in 6 of 36 
cases, was described as consisting of a polymorphic infiltrate around residual germinal 
centers that lack a clear mantle cuff. The remainder of the cases were of the MALT type, 
characterized by perisinusoidal and perivascular infiltration of monocytoid and centrocytoid 
cells next to residual germinal centers with a well-preserved mantle cuff. Splenic type NMZLs 
were IgD positive, a feature that was confirmed in some studies163, 199, but not in others.165, 193 
Unfortunately, not all these studies reported IgD expression and it was not reported in relation 
to growth pattern.163 
Kojima et al. adopted yet another morphological scheme which recognized a splenic type, MALT 
type, floral type, and diffuse large B-cell lymphoma (DLBCL) + MALT type.165 In their study of 
65 patients, the MALT and DLBCL+MALT type were most frequent (in 45 and 31% respectively). 
The splenic and floral type were present in 11 and 14%, respectively. 
A floral variant was also reported by Karube et al. in 6 cases of NMZL.181 These showed a 
proliferation of medium sized-cells in the marginal zone which surrounded enlarged germinal 
centers with a thick and irregular mantle zone which sometimes extended into the germinal 
center, similar to progressively transformed germinal centers. Rarely, NMZL with numerous 
epithelioid histiocytes, hyaline-vascular Castleman disease-like features and NMZL in 
association with Rosai-Dorfman disease, light- and heavy chain deposition disease, and non-
lymphomatous skin lesions has been reported.200-205
The pattern of bone marrow infiltration has been described in only a small number of cases, 
with a nodular and paratrabecular pattern in most cases, followed by an interstitial pattern.1, 
185, 206 One study reported intrasinusoidal growth, which was the sole pattern present in a single 
case.185
The impact of centroblasts percentage on prognosis and the dividing line between DLBCL and 
NMZL remain unclear. Some authors diagnosed a case as being transformed if >20% of cells 
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were centroblasts, which rendered a diagnosis of concurrent DLBCL in 20% of NMZLs.161, 207 
Two other studies diagnosed DLBCL if more than 50% of tumour cells were centroblasts, which 
was present in 25 and 31%.160, 165 Others have been more reluctant to diagnose transformation 
if large cells are still admixed with smaller tumour cells.29, 208, 209 In a study by Traverse-Glehen 
and colleagues, the presence of more than 20% of large cells had no significant effect on 
prognosis.1 However, as put forward by Kaur, these patients were mostly treated with 
aggressive chemotherapy, irrespective of large cell percentage.210 This could have prevented 
the detection of a significant effect of large cell percentage. In our own practice, we diagnose 
transformation in NMZL only if sheets of large cells are present, similar to the criterion used 
in other lymphoma types (Figure 2.2).211
Figure 2.2. NMZL with transformation to diffuse large B-cell lymphoma (DLBCL). A: low-grade 
component, showing mainly small lymphocytic cells with scattered histiocytes and only rare large cells. 
B: high-grade component in the same lymph node, consisting mainly of large cells that are arranged in 
sheets, indicating transformation to DLBCL. C-D: Ki-67 immunohistochemistry shows low proliferative 
activity in the low-grade component (C), and high proliferative activity in the high-grade component (D).
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IMMUNOPHENOTYPE
NMZL cells express pan B-cell markers including CD20, CD79a, and PAX5. The majority 
of cases is BCL2 positive, although numbers vary from 43 to 100% of cases.1, 163, 181, 193, 197, 199 
Most studies report no expression of BCL6, although one study describes BCL6 staining in 
a proportion of cells or large cells only in 43% of cases.1 CD10 positivity has been reported 
only rarely.199, 212 CD5 and CD23 are usually negative, being reported in 0-17% and 0-29% of 
cases, respectively.1, 163, 193, 197, 199, 213 Although studied in only few patients, the majority of NMZLs 
appears to express MUM1.1, 163, 199 CD43 expression varies between studies from 5-75%.163, 193, 
197, 199 One study detected cyclin D1 expression in 2 out of 24 cases, but only in scattered cells 
and with a lower intensity than in mantle cell lymphoma.197 Other studies showed no cyclin D1 
expression.163, 193, 199, 214 DBA.44 expression has been reported in a subset of NMZLs in small 
studies.163, 215
The germinal center markers HGAL and LMO2 are expressed only very rarely in NMZL; only 
one study reported expression of these markers in 1 of 18 and 1 of 5 cases, respectively.216 A 
larger study showed no expression in 43 cases193, but in this study, cases with expression of 
germinal center markers were excluded from the NMZL group.
Recently, new positive markers for marginal zone cells have been reported that could help 
in the diagnosis of NMZL. Myeloid cell nuclear differentiation antigen (MNDA) is expressed 
by cells of the myelomonocytic lineage, but has also been shown to be expressed by a B-cell 
subset that is located around the germinal center and interfollicular.217 Accordingly, a recent 
study showed frequent MNDA expression in NMZL (in 75%), but only rarely (in 5%) in follicular 
lymphoma (FL).218
In a similar way, immunoglobulin superfamily receptor translocation-associated 1 (IRTA1) was 
shown to be expressed on marginal zone and monocytoid B-cells219 and also subsequently on 
MZLs.220 In the latter study, 73% of NMZLs were IRTA1-positive in contrast to none of 320 FLs.
CYTOGENETICS
Multiple studies have investigated the cytogenetic features of NMZL, using classical 
cytogenetics, comparative genomic hybridization, and fluorescence in-situ hybridization. 
Although numerous cytogenetic abnormalities have been reported, no specific alterations have 
been identified thus far. Figure 2.3 summarises gains and losses of chromosome regions and 
whole chromosomes reported in the literature.1-14 Gains of chromosome 1q, 2p, 3p, 3q, 6p, and 
6q are most frequent, as are losses of 1q and 6q. Chromosomes 3, 12, and 18 most often show 
trisomy. Monosomy is more rarely observed and most frequently involves chromosomes 9, 13, 
and 14.
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Figure 2.3. Overview of cytogenetic abnormalities in NMZL. A: Overview of chromosomal gains (top, in 
green) and losses (bottom, in red). Results for the small arm (p, left) and long arm (q, right) are indicated 
separately. B: Overview of trisomies (top, green) and monosomies (bottom, red). Results represent an 
aggregation of data from multiple studies, comprising 100 patients.1-13 For most patients (n=75), all 
detected karyotypic abnormalities were reported. In one CGH study with 25 patients, only recurrent gains 
(in ≥4 cases) were reported.10 For monosomies and trisomies of chromosomes 3, 7, and 12, an additional 
study of 12 patients has been included.14
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Multiple translocations have been reported in NMZL, but they do not share a common 
breakpoint region. This is in contrast to MALT lymphomas, which frequently have translocations 
involving BIRC3, MALT1, BCL10, and FOXP1. The translocations that have been described in 
NMZL do not include regions harbouring these genes.1, 3-5, 7, 8, 11, 13, 106, 221, 222 Although Dierlamm 
and colleagues did not detect translocations involving BCL6 in NMZL3, 5, 168, the karyotypes of 3 
of 21 patients described by Traverse-Glehen et al. do suggest translocations involving BCL6.1 
MOLECULAR FEATURES
Gene expression studies in NMZL have generated different results. One study of 16 NMZL and 8 
FL cases identified MNDA as a gene that is differentially expressed between FL and NMZL, with 
a rather low ranking of genes that are known to be expressed more often in FL than NMZL (e.g. 
CD10, BCL6).218 Another study of 15 NMZLs and 16 FLs reported a rather homogeneous gene 
expression profile in NMZLs, resembling marginal zone and memory B-cells.223 Compared to 
FL, NMZL showed overexpression of NF-κB-related and -binding genes (TRAF4, CD82), IL-32, 
histones, members of the TNF family (TACI, TNFRSF14), and genes involved in lymphocyte 
activation (TGFB1). FLs showed higher expression of germinal center markers (CD10, BCL6, 
GCET1, LMO2) in comparison to NMZL. This study also examined microRNA profiles; NMZL 
showed increased expression of miR-221, miR-223, and let-7f. In FLs, strong expression of 
miR-494 was observed. Activation of the NF-κB pathway is a known feature of extranodal MZL, 
which is frequently a result of specific translocations or mutations in NF-κB inhibitors. As 
discussed above, recurrent NF-κB activating translocations are not a feature of NMZL, but 
inactivating mutations of TNFAIP3, an inhibitor of the NF-κB pathway, have been shown in 3 
out of 9 cases of NMZL in one study.224 This is an interesting finding with potential diagnostic 
utility, but needs confirmation in larger studies.
 In conclusion, there is variability on the morphological, phenotypical, and molecular 
level, that may be due to variability of the disease itself, or the variability of the criteria used for 
the diagnosis.
DIFFERENTIAL DIAGNOSIS
Reactive conditions
Toxoplasmosis and human immunodeficiency virus (HIV)-associated lymphadenopathy can 
show hyperplasia of monocytoid B-cells. Morphologic differentiation from NMZL can be difficult 
in some cases. Immunohistochemistry can be helpful; normal monocytoid B-cells are BCL2 
negative whereas NMZL cells are usually BCL2 positive.214, 225 In case a final diagnosis cannot 
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be made by morphology and immunohistochemistry, clonality testing can provide important 
additional information.226
Follicular lymphoma
The classical case of FL is easily distinguished from NMZL, but areas of overlap exist. First, 
some FLs grow in a marginal zone pattern resembling NMZL. In addition, NMZLs frequently 
show follicular colonization that can cause resemblance to FL. In follicular colonization, the 
lymph node retains a nodular architecture on low power. The BCL2 positive NMZL cells that 
infiltrate the germinal centers falsely suggest BCL2-positive follicles. The residual follicular 
cells in the background give a false impression of BCL6- and CD10-positivity. Accordingly, an 
erroneous diagnosis of FL is easily made. The key to solving this problem lies in careful review 
at high power which shows BCL2-negative centroblasts and centrocytes that express BCL6 
and CD10, with the truly neoplastic BCL2-positive cells in between (Figure 2.4). Another clue 
for the presence of pre-existent rather than neoplastic germinal centers comes from a high 
proliferative index as shown by immunohistochemistry for Ki-67. 
Figure 2.4. Follicular colonization. A single section was sequentially stained with multiple antibodies, 
allowing assessment of the expression of multiple proteins in the same section. A: A pre-existent germinal 
center is present in the bottom-left corner, which is highlighted by BCL6 staining. B: the germinal center 
cells are BCL2 negative, whereas the infiltrating lymphoma cells are BCL2 positive. C: MNDA expression 
largely overlaps with BCL2 expression, confirming that indeed the lymphoma cells are the BCL2 positive 
cells. D: Ki-67 highlights the pre-existent germinal center similar to the BCL6 stain, indicating that the 
proliferative activity is high in the germinal center cells, but low in lymphoma cells.
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In the majority of cases, demonstration of a translocation involving BCL2 will help in diagnosing 
FL, but approximately 10% of FLs do not have this translocation. At present there are no good 
criteria by which t(14;18) negative follicular lymphoma can be separated from NMZL with 
complete follicular colonization. Therefore, in some cases, a definitive diagnosis cannot be 
made. New immunohistochemical markers could further reduce this ambiguous group (also 
discussed under ‘immunophenotype’). LMO2 and HGAL are germinal center markers that are 
frequently positive in FL. MNDA and IRTA have recently been identified as markers of MZL, 
although both have only been reported in single studies (see above). With flow cytometry, the 
junctional adhesion molecule C (JAM-C) has been shown to be expressed in the large majority 
of MZLs, but not in FLs. This is a potentially interesting finding, although it needs confirmation 
in larger studies with specification of the specific subtypes of MZL.227
Extranodal marginal zone lymphoma
By definition, the distinction of NMZL from lymph node involvement by EMZL must be made 
by a thorough clinical search for extranodal disease (Figure 2.5A-B). However, some features 
suggest a primary extranodal lymphoma. Pure monocytoid morphology is more typical of MALT 
lymphoma than NMZL. In addition, EMZL frequently have specific translocations involving 
BCL10 and MALT1, which have not been reported in NMZL. 
Splenic MZL (SMZL) only rarely presents with lymphadenopathy. It virtually always infiltrates 
the bone marrow with a characteristic intertrabecular and intrasinusoidal pattern, which is not 
typical of NMZL (Figure 2.5C-D). IgD negativity is an argument against SMZL. Approximately 
40% of splenic MZLs have a loss of chromosome 7q, which is present in less than 5% of NMZLs.
Lymphoplasmacytic lymphoma
NMZL and lymphoplasmacytic lymphoma (LPL) are both low-grade B-cell lymphomas with 
a morphology ranging from lymphocytes to plasma cells, making distinction between these 
entities problematic in some cases. Again, it is important to take clinical features into 
account; LPL generally presents in the bone marrow with hyperviscosity (Waldenströms 
macroglobulinemia), whereas NMZL generally present with lymphadenopathy. However, 
especially in lymph nodes, differentiation can be difficult or impossible. Arguments in favor of 
NMZL include monocytoid cellular morphology, a marginal zone growth pattern, and follicular 
colonization. LPL classically shows (partial) retention of the architecture with dilated sinuses, 
although other patterns frequently occur. We feel that the use of three diagnostic categories 
(i.e. NMZL, LPL, and ambiguous: low-grade B-cell lymphoma with plasmacytic differentiation) 
is a sensible approach to this diagnostic problem. The recent discovery of L265P hotspot 
mutations in MYD88 in the large majority of LPLs but not in MZLs is of great potential use 
for the differential diagnosis between LPL and NMZL.228 This is illustrated by a case we had 
classified as NMZL but was shown to carry a L265P mutation in MYD88. Subsequent evaluation 
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indeed revealed clinical features of Waldenströms macroglobulinemia which led to a diagnosis 
of LPL rather than NMZL.
Figure 2.5. Extranodal and splenic marginal zone lymphoma. A and B: extranodal marginal zone 
lymphoma of the parotid gland, showing the typical lymphoepithelial lesions; hematoxylin and eosin stain 
shows infiltration and destruction of glandular epithelium (A), which is highlighted by immunohistochemical 
staining of lymphoma cells with anti-CD20 (B). C and D: bone marrow involvement of splenic marginal zone 
lymphoma. Hematoxylin and eosin stain shows scattered strands of lymphoid cells in a background of pre-
existent haematopoiesis (C). The typical sinusoidal pattern of infiltration is highlighted by CD20 staining 
(D), which shows strands of lymphoid cells with a somewhat rounded contour.
Other B-cell lymphomas
Mantle cell lymphoma sometimes resembles NMZL morphologically. It can be reliably 
distinguished from NMZL by its positivity for CD5 and cyclin D1 and the presence of a CCND1 
translocation. Similarly, chronic lymphocytic leukemia differs from NMZL by its expression of 
CD5 and CD23.
NMZL frequently contains significant numbers of centroblasts, which can cause confusion with 
diffuse large B-cell lymphoma (DLBCL). A clear boundary between NMZL and DLBCL has not 
been established. In our own practice, we only diagnose transformation to DLBCL if sheets of 
blasts are present without interspersed smaller tumor cells.
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PEDIATRIC NODAL MARGINAL ZONE LYMPHOMA
In 2003, Taddese-Heath and colleagues recognized a pediatric subtype of NMZL.229 Characteristic 
features were a striking male predominance and an indolent disease course. In contrast to 
NMZL in adults, pediatric NMZLs presented with only localized disease, corresponding with an 
excellent prognosis. Of note, ‘pediatric NMZL’ might also occur in (young) adults; patients with 
an age up to 44 years have been reported.230  Histologically, pediatric NMZL was frequently 
associated with progressively transformed germinal center-like changes (in 66%), which is 
not a feature of adult NMZL. Cytogenetic abnormalities that characterize adult EMZL have 
only been rarely observed in pediatric MZL, with trisomy 18 and trisomy 3 as the most frequent 
aberrations.231 There are no data regarding the expression of IRTA1 and MNDA. Based on these 
features it seems relevant to keep the pediatric lesions separate from adult NMZL and to try to 
find markers for both.
TREATMENT AND PROGNOSIS
There is currently no consensus on how to treat NMZL patients. Usually, guidelines for follicular 
lymphoma or chronic lymphocytic leukemia/ small lymphocytic lymphoma are adopted.232 
Different studies have reported different (combinations of) treatments, including watchful 
waiting, surgery, radiotherapy, different chemotherapeutic regimens, rituximab, and autologous 
stem cell transplantation.1, 29, 160, 163-167 However, no optimal treatment strategy can be deduced 
from these studies. Complete response is achieved in 55-74% of patients.1, 29, 160, 164-166 
A phase 2 study in 26 patients with marginal zone lymphomas, mostly NMZLs, illustrated that 
treatment regimens in other low-grade B-cell lymphomas cannot be simply applied to MZL.233 
Although treatment with fludarabine and rituximab was highly effective, it came with significant 
toxicity that had not been observed in other lymphoma types to that extent. 
Five-year overall survival rates range from 64-89%.1, 29, 162, 164-167 The FLIPI (Follicular Lymphoma 
International Prognostic Index) has been reported to predict overall survival29 and progression-
free survival164 for patients with NMZL, but this could not be confirmed for the NMZL subgroup 
in a recent study with 32 NMZL patients.167 Age, the presence of B-symptoms, Ann Arbor stage, 
anemia, performance score, sex, race, and chemotherapy were associated with progression-
free survival or event-free survival in multivariate analyses.29, 162, 164
It is clear that better understanding of this lymphoma type is needed in order to select these 
patients for newer, targeted therapies and to improve outcome.
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CONCLUSIONS AND RECOMMENDATIONS
NMZL remains an enigmatic entity with accompanying difficulties in diagnosis and lack of 
knowledge on prognosis and treatment. Because of its rarity, it is hard to obtain large study 
groups. Also, because NMZL is frequently a diagnosis of exclusion, the series that have been 
studied might contain a somewhat heterogeneous group of low-grade B-cell lymphomas. 
Nevertheless, progress is being made; recent studies have identified positive markers for MZL 
(i.e. MNDA and IRTA1) and gene expression studies have identified a specific gene expression 
profile that separates NMZL from other lymphoma types. 
 In routine practice the diagnosis of NMZL can be established based on the criteria 
described above and by excluding other lymphoma entities. As we have indicated, this likely 
results in misdiagnosis in some cases which is probably not a large problem since prognosis 
and treatment are quite similar. However, as more and more targeted treatments are becoming 
available, better knowledge of the pathogenesis of NMZL will be necessary to determine which 
targeted pharmaceuticals will be of benefit to patients suffering from NMZL.
 For the further understanding of this disease, series that are being investigated for 
pathological criteria and clinical features will need very rigorous exclusion of cases, including 
molecular testing and inclusion of complete clinical data. By doing that the group of cases in a 
study may become rather small, but the chance to find relevant new data will increase.
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A subset of low-grade B-cell lymphomas 
with a follicular growth pattern but without 
a BCL2 translocation shows features 
suggestive of nodal marginal zone lymphoma
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ABSTRACT
Background and aims
In our consultation practice, it was noted that many cases that were considered to represent 
follicular lymphoma (FL) without a BCL2 translocation, were ultimately classified as nodal 
marginal zone lymphoma (NMZL). This study set out to define recurrent morphological features 
of these cases.
Methods
Thirty-three low-grade B-cell lymphomas without a BCL2 rearrangement were studied for 
recurrent morphological features. These features were then applied on 20 randomly selected 
cases to verify if these criteria are able to distinguish between lymphomas with and without 
a BCL2 rearrangement, assigning them to one of five categories ranging from ‘certain FL’ to 
‘certain NMZL’.
Results and discussion
Highly recurrent morphological features were noted in the lymphomas without a BCL2 
rearrangement, which were strongly overlapping with the morphological features of NMZL.  All 
six cases that were assigned to the category of certainly FL or most likely FL indeed harbored 
a BCL2 rearrangement, whereas all twelve cases assigned to the category of most likely NMZL 
or certain NMZL had no BCL2 break. Of the two cases in the ambiguous category, one had 
received a final diagnosis of FL and the other of NMZL.
Conclusion
This study raises the hypothesis that a subset of low-grade B-cell lymphomas with a follicular 
growth pattern but without a BCL2 translocation actually represents NMZL. This is at present 
difficult to prove, because no gold standard is available to differentiate between NMZL and FL 
without a BCL2 rearrangement, so further investigations are needed.
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INTRODUCTION
Follicular lymphoma (FL) is a low-grade B-cell lymphoma that has a translocation involving BCL2 
in up to 90% of cases, resulting in BCL2 upregulation. It usually has a follicular growth pattern 
with expression of germinal center markers (e.g. CD10 and BCL6). In most cases, a diagnosis 
of FL is rather straightforward and can be made by morphology and immunohistochemistry 
alone. However, in the absence of characteristic morphology, typical immunophenotype, or 
in the absence of a BCL2 translocation, the diagnosis becomes more difficult. An important 
difficulty results from the morphological and immunohistochemical  overlap between FL and 
nodal marginal zone lymphoma (NMZL) with a nodular/follicular growth pattern. NMZL is 
currently defined as “a primary nodal B-cell neoplasm that morphologically resembles lymph 
nodes involved by MZL of extranodal or splenic types, but without evidence of extranodal or 
splenic disease”.234 The main problem is the lack of positive markers for NMZL, in fact making 
this a diagnosis of exclusion. Previous case reports and small studies indicate that NMZL 
may easily be misdiagnosed, especially when there is extensive follicular colonization.199, 235, 236 
The follicles that are colonized result in a nodular architecture with partial positivity for CD10 
and BCL6 due to the pre-existent germinal center cells that are in the same compartment 
as the tumor cells and acquisition of BCL6 expression by the colonizing neoplastic cells. The 
colonizing NMZL cells are usually BCL2 positive which causes the suggestion of BCL2-positive 
follicles.
 In routine diagnostic practice, it was noted that lymphomas that lack a BCL2 
translocation, but display BCL2-positive follicles at low power, were often considered to 
represent FL. However, careful study of BCL2 at high power in these cases often showed 
negative cells  as a sign of follicular colonization, suggesting a diagnosis of NMZL rather than 
FL. In this study, we set out to substantiate the hypothesis that a subset of lymphomas that 
are initially classified as FL without BCL2 translocation (translocation negative FL), actually 
represent NMZL.
MATERIAL AND METHODS
Case selection
Fifty-six primary nodal B-cell lymphomas, both from in-house patients (n=21) and consultation 
cases (n=35), were retrieved from the archive of the Department of Pathology of the Radboud 
university medical center (Nijmegen, the Netherlands). These were selected based on the fact 
that they had been tested for a BCL2 translocation by fluorescence in-situ hybridization (FISH) 
between 2004 and 2010. During this period, FISH was used in diagnostic practice in all cases 
with a differential diagnostic consideration of FL and NMZL. 
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Three cases that had originally been classified as NMZL were excluded because they were 
considered by the study group to represent chronic lymphocytic leukemia, diffuse large B-cell 
lymphoma, and follicular lymphoma grade 3B, respectively. The study group therefore consisted 
of 53 cases, 33 without a BCL2 rearrangement and 20 with a BCL2 rearrangement.
Immunohistochemistry
Immunohistochemistry was performed in routine diagnostic practice according to standard 
laboratory procedures. Briefly, 4 µm sections were cut from formalin-fixed paraffin-embedded 
(FFPE) tissue, dried, deparaffinized, rehydrated, and subjected to heat-mediated antigen 
retrieval. Specific retrieval procedures for each antigen are indicated in table 3.1. Subsequently, 
endogenous peroxidase was blocked after which the primary antibody (Table 3.1) was applied 
for 1 hour at room temperature (RT). The secondary antibody (Powervision poly-HRP-anti MS/
Rb/Rt, Immunologic, Klinipath, Duiven, the Netherlands) was then applied for 30 min at RT 
after which visualization was performed using bright 3,3’-diaminobenzidine. Hematoxylin was 
used as a nuclear counterstain.
Table 3.1  Overview of antibodies
Antigen Manufacturer Dilution Retrieval
BCL2 Dako (clone 124) 1:160 Citrate pH 6.0, 10 min 96°C
BCL6 Novocastra (Clone LN22) 1:40 Citrate pH 6.0, pressure cooker
CD5 Menarini (Clone 4C7) 1:80 Citrate pH 6.0, 10 min 96°C
CD10 Monosan (Clone 56C6) 1:20 Citrate pH 6.7, 30 min 100°C
CD20 Thermo Scientific (Clone L26) 1:300 Citrate pH 6.0, pressure cooker
CD23 Thermo Scientific (Clone 1B12) 1:10 Citrate pH 6.0, 10 min 96°C
CD79a Dako (Clone JCB117) 1:400 Citrate pH 6.7, 30 min 100°C
Cyclin D1 Immunologic (Clone SP4) 1:80 Citrate pH 6.7, 30 min 100°C
Ki-67 Dako (Clone MIB1) 1:200 Citrate pH 6.0, 10 min 96°C
Fluorescence in-situ hybridization
FISH was performed on 4 µm sections from FFPE tissue that were dried, deparaffinized, 
rehydrated, and heated for 10 min in sodium citrate (pH 6.0). Slides were rinsed in 0.01 M 
hydrochloric acid before 15 minutes of pepsin digestion. After three rinses of 0.01 M hydrochloric 
acid and 5 minutes of fixation in 1% formaldehyde in PBS, sections were dehydrated and 
dried after which the probe was added (BCL2 DNA probe, Dako, Y5407, Glostrup, Denmark; 
BCL6 DNA probe, Dako, Y5408, Glostrup Denmark). After 5 minutes of denaturation at 82°C, 
hybridization was performed overnight at 45°C in a Dako S2451 hybridizer (Dako). Sections were 
then dehydrated, dried, and mounted using medium containing DAPI as a nuclear counterstain 
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(Vectashield, Vector Laboratories, Burlingame, CA). Stained sections were assessed with a 
Leica DM 4000B fluorescence microscope.
For BCL2 FISH, all cases were evaluated and documented by the technician (PvC), with 
subsequent confirmation by one of the hematopathologists (KH, JvK). FISH for BCL6 was 
scored by a single observer (MvdB). Split signals in 20% of cells or more was regarded as 
positive, although in most positive cases, the amount of positive cells was far above 20%.
Morphological evaluation
Based on cases lacking a BCL2 translocation, firstly (immuno)morphological criteria were set 
for the diagnosis of NMZL (see below) (JVK, OB).
Subsequently, these criteria were applied on 20 of the 53 cases (including 7 cases with and 
13 without BCL2 translocation) by 4 hematopathologists (JvK, OB, DdJ, KH) at a multi-headed 
microscope with all histochemical and immunohistochemical stainings, but without clinical 
information or knowledge of BCL2 translocation status. These cases were scored on a 5 point 
scale: certainly FL (1), most likely FL (2), ambiguous (3), most likely NMZL (4), or certainly 
NMZL (5). 
RESULTS AND DISCUSSION
This study followed on the recognition that in consultation practice, lymphomas that lack a BCL2 
translocation, but display BCL2-positive follicles at low power, may easily be misdiagnosed as 
FL. However, after careful evaluation of H&E morphology and BCL2 immunohistochemical 
staining at high power, NMZL could be recognized. From this observation, we hypothesized 
that a subset of lymphomas that are initially classified as translocation negative FL, are actually 
better classified as NMZL. 
To investigate this, 53 low-grade B-cell lymphomas in the spectrum of the differential diagnosis 
of FL and NMZL were selected. Of these, 20 did show a BCL2 rearrangement with a FISH 
split probe and were classified as FL. Thirty-three cases did not show a BCL2 rearrangement. 
Table 3.2 shows the diagnoses that were made at the time the biopsy was taken and the 
final diagnosis, which was established during this study, for all lymphomas lacking a BCL2 
translocation. 
In a first effort, the morphological features in the translocation negative group were evaluated. 
The following features were observed to be highly recurrent  (Figure 3.1): 1) effaced architecture 
of the lymph node by a small B-cell proliferation with a follicular, marginal zone, or diffuse growth 
pattern. 2) centrocytic or ‘CLL-like’ small cell morphology with intermingled centroblasts. 
3) an immunophenotype  of a mature B-cell (CD20 and CD79a positive) with BCL2 positivity 
and lacking expression of cyclin D1 and CD5. 4) The cases with a follicular/ nodular growth 
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pattern showed follicular colonization; the presence of both neoplastic and reactive cells in a 
follicle. For the assessment of follicular colonization, BCL2 and Ki67 immunohistochemistry 
were carefully evaluated. For BCL2, positive cells (the colonizing lymphoma cells) could be 
recognized among negative cells (the pre-existent cells) at high power. For Ki67, clusters 
of highly proliferative cells characterized follicles being colonized whereas truly neoplastic 
follicles were characterized by a relatively low proliferative index.
Expression of CD10 in the BCL2 positive cells was observed only rarely (in 5 out of 21 cases), 
with mostly weak staining. In 3 out of 16 cases, weak BCL6 expression was observed in BCL2 
positive cells.
Table 3.2 Diagnosis of cases without a bcl2 break
Referring center diagnosis Referral center diagnosis Final diagnosis within this study n
Primary cases (n=13)
NMZL NMZL 9
FL NMZL 4
Referral cases (n=20)
NMZL NMZL NMZL 1
FL NMZL NMZL 7
FL FL NMZL 2
FL/NMZL NMZL NMZL 2
Low-grade B NMZL NMZL 3
Low-grade B FL NMZL 2
reactive NMZL NMZL 1
reactive FL 3B NMZL 1
CLL/SLL NMZL NMZL 1
NMZL, nodal marginal zone lymphoma; CLL/SLL, chronic lymphocytic leukemia/ small lymphocytic 
lymphoma; FL, follicular lymphoma grade 1-2; Low-grade B, low-grade B-cell lymphoma; FL 3B, follicular 
lymphoma grade 3B.
The strong overlap between the morphological features in lymphomas lacking BCL2 
rearrangements in this series and the morphological features of NMZL is in line with our 
hypothesis that a subset of lymphomas that are initially classified as translocation negative FL, 
actually have features of NMZL.
To verify if the criteria defined above were able to recognize lymphomas without a BCL2 
rearrangement, they were applied to 20 cases that were selected randomly from the total of 53 
cases. These 20 cases were reviewed without knowledge of clinical features or the presence of 
a BCL2 translocation and assigned to one of five categories ranging from ‘certain FL’ to ‘certain 
NMZL’, as indicated in table 3.3. All six cases that were assigned to the category of certainly FL 
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Figure 3.1. Morphological features of cases without BCL2 translocation. A-F: lymph node showing 
completely effaced architecture with a nodular appearance on low power (A). On medium power (B), residual 
follicles are seen which are BCL2 negative (C) and show a high proliferative index (D). CD10 (E) is expressed 
in the residual follicles, but also in the surrounding neoplastic cells. BCL2 staining shows blasts without 
BCL2 expression at high power (F). This case was classified as ‘certainly NMZL’ based on morphological 
features. G-J: another lymphoma with nodular architecture on high power (G). BCL2 immunohistochemistry 
shows poorly defined areas with BCL2 negative cells (H). In these areas, a high proliferative index is present, 
indicated by frequent Ki-67 positive cells (I). BCL6 shows diffuse positivity with heterogeneous intensity (J). 
This case was classified as ‘most likely NMZL’ based on morphological features.
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or most likely FL indeed harbored a BCL2 rearrangement, whereas all twelve cases assigned 
to the category of most likely NMZL or certain NMZL had no BCL2 break. Of the two cases in 
the ambiguous category, one had received a final diagnosis of FL and the other of NMZL.
Table 3.3  Application of nmzl criteria
Morphological score n BCL2 break
n 
Final diagnosis
n (%)
1: certainly FL 1 1 FL
NMZL
1 
0 
2: most likely FL 5 5 FL
NMZL 
5 
0
3: ambiguous 2 1 FL
NMZL 
1 
1 
4: most likely NMZL 2 0 FL
NMZL
0 
2 
5: certainly NMZL 10 0 FL
NMZL
0 
10 
FL, follicular lymphoma; NMZL, nodal marginal zone lymphoma.
As indicated in table 3.2, many cases (42%) that received a final diagnosis of NMZL in this 
study were at some point considered to be FL. Only one BCL2 translocation negative case 
was ultimately classified as follicular lymphoma. Because the morphological criteria for the 
absence of a BCL2 rearrangement showed strong overlap with the morphological criteria for 
NMZL, and because the large majority of lymphomas without a BCL2 rearrangement were 
ultimately diagnosed as NMZL, these results suggest that a subset of lymphomas that are 
classified as translocation negative FL are actually NMZLs. Although the results are suggestive, 
establishing a final proof for this hypothesis is currently very difficult if not impossible, 
because specific criteria for NMZL are lacking. The fact that some lymphomas without a BCL2 
rearrangement showed expression of the germinal center markers CD10 and/ or BCL6 is an 
argument in favor of a diagnosis of FL. However, the morphological features outlined above 
that were present in these lymphomas argue against this. Also, expression of CD10 and BCL6 
has been reported in NMZL.1, 199, 212 In our series, CD10 was positive in the BCL2 positive 
cells in 5 out of 21 (24%) cases, with mostly weak staining. BCL6 showed weak staining in the 
BCL2 positive cells in 3 out of 16 (19%) cases. The most important feature to be recognized in 
this setting is follicular colonization. We determined the presence of follicular colonization by 
combining BCL2 and Ki67 staining. Although colonized follicles seemed to be BCL2-positive 
on low power examination, at high power both BCL2-positive (the colonizing lymphoma cells) 
and BCL2-negative (the pre-existent cells) cells were recognized. A high proliferative index, as 
indicated by a high proportion of Ki67 positive cells also characterized follicles being colonized 
whereas truly neoplastic follicles were characterized by a relatively low proliferative index. 
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Finally, in many cases of FL the BCL2 expression is stronger than that of remaining mantle 
zone B-cells and T-cells.
FLs without a BCL2 rearrangement might have a rearrangement involving BCL6. We studied 
22 of the cases without a BCL2 rearrangement for the presence of a rearrangement involving 
BCL6, using a dual-color break-apart probe locating to BCL6. In 5 out of 22 cases (23%), a 
rearrangement of BCL6 was identified. Of these 5 cases with a BCL6 rearrangement, one was 
weakly positive for CD10, one was positive for CD10 and weakly positive for BCL6, one was 
weakly positive for BCL6, and two were negative for both CD10 and BCL6. In summary, 3 out 
of 5 (60%) cases with a BCL6 rearrangement showed expression either CD10 or BCL6 versus 
2 out of 12 (17%) cases without a BCL6 rearrangement. Although these results suggest some 
enrichment for germinal center marker expression in cases with a BCL6 rearrangement, the 
difference between these groups was not statistically significant (p = 0.117 with Fishers exact 
test). This finding is of potential interest, but a definitive conclusion would require the study of 
additional cases.
Cases were included in this study when they had been tested for a BCL2 translocation with FISH. 
In general, BCL2 FISH is not performed on cases that are considered to be straightforward 
FL by morphology and immunohistochemistry, resulting in a bias toward atypical cases in 
our study. This also means that the group of ‘straightforward’ FLs, that was not included in 
this study, might contain BCL2 translocation negative cases, and we therefore cannot make 
any conclusions on the frequency of BCL2 translocation negative FL. However, our study does 
suggest that a proportion of lymphomas regarded as BCL2 translocation negative FL are in fact 
NMZLs. Because NMZL is often a diagnosis of exclusion this suggestion is currently hard to 
prove. However, previous studies suggest that BCL2 translocation negative FLs are genetically 
different from FLs with a BCL2 translocation and have at least some features of NMZL. One 
study reported specific features of MUM1-positive and CD10-negative follicular lymphomas, 
including a frequent lack of BCL2 translocations.236 The combination of CD10-negativity and 
MUM1-positivity, both features of NMZL, and the lack of BCL2 translocations, suggests that 
this series might very well include NMZLs. A comparative genomic hybridization and gene 
expression study in BCL2 translocation negative FLs demonstrated less frequent expression 
of CD10 and enriched NF-κB signatures, both features of NMZL.237 This suggests that (some 
of) these cases really are NMZLs, although the authors raise arguments against this, including 
strong BCL6 expression in all cases. We have however convincing data that NMZL cells can 
acquire BCL6 expression upon entering the follicular dendritic cell environment (manuscript 
in preparation). In a more recent comparative genomic hybridization study, translocation 
negative FL showed aberrations that clustered more with NMZL than with FL with a BCL2 
translocation.238
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To finally resolve these issues, a positive marker for NMZL is highly needed. In addition to 
proposed new immunohistochemical markers for NMZL220, 239, 240, better insight into its 
pathogenesis is essential for its proper classification. Here, a complicating factor is the fact 
that NMZL is often a diagnosis of exclusion, and therefore we cannot be sure that it represents 
a single entity. This possible heterogeneity might also be an impediment for studies into the 
pathogenesis of NMZL.
 In conclusion, we have established immunomorphological characteristics of a group 
of low-grade B-cell lymphomas that lacked a BCL2 translocation. These criteria largely 
overlapped with the features of NMZL and we propose that a subset of lymphomas that is 
currently often classified as FL without a BCL2 translocation is actually better classified as 
NMZL.
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Clinical features of patients with nodal 
marginal zone lymphoma compared to 
follicular lymphoma: similar presentation, 
but differences in prognostic factors and rate 
of transformation
62
CHAPTER 4
ABSTRACT
Nodal marginal zone lymphoma (NMZL) is a rare type of B-cell non-Hodgkin lymphoma. This 
study assessed the clinical features of fifty-six patients with NMZL in comparison to forty-
six patients with follicular lymphoma (FL). Patients with NMZL and FL had a largely similar 
clinical presentation, but patients with FL had a higher disease stage at presentation, more 
frequent abdominal lymphadenopathy and bone marrow involvement, and showed more 
common transformation into diffuse large B-cell lymphoma (DLBCL) during the course of 
disease. Overall survival and event-free survival were similar for patients with NMZL and FL, 
but factors associated with worse prognosis differed between the two groups. Transformation 
into diffuse large B-cell lymphoma was associated with a significantly poorer outcome in both 
groups, but the phenotypes were different: DLBCL arising in FL was mainly of germinal center 
B-cell phenotype whereas DLBCL arising in NMZL was mainly of non-germinal center B-cell 
phenotype.
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INTRODUCTION
Nodal marginal zone lymphoma (NMZL) is a rare type of B-cell lymphoma, accounting for 1.5-
1.8% of all B-cell lymphomas, although its incidence appears to be increasing 160, 161, 241. It is 
defined as a primary nodal B-cell lymphoma that is characterized by enlarged lymph nodes with 
a morphological appearance similar to that encountered in extranodal and splenic subtypes of 
marginal zone lymphoma. By definition, there is no evidence of extranodal or splenic disease 
19. This means that a diagnosis of NMZL can only be made with sufficient clinical information 
on the localization of the disease.
NMZL is often difficult to diagnose, because it has no specific clinical, morphological, 
immunophenotypic, cytogenetic, or molecular features 242. As a result, NMZL is often a diagnosis 
of exclusion. Accordingly, differentiating NMZL from other low-grade B-cell lymphomas can be 
very difficult. In particular, distinguishing between NMZL and follicular lymphoma (FL) can be 
difficult, especially for FLs that lack a rearrangement of the BCL2 gene. 
Due to its low incidence and problems with the diagnosis, information on the clinical features 
of NMZL is limited. Also, differences in clinical features between NMZL and other nodal B-cell 
neoplasms have not been documented well. This study describes the clinical features of 56 
patients with NMZL in comparison to 46 patients with FL. 
MATERIALS AND METHODS
Sixty-one NMZL patients were selected from the archives of the Department of Pathology of 
the Radboud university medical center, Nijmegen, the Netherlands. Primary diagnoses had 
been made between November 1996 and April 2011. All cases were reviewed and a histological 
diagnosis was made in accordance to the 2008 WHO classification 19. The following morphological 
diagnostic criteria were used: 1) effaced architecture of the lymph node, due to a small B-cell 
proliferation with a follicular, marginal zone, or diffuse growth pattern, 2) either centrocytoid or 
more round cells with intermingled centroblasts, 3) a mature B-cell immunophenotype (CD20 
and CD79a expression) with BCL2 positivity, 4) those cases with a follicular/ nodular growth 
pattern showed follicular colonization, 5) not fitting a diagnosis of mantle cell lymphoma or 
small lymphocytic lymphoma. Four patients had concurrent diffuse large B-cell lymphoma 
at the time of diagnosis, which was defined as the presence of sheets of blasts. Five patients 
had to be excluded upon review because of an alternative primary diagnosis (n=3), splenic 
localization (n=1), or incomplete histopathological data (n=1). From the resulting 56 patients, 
we were able to study the clinical records of 46 patients. For comparison, 46 FLs that had been 
shown to have a BCL2 rearrangement were selected from the same 
64
CHAPTER 4
Ta
bl
e 
4.
1 
C
lin
ic
al
 c
ha
ra
ct
er
is
tic
s 
of
 n
m
zl
A
ll
 N
M
ZL
 p
at
ie
nt
s
N
M
ZL
 (n
o 
D
LB
C
L)
N
M
ZL
 +
 c
on
cu
rr
en
t D
LB
C
La
n
56
52
4
M
:F
30
:2
6
27
:2
5
3:
1
A
ge
 (r
an
ge
)
M
ed
ia
n 
59
 y
ea
rs
 (2
1-
87
)
M
ed
ia
n 
59
 y
ea
rs
 (2
1-
87
)
M
ed
ia
n 
53
 y
ea
rs
 (4
5-
62
)
St
ag
e 
at
 p
re
se
nt
at
io
n 
(n
)
   
 I
   
 II
   
 II
I
   
 IV
   
 U
nk
no
w
n
14
 
7 9 16
 
10
 
(2
5%
)
(1
3%
)
(1
6%
)
(2
9%
)
(1
8%
)
13
 
6 9 14
 
10
 
(2
5%
)
(1
2%
)
(1
7%
)
(2
7%
)
(1
9%
)
1 1 0 2 0 
(2
5%
)
(2
5%
)
(0
%
)
(5
0%
)
(0
%
)
A
nn
 A
rb
or
 s
ta
ge
 II
I o
r 
IV
25
/4
7
(5
3%
)
23
/4
3 
(5
4%
)
2/
4 
(5
0%
)
EC
O
G
 s
co
re
 (n
)
   
 0
   
 1
   
 2
   
 3
   
 4
   
 U
nk
no
w
n
19
 
16
 
3 1 0 17
 
(3
4%
)
(2
9%
)
(5
%
)
(2
%
)
(0
%
)
(3
0%
)
17
 
14
 
3 1 0 17
 
(3
3%
)
(2
7%
)
(6
%
)
(2
%
)
(0
%
)
(3
3%
)
2 2 0 0 0 0 
(5
0%
)
(5
0%
)
(0
%
)
(0
%
)
(0
%
)
(0
%
)
FL
IP
I c
at
eg
or
y
   
 L
ow
   
 In
te
rm
ed
ia
te
   
 H
ig
h
   
 U
nk
no
w
n
19
 
8 9 20
 
(3
4%
)
(1
4%
)
(1
6%
)
(3
6%
)
17
 
8 7 20
 
(3
3%
)
(1
5%
)
(1
4%
)
(3
9%
)
2 0 2 0 
(5
0%
)
(0
%
)
(5
0%
)
(0
%
)
P
er
ip
he
ra
l l
ym
ph
ad
en
op
at
hy
 (n
)
37
/4
6 
(8
0%
)
34
/4
2 
(8
1%
)
3/
4 
(7
5%
)
C
er
vi
ca
l l
ym
ph
ad
en
op
at
hy
 (n
)
22
/4
4 
(5
0%
)
19
/4
0 
(4
8%
)
3/
4 
(7
5%
)
A
bd
om
in
al
 ly
m
ph
ad
en
op
at
hy
 (n
)
23
/4
4 
(5
2%
)
20
/4
0 
(5
0%
)
3/
4 
(7
5%
)
M
ed
ia
st
in
al
 ly
m
ph
ad
en
op
at
hy
 (n
)
15
/4
4 
(3
4%
)
13
/4
0 
(3
3%
)
2/
4 
(5
0%
)
65
CLINICAL FEATURES OF NMZL VS. FL
C
ha
pt
er
 4
B
-s
ym
pt
om
s 
(n
)
5/
44
 
(1
1%
)
4/
40
 
(1
0%
)
1/
4 
(2
5%
)
B
on
e 
m
ar
ro
w
 in
vo
lv
em
en
t (
n)
15
/4
3 
(3
5%
)
13
/3
9 
(3
3%
)
2/
4
(5
0%
)
B
ul
ky
 tu
m
ou
r 
(t
um
ou
r 
m
as
s 
≥ 
5 
cm
) (
n)
3/
44
 
(7
%
)
3/
40
 
(8
%
)
0/
4 
(0
%
)
A
ne
m
ia
 (H
em
og
lo
bi
n 
< 
12
0g
/l
) (
n)
8/
41
 
(2
0%
)
7/
37
 
(1
9%
)
1/
4 
(2
5%
)
LD
H
 >
 n
or
m
al
 (n
)
12
/4
1 
(2
9%
)
10
/3
7 
(2
7%
)
2/
4 
(5
0%
)
M
-p
ro
te
in
 (n
)
4/
30
 
(1
3%
)
4/
27
 
(1
5%
)
0/
3 
(0
%
)
Tr
an
sf
or
m
at
io
n 
to
 D
LB
C
L 
at
 d
ia
gn
os
is
4/
56
 
(7
%
)
0/
52
 
(0
%
)
4/
4 
(1
00
%
)
Tr
an
sf
or
m
at
io
n 
to
 D
LB
C
L 
at
 a
ny
 ti
m
e
9/
56
 
(1
6%
)
5/
52
 
(1
0%
)
4/
4 
(1
00
%
)
M
ed
ia
n 
ti
m
e 
to
 tr
an
sf
or
m
at
io
n 
(r
an
ge
) i
n 
m
on
th
s
7 
(0
-1
68
)
28
 
(7
-1
68
)
0 
(0
-0
)
P
ri
m
ar
y 
tr
ea
tm
en
t
   
 W
ai
t a
nd
 s
ee
   
 C
he
m
ot
he
ra
py
   
 R
-c
he
m
ot
he
ra
py
   
 R
ad
io
th
er
ap
y
   
 S
ur
ge
ry
   
 O
th
er
   
 U
nk
no
w
n
12
 
5 13
 
12
 
1 1 12
 
(2
1%
)
(9
%
)
(2
3%
)
(2
1%
)
(2
%
)
(2
%
)
(2
1%
)
12
 
4 11
 
11
 
1 1 12
 
(2
3%
)
(8
%
)
(2
1%
)
(2
1%
)
(2
%
)
(2
%
)
(2
3%
)
0 1 2 1 0 0 0 
(0
%
)
(2
5%
)
(5
0%
)
(2
5%
)
(0
%
)
(0
%
)
(0
%
)
Tr
ea
tm
en
t a
t a
ny
 ti
m
e
   
 C
he
m
ot
he
ra
py
 +
/-
 r
it
ux
im
ab
   
 R
ad
io
th
er
ap
y
28
/4
4 
16
/4
4 
(6
4%
)
(3
6%
)
24
/4
0 
15
/4
0 
(6
0%
)
(3
8%
)
4/
4 
1/
4 
(1
00
%
)
(2
5%
)
Ab
br
ev
ia
tio
ns
: 
D
LB
C
L:
 d
iff
us
e 
la
rg
e 
B
-c
el
l 
ly
m
ph
om
a 
EC
O
G
: 
Ea
st
er
n 
C
oo
pe
ra
tiv
e 
O
nc
ol
og
y 
G
ro
up
; 
F:
 f
em
al
e;
 F
LI
P
I: 
fo
lli
cu
la
r 
ly
m
ph
om
a 
in
te
rn
at
io
na
l 
pr
og
no
st
ic
 in
de
x;
 L
D
H
: l
ac
ta
te
 d
eh
yd
ro
ge
na
se
; M
: m
al
e;
 N
M
ZL
: n
od
al
 m
ar
gi
na
l z
on
e 
ly
m
ph
om
a.
66
CHAPTER 4
archive. For FLs, primary diagnoses had been made between November 1991 and April 2011. 
Twenty-eight of the FLs were grade 1-2, and 18 were grade 3A. Three patients presented with 
FL and concurrent DLBCL.
Data were obtained from patient files using a standardized data input form. The clinical 
features that were collected are indicated in Table 4.1. In addition, the occurrence of adverse 
events (disease progression, relapse, second tumor, death from any cause), transformation to 
DLBCL, death, and cause of death were recorded. Overall survival was defined as the time from 
date of diagnosis until the time of last follow-up or death. Event-free survival was defined as 
the time from date of diagnosis until the time of last follow-up or an adverse event.
Immunohistochemistry was used to distinguish DLBCL phenotypic subtypes, using antibodies 
against FOXP1, CD10, and BCL6. Patients were assigned to the GCB-DLBCL or non-GCB-
DLBCL group according to the cut-off values and algorithm proposed by Visco and colleagues 
243. Immunohistochemistry is described in more detail in the Supporting Information. 
Data were analyzed using IBM SPSS Statistics version 20. Pearson’s Chi square test was used 
for comparison of categorical variables. The influence of transformation to DLBCL on survival 
was studied using a proportional hazard model (Cox regression) with the diagnosis (FL/NMZL) 
as factor, the occurrence of transformation to DLBCL (yes/no) as a time dependent covariate, 
and their interaction. The interaction allows the model to distinguish different hazard ratios for 
the two diagnosis groups. Survival analysis was performed using Kaplan-Meier statistics with 
log-rank tests. Two-tailed p values of 0.05 or lower were considered statistically significant.
This study was reviewed and approved by the local ethical committee (reference number 
2011/270).
RESULTS
Clinical Features of Nodal Marginal Zone Lymphoma
Table 4.1 summarizes the clinical features of all patients in this study and also compares the 
clinical features of patients with concurrent DLBCL at diagnosis with patients only showing 
low-grade lymphoma at diagnosis. Males and females were affected with approximately equal 
frequency, with a median age of presentation of 59 years, but a wide age range from 21 up to 
87 years. Approximately half of patients presented with advanced stage disease (stage III or IV). 
Peripheral lymph nodes were affected in 81% of patients, but central lymphadenopathy was 
also quite common with abdominal and mediastinal lymphadenopathy being present in 50% 
and 33% of patients, respectively. A bulky tumor was present in 8% of patients. B-symptoms 
were present in 10% of patients presenting with low-grade disease and in 1 out of 4 patients 
presenting with NMZL and concurrent DLBCL.
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Table 4.2 summarizes the clinical features at diagnosis of NMZLs included in this study in 
comparison to previous reports on NMZLs. Most observations were in agreement with those 
from previous reports, although we observed some differences. Peripheral lymphadenopathy 
was observed in a smaller proportion of patients in our study, compared to the literature (81% 
vs. 95-100%). Also, a bulky tumor mass was seen less frequently in comparison to previous 
studies (8% vs. 11-31%). Of note, in the study by Kojima et al., patients infrequently presented 
with advanced stage disease and none of the patients studied showed lymphoma localization in 
the bone marrow 165. This might be due to geographical differences, but the underlying causes 
for this possible difference remain to be elucidated.
Comparison Between Nodal Marginal Zone Lymphoma and Follicular Lymphoma
Table 4.3 compares the clinical features of patients with NMZL with a group of patients with FL 
that was selected from the same archive, excluding patients that showed concurrent DLBCL at 
diagnosis. Patients with FL presented more frequently with high-stage disease stage (in 78% 
vs. 54%, p = 0.018) and abdominal lymphadenopathy (83% vs. 50%, p = 0.002). Although this 
difference was not statistically significant, FLs more frequently involved the bone marrow (53% 
vs. 33%, p = 0.089) Also, FLs more often showed transformation to DLBCL during the course of 
the disease in comparison to NMZL (28% (12/43) vs. 10% (5/52), p = 0.021). 
Table 4.3 Clinical characteristics of nmzl vs. Fl
NMZL FL
n 52 43
M:F 27:25 23:20 p = 0.879
Age (range) Median 59 years 
(21-87)
Median 55 years 
(32-92)
Stage at presentation (n)
    I
    II
    III
    IV
    Unknown
13 
6 
9 
14 
10 
(25%)
(12%)
(17%)
(27%)
(19%)
6 
3 
12 
20 
2 
(14%)
(7%)
(28%)
(47%)
(5%)
p = 0.168
Ann Arbor stage III or IV 23/43 (54%) 32/41 (78%) p = 0.018*
ECOG score (n)
    0
    1
    2
    3
    4
    Unknown
17 
14 
3 
1 
0 
17 
(33%)
(27%)
(6%)
(2%)
(0%)
(33%)
15 
15 
4 
1 
0 
8 
(35%)
(35%)
(9%)
(2%)
(0%)
(19%)
p = 0.960
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FLIPI category
    Low
    Intermediate
    High
    Unknown
17 
8 
7 
20 
(33%)
(15%)
(14%)
(39%)
14 
11 
9 
9 
(33%)
(26%)
(21%)
(21%)
p = 0.621
Peripheral lymphadenopathy (n) 34/42 (81%) 30/40 (75%) p = 0.515
Cervical lymphadenopathy (n) 19/40 (48%) 21/39 (54%) p = 0.573
Abdominal lymphadenopathy (n) 20/40 (50%) 33/40 (83%) p = 0.002*
Mediastinal lymphadenopathy (n) 13/40 (33%) 18/40 (45%) p = 0.251
B-symptoms (n) 4/40 (10%) 8/40 (20%) p = 0.210
Bone marrow involvement (n) 13/39 (33%) 19/36 (53%) p = 0.089
Bulky tumour (tumour mass ≥ 5 cm) (n) 3/40 (8%) 4/40 (10%) p = 0.692
Anemia (Hemoglobin< 120g/L) (n) 7/37 (19%) 7/38 (18%) p = 0.956
LDH elevation (n) 10/37 (27%) 5/36 (14%) p = 0.165
M-protein (n) 4/27 (15%) 3/29 (10%) p = 0.613
Transformation to DLBCL 5/52 (10%) 12/43 (28%) p = 0.021*
Median time to transformation (range) in months 28 (7-168) 60 (5-133)
Primary treatment
    Wait and see
    Chemotherapy
    R-chemotherapy
    Radiotherapy
    Surgery
    Other
    Unknown
12 
4 
11 
11 
1
1 
12 
(23%)
(8%)
(21%)
(21%)
(2%)
(2%)
(23%)
14 
5 
12 
8 
0
1 
3 
(33%)
(12%)
(28%)
(19%)
(0%)
(2%)
(7%)
p = 0.878
P-values were calculated using Pearson’s Chi-square test. Asterisks (*) indicate statistical significance at 
the 0.05 level Abbreviations: DLBCL: diffuse large B-cell lymphoma; ECOG: Eastern Cooperative Oncology 
Group; F: female; FL: follicular lymphoma; FLIPI: follicular lymphoma international prognostic index; 
LDH: lactate dehydrogenase; M: male; NMZL: nodal marginal zone lymphoma..
Survival and Prognosis
Median follow-up was 63 months for patients with NMZL and 83 months for patients with FL. 
Both groups showed a similar survival curve (Figure 1A, p = 0.648), with estimated five-year 
overall survival rates of 74% (95% confidence interval (CI) 57-92%) for patients with NMZL and 
75% (95% CI 60-90%) for FL patients. Event-free survival was also similar with an estimated 
five-year event-free survival of 38% (95% CI 21-55%) for patients with NMZL and 40% (95% CI 
24-57%) for FL patients, respectively (Figure 1B, p = 0.365).
The effect of transformation on survival was tested for all cases, including those that showed 
transformation at diagnosis, using a proportional hazard model. In the NMZL group the hazard 
ratio for transformation to DLBCL was 7.27 (95% CI 2.26-23.40, p < 0.001) and in the FL group 
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3.87 (95% CI 1.30-11.48, p = 0.015) (Figure 2). These two hazard ratios were not significantly 
different (p = 0.44). 
Figure 4.1. Survival analyses. A-B: Nodal marginal zone lymphoma (NMZL) and follicular lymphoma (FL) 
showed a similar curve for overall survival (A) and progression-free survival (B).
Figure 4.2. The effect of transformation to diffuse large B-cell lymphoma on prognosis. For both nodal 
marginal zone lymphoma (NMZL, solid line) and follicular lymphoma (FL, dotted line), overall survival in 
patients up to the moment of transformation (shown in panel A) is significantly better in comparison to 
survival after the moment of transformation (shown in panel B).
Additional factors that influenced survival were analyzed by univariate survival analysis using 
Kaplan-Meier statistics and log-rank tests after exclusion of cases that showed transformation 
to DLBCL at presentation. NMZL and FL showed different prognostic parameters (Table 4.4). For 
patients with NMZL, only a poor performance status was associated with a significantly worse 
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survival. In addition, patients with NMZL presenting at an advanced disease stage showed a 
trend towards worse survival, but this did not reach statistical significance. For patients with 
FL, age >60 years, poor performance status, and anemia were associated with a significantly 
worse survival. LDH elevation, higher FLIPI category, and the presence of B-symptoms showed 
a trend towards an association with poorer survival, but this was not statistically significant. For 
both NMZL and FL, we did not observe a relationship between proliferative activity as assessed 
by Ki67 immunohistochemistry and overall or event-free survival.
Table 4.4 Prognostic features in nmzl and fl
Prognostic feature   p-value (log-rank test)
  NMZL FL
Age > 60 years 0.834 0.004*
Stage III or IV at diagnosis 0.073 0.683
ECOG score 2-4 0.000* 0.007*
LDH > normal 0.309 0.071
Anaemia (Haemoglobin< 120g/L) 0.894 0.041*
>4 nodal sites involved 0.102 0.462
FLIPI category 0.148 0.056
B-symptoms 0.365 0.073
Bone marrow involvement 0.394 0.400
Abbreviations: ECOG: Eastern Cooperative Oncology Group; FL: follicular lymphoma; FLIPI: Follicular 
Lymphoma International Prognostic Index; LDH: lactate dehydrogenase; NA: not available; NMZL: 
nodal marginal zone lymphoma. Asterisks (*) indicate statistical significance at the 0.05 level.
DLBCL Subtypes in Transformed NMZL and FL
A non-germinal center B-cell phenotype of DLBCL (non-GCB-DLBCL) carries a worse 
prognosis compared to a germinal center germinal center B-cell phenotype of DLBCL (GCB-
DLBCL)244. Because few data exist on the phenotype of transformed low grade lymphomas, 
we investigated if differences exist in DLBCL subtype between transformed NMZLs and FLs. 
We performed immunohistochemistry for CD10, BCL6, and FOXP1 and assigned patients to 
the GCB-DLBCL or non-GCB-DLBCL group according to the cut-off values and algorithm 
proposed by Visco and colleagues 243.
As is expected considering the germinal center derivation of FL, DLBCL arising in FL showed 
predominantly a GCB phenotype (in 13/14 cases). Of the DLBCLs arising in NMZL, sufficient 
material was available in 5 cases. Only one out of 5 (20%) DLBCLs arising in NMZL was of GCB 
type compared to 13 out of 14 (93%) DLBCLs arising in FL (p = 0.001, Figure 3).
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Figure 4.3. Immunohistochemistry for diffuse large B-cell lymphoma (DLBCL) phenotype. A-C: DLBCL 
arising in a patient with a history of nodal marginal zone lymphoma (NMZL). Hematoxylin & eosin (H&E) 
morphology (A) shows sheets of large tumor cells which are positive for FOXP1, but negative for CD10, 
fitting a non-germinal center B-cell-DLBCL (non-GCB-DLBCL) phenotype. D-F: another case of DLBCL 
arising in a NMZL at first presentation. H&E morphology (D) shows both a small-cell, low grade component 
with rare scattered centroblasts and a high grade component consisting of sheets of large cells (indicated 
by asterisk). The small-cell component is negative for CD10, but the large cell-component does express 
CD10, corresponding to a GCB-DLBCL phenotype (E). Ki67 shows high proliferative activity in the high-
grade component, in contrast to the small-cell component (F). Original magnification A-F: 200x.
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DISCUSSION
In this study, we assessed the clinical features of a group of 56 patients with NMZL. Our 
findings are largely in line with earlier reports, although we less often observed peripheral 
lymphadenopathy and a bulky tumor mass in comparison to earlier studies. Patients were 
selected from the pathology archive of an academic hospital that covers the east of the 
Netherlands. This method of selection might have created bias, as the cases that were sent 
in for consultation by the external hospitals might have been selected for difficult cases. To 
compare NMZL with FL, we selected a similar set of patients with FL from the same archive. 
Although patients with FL were selected at random from a similar period of time, selection 
bias cannot be fully excluded here. To circumvent this selection bias would require population-
based studies which are very difficult to perform due the rareness of NMZL.
Patients with NMZL and FL showed similar overall survival and event-free survival. We 
studied factors influencing survival by univariate survival analyses, which showed a significant 
association between poor performance and worse overall survival in patients with NMZL. 
This association is in line with the study by Oh et al., who also found an association between 
poor performance and worse overall survival 164. We observed a trend towards worse survival 
in patients presenting at an advanced disease stage, which is in line with previous studies 
164, 241. Associations between overall survival and anemia, presence of B-symptoms, bone 
marrow involvement, age above 60 years, FLIPI score, and elevated LDH, which were reported 
in previous studies, were not confirmed in the present study 29, 164, 241. Obviously, the study of 
prognostic factors is hampered by the small size of the studies reported thus far. The study by 
Olszewski et al., who included 4724 NMZL patients, is an exception, but this study only looked 
at a limited number of possible prognostic factors and pathology was not reviewed centrally 241.
We compared the clinical features of NMZL with a similar series of FLs. Overall, NMZL and FL 
showed a similar disease presentation, but FLs presented at a higher stage with more frequent 
abdominal lymphadenopathy and also showed more frequent transformation to DLBCL during 
the course of the disease.
In NMZL, we observed transformation to DLBCL at the time of diagnosis in 7% of patients. This 
number is low in comparison to previous reports which noted concurrent DLBCL in 20-31% 
of patients 160, 161, 165. This difference could be explained by the definition of transformation to 
DLBCL. Depending on the study, earlier reports diagnosed concurrent DLBCL if the percentage 
of blasts exceeded 20 or 50% of tumor cells. In contrast, we diagnosed DLBCL only if sheets of 
blasts were present. The strong association with worse survival in patients with transformation 
indicates that this is indeed a relevant criterion.
After a median follow up of 51 months, 10% of patients with NMZL showed progression to 
DLBCL. Previous literature on the risk of transformation in NMZL is scarce. In a study including 
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35 patients with NMZL, Meyer and colleagues reported transformation in 16% of patients, but 
the specific follow-up time for the subgroup of NMZL was not reported 245.
In comparison to NMZL, FLs more often showed transformation to DLBCL during the course of 
the disease (in 28% after a median follow-up of 6 years). These numbers are somewhat higher 
than previous reports, which noted transformation in up to a quarter of patients after 6 years 
246, 247.
Interestingly, prognostic factors for NMZL and FL showed only limited overlap. In NMZL, only 
poor performance status was significantly associated with worse survival and a trend was 
observed towards an association between an advanced disease stage and worse survival. This 
is in contrast to FL, where significant associations between survival and age, performance 
status, and anemia were seen and LDH, FLIPI category, and the presence of B-symptoms 
showed a trend towards an association with survival. This illustrates the fact that NMZL and 
FL are different entities that deserve their own tailored clinical approach. However, due to the 
small size of the study group, additional features could have prognostic value when studied in 
larger groups of patients.
Transformation to DLBCL was associated with a significantly worse survival in both NMZL 
and FL. The phenotype of the transformed lymphoma significantly differed between NMZL and 
FL, however. DLBCLs arising in FL were mostly of GCB phenotype versus mostly non-GCB 
phenotype in NMZL. Nonetheless, transformation of FL to non-GCB-DLBCL and transformation 
of NMZL to GCB-DLBCL was observed in single cases, indicating that the type of lymphoma 
does not necessarily predict the subtype of DLBCL it will transform to. 
For FL, these findings are in line with earlier studies that report predominant, but not exclusive 
transformation to GCB-DLBCL in FL 248, 249. To the best of our knowledge, no results on the 
DLBCL subtype in transformed NMZL have been published. Of DLBCLs arising in MALT 
lymphoma, small series show that 62-65% are non-GCB-DLBCLs 250, 251.
In conclusion, we assessed the clinical and prognostic features of a series of NMZL and 
compared these to a group of FLs. This showed overlap in clinical features, but also differences 
that need to be taken into account when treating patients with low-grade B-cell lymphomas.
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Immunohistochemical differentiation 
between follicular lymphoma and nodal 
marginal zone lymphoma – combined 
performance of multiple markers
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Although many lymphomas can be classified reliably according to the World Health Organization 
Classification of 200819, the differentiation between nodal marginal zone lymphoma (NMZL) 
and follicular lymphoma (FL) is problematic in some cases. In fact, NMZL is often diagnosed 
by exclusion, resulting in heterogeneity in the diagnostic category of NMZL. New markers for 
NMZL have been described, but they have not yet been tested in combination.218, 219 In this 
study, we compared multiple immunohistochemical markers for their use in distinguishing 
NMZL from FL. From the results, we constructed an algorithm that combines these markers 
to help distinguish between FL and NMZL. Importantly, this algorithm also contains a category 
of “B-cell lymphoma, unclassifiable”, stressing the difficulty that remains in distinguishing 
NMZL from FL. 
For the initial test series, we selected 47 patients with FL with a chromosomal rearrangement 
of BCL2 and 44 patients with a diagnosis of NMZL or probable NMZL from the archive of 
the Department of Pathology at the Radboud university medical center (Nijmegen, the 
Netherlands). For all NMZLs, BCL2 translocations were excluded using fluorescent in-situ 
hybridization with split-signal probes. Patient characteristics are described in Supplementary 
Table 5.1. For a diagnosis of NMZL, the following diagnostic criteria were used: 1) effaced 
architecture of the lymph node, due to a small B-cell proliferation with a follicular, marginal 
zone, or diffuse growth pattern, 2) either centrocytoid or more round cells with intermingled 
centroblasts, 3) a mature B-cell immunophenotype with expression of BCL2, 4) in cases with a 
follicular/ nodular growth pattern, signs of follicular colonization (presence of BCL2 negative 
cells and high Ki67 staining), 5) not fitting a diagnosis of chronic lymphocytic leukemia/small 
lymphocytic lymphoma, mantle cell lymphoma, or lymphoplasmacytic lymphoma. Expression 
of germinal center markers was not considered an exclusion criterion for a diagnosis of NMZL 
in this study.
As expected, immunohistochemistry showed significant differences between NMZL and FL 
(Table 5.1). Overall, FLs were positive for germinal center markers (CD10, BCL6, LMO2, HGAL) 
and negative for MNDA and IRTA1 (Supplementary Figure 5.1). NMZLs mostly showed an 
opposite pattern with positivity for MNDA in approximately two thirds of cases, IRTA1 staining 
in approximately one fifth of cases and usually no staining with germinal center markers. 
However, all germinal center markers were positive in a subset of NMZLs, and similarly, FLs 
with expression of MNDA were also identified (Supplementary Figure 5.2). 
Based on the immunohistochemistry results, a combination of markers was used to design 
an algorithm that helps to distinguish NMZL from FL (Figure 1). This algorithm was built 
empirically, allowing inclusion of a category of “B-cell lymphoma, unclassifiable” to prevent 
contamination of the NMZL category. As expected, this algorithm classified most lymphomas 
according to their original diagnosis (Table 5.2). However, in the initial test series, one case 
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of FL was classified as NMZL, and 6 cases of NMZL were classified as FL by the algorithm; a 
significant proportion of cases (13%) were considered “B-cell lymphoma, unclassifiable” by the 
algorithm. Most (75%) of these unclassifiable cases had an original diagnosis of NMZL.
Table 5.1 Immunohistochemistry results
Number of positive cases n (%) Sensitivity and Specificity (%)
   Initial series   Validation series Initial series Validation 
series
 NMZL
(n=44)
FL
(n=47)
NMZL
(n=13)
FL
(n=21)
Se Sp Se Sp
BCL6 5 (11) 44 (94) 3 (23) 21 (100) 94 89 100 77
CD10 8 (18) 42 (89) 2 (15) 21 (100) 89 82 100 85
HGAL 11 (25) 44 (94) 1 (8) 17 (81) 94 75 81 92
LMO2 12 (27) 41 (87) 1 (8) 14 (67) 87 73 67 92
4/4 GCM1 2 (5) 36 (77) 0 (0) 11 (52) 77 95 52 100
MNDA 31 (70) 6 (13) 9 (69) 4 (19) 70 87 69 81
IRTA1 6 (14) 0 (0) 6 (46) 0 (0) 14 100 46 100
14/4 GCM: 4 out of 4 germinal center markers positive. FL: follicular lymphoma; NMZL: nodal marginal 
zone lymphoma; Se: sensitivity; Sp: specaficity.
To validate the algorithm, a second validation group of 21 FLs and 13 NMZLs, collected from 
the archive of the Department of Pathology at the Hospital del Mar (Barcelona, Spain) was 
stained for the same markers as the initial group. Overall, staining results were comparable to 
those in the test group with a high sensitivity of BCL6 for FL and a high specificity of IRTA1 for 
NMZL (Table 5.1); CD10 expression had a higher sensitivity in comparison to the test group, but 
a lower specificity. LMO2 and HGAL were less sensitive but more specific. 
In this validation group, the algorithm gave a concordant classification as either NMZL or FL 
in 85% of cases (Table 5.2). No follicular lymphoma was misclassified as NMZL, and only one 
NMZL was misclassified as FL. Four cases (12%) were considered unclassifiable, three of 
which had an original diagnosis of FL and one with an original diagnosis of NMZL.
The algorithm was designed based on a comparison of NMZLs with FLs with a translocation 
involving BCL2. However, because a BCL2 translocation can be demonstrated relatively easily, 
the actual problem we are faced with in daily practice is the separation of NMZL from FL 
without a BCL2 translocation. FLs with and without a BCL2 translocation might be different 
from each other, as has been suggested by a gene expression study237, and also by a recent 
comparative genomic hybridization study.238 In the latter study, genetic aberrations in FLs 
without a BCL2 translocation showed more resemblance to those in NMZL than in FLs with a 
81
IMMUNOHISTOCHEMISTRY FOR NMZL VS. FL
C
ha
pt
er
 5
Figure 5.1. Immunohistochemical algorithm for separation of nodal marginal zone lymphoma (NMZL) 
from follicular lymphoma (FL). The algorithm starts at the top with a lymphoma that is considered to be 
either FL or NMZL. If all four germinal center markers (BCL6, CD10, LMO2, HGAL) are positive, a diagnosis 
of FL is made. If not, IRTA1 expression is determined. If IRTA1 is positive, a diagnosis of NMZL is made. 
If IRTA1 is negative, MNDA and germinal center markers are used to divide the remaining cases in three 
categories: NMZL for MNDA positive cases with positivity for none or only one germinal center marker, 
FL for MNDA negative cases with expression of 2 or 3 germinal center markers and low-grade B-cell 
lymphoma, unclassifiable for cases that do not fit into these other two categories.
Table 5.2 Algorithm results
Diagnosis Initial series
n (%)
Validation series
n (%)
FL NMZL FL NMZL
FL 43 (91) 6 (14) 18 (86) 1 (8)
B-cell lymphoma, unclassifiable  3 (6) 9 (20) 3 (14) 1 (8)
NMZL 1 (2) 29 (66) 0 (0) 11 (85)
FL: follicular lymphoma; NMZL: nodal marginal zone lymphoma
BCL2 translocation. To address this problem, we tested a small series of 6 FLs without a BCL2 
translocation, which were all classified as FL by the algorithm. This supports the idea that this 
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algorithm also applies to FLs without a BCL2 translocation, but confirmation will require the 
study of larger series.
Thus far, the majority of the markers in the algorithm has only been described in single studies. 
Kanellis and colleagues reported expression of MNDA in 75% of NMZLs versus 5% of FLs.218 In 
our series, a less pronounced, but similar difference was observed, with MNDA expression in 
NMZL and FL in 70% and 15%, respectively. In accordance with Falini and colleagues220, IRTA1 
also discriminated between NMZL and FL in our series. However, in their study 73% of NMZLs 
expressed IRTA1, compared to only 21% in our study. This difference could be caused by a 
difference in interpretation. In our hands, faint IRTA1 expression was quite frequently observed 
in NMZLs, but also in some FLs. Because the reproducibility of the scores assigned to these 
cases proved to be very poor amongst different observers, a case was only considered positive 
if 30% or more of the cells showed moderate or strong expression of IRTA1. This approach, 
which caused a strong improvement in the diagnostic value of IRTA1 in our series, explains the 
small proportion of NMZLs positive for IRTA1. 
Expression of the germinal center markers HGAL and LMO2 in lymphomas has been described 
by the group of Natkunam, who showed expression in the majority of FLs and only very rare 
expression in NMZL.193, 216, 252, 253 For both markers, they detected only a single case of NMZL 
that was positive.216, 252 In our series, we observed more frequent expression of both LMO2 and 
HGAL in NMZL. We believe this could be caused by differences in inclusion criteria between our 
study and the previous studies. In the study by Salama et al., which contains the large majority 
of NMZLs previously studied for LMO2 and HGAL, cases were excluded from the NMZL group if 
they expressed germinal center markers193, which explains why expression of germinal center 
markers was not detected in NMZLs in their study. A recent study by Dyhdalo and colleagues 
reported LMO2 staining in 2 out of 25 NMZLs, of which one case also expressed BCL6.254 In our 
study, expression of germinal center markers was not considered an exclusion criterion. We 
made this choice because, in our experience, typical cases of NMZL do occasionally express 
germinal center markers and expression of CD10 and BCL6 in NMZL has been reported 
previously.1, 199, 212
The FLs that were used to build the algorithm were all required to have a BCL2 break, 
which, together with morphology, ensured that the diagnosis of FL is correct. Therefore, 
misclassification of FL with a BCL2 break as NMZL has been excluded. Unfortunately, no 
markers for NMZL can compare with the BCL2 translocation for FL. Therefore, the NMZL 
group can still be expected to be more heterogeneous than the FL group, with some cases 
representing FL or other lymphomas rather than NMZL. Indeed, ‘NMZLs’ were rather 
frequently considered FL (in 12%) or unclassifiable (in 18%). This illustrates the difficulty that 
remains in the definition and diagnosis of NMZL; the lack of a sharp definition and the lack of 
positive diagnostic markers for NMZL result in a heterogeneous diagnostic category.
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The ultimate question is: what is the gold standard? For this study we have used the combination 
of morphology and phenotyping for follicular colonization as defining criteria for NMZL. The 
addition of extensive immunohistochemistry, including new markers, might help to create a 
better gold standard for NMZL. At present however, it is very difficult to compare different 
strategies to diagnose NMZL as no perfect positive marker for NMZL is available. Hopefully, 
elucidation of the pathogenesis of NMZL will provide us with better positive markers for 
NMZL. The results from this study could assist in achieving this goal; the addition of extensive 
immunohistochemistry to conventional criteria for NMZL will help to establish smaller, but 
potentially more homogeneous study groups, facilitating studies into the pathogenesis of 
NMZL.
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SUPPLEMENTARY MATERIALS AND METHODS
Immunohistochemistry
Briefly, 4 µm sections were cut, dried, deparaffinized, and subjected to heat-mediated antigen 
retrieval, according to Table 1. After blocking of endogenous peroxidase, sections were 
incubated with the primary antibody (Supplementary Table 1) for 1 hour at room temperature. 
The secondary antibody (for Nijmegen cases: PowerVision poly-horse radish peroxidase-
anti-mouse/rabbit/rat, Klinipath, Duiven, the Netherlands; for Barcelona cases: secondary 
antibody from Dako EnVision™ FLEX Mini Kit, High pH, Dako, Glostrup, Denmark) was applied 
for 30 min at room temperature before visualization with 3,3’diaminobenzidine and nuclear 
counterstaining with hematoxylin. 
The immunohistochemical stainings of the initial series were scored independently by two 
observers (JvK, MvdB) as positive or negative. Antibodies with cut-off values are indicated in 
Supplementary Table 2. In case of discrepancies between observers, consensus was achieved 
at a multi-headed microscope. The validation series was scored independently by two other 
observers (JM, MGG) in a similar way, with the same cut-off values.
Fluorescence in-situ hybridization (FISH)
FISH for a BCL2 break (split probe approach) was performed on all cases. A similar protocol 
was used for the Nijmegen and the Barcelona series. In short, sections from FFPE tissue were 
dried, deparaffinized, rehydrated, and heated for 10 minutes in sodium citrate (pH 6.0). Slides 
were rinsed in 0.01 M hydrochloric acid before 15 minutes of pepsin digestion. After three rinses 
of 0.01 M hydrochloric acid and 5 minutes of fixation in 1% formaldehyde in PBS, sections were 
dehydrated and dried, after which the BCL2 DNA probe was added (Dako Y5407, Glostrup, 
Denmark). After 5 minutes of denaturation at 82°C, hybridization was performed overnight 
at 45°C in an S2451 hybridizer (Dako). Sections were then dehydrated, dried, and mounted 
using medium containing DAPI as a nuclear counterstain (Vectashield, Vector Laboratories, 
Burlingame, CA). Cases with split signals in 20% of cells or more were regarded as positive.
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Supplementary table 5.1 – Additional patient characteristics
Initial series (Nijmegen)
Nodal marginal zone lymphoma (n=44)
Male:Female 26:18
Median age (years) 59
Tumor localization
    - Nodal
    - Extranodal
Concurrent diffuse large B-cell lymphoma at 
diagnosis
48 (100%)
0 (0%)
3 (7%) 
Follicular lymphoma (n=47)
Male:Female 26:21
Median age (years) 55
Tumor localization
    - Nodal
    - Extranodal
43 (91%)
4 (9%) (tonsil, spleen, parotid gland, small bowel)
Grade
    - Grade 1-2
    - Grade 3A
    - Grade 3B
Concurrent diffuse large B-cell lymphoma at 
diagnosis
28 (60%)
18 (38%)
1 (2%)
3 (6%)
Validation series (Barcelona)
Nodal marginal zone lymphomas (n=13)
Male:Female 7:6
Median age (years) 60
Tumor localization
    - Nodal
    - Extranodal
13 (100%)
0 (0%)
Follicular lymphoma (n=21)
Male:Female 14:7
Median age (years) 65
Tumor localization
    - Nodal
    - Extranodal
21 (100%)
0 (0%)
Grade
    - Grade 1-2
    - Grade 3A
    - Grade 3B
10 (48%)
10 (48%)
1 (5%)
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Follicular lymphomas without a BCL2 translocation (n=6)
Male:Female 1:5
Median age (years) 63
Tumor localization
    - Nodal
    - Extranodal
    - Unknown
5 (83%)
0
1 (17%)
Grade
    - Grade 1-2
    - Grade 3A
    - Grade 3B
2 (33%)
3 (50%)
1 (17%)
Supplementary table 5.2 Antibodies
Antigen Source Antigen retrieval Antibody 
dilution
Cut-off for positive 
staining  
(% of cells)
BCL6 Novocastra NCL-L-BCL6-564 Citrate pH 6.0, 
pressure cooker
1:40 ≥ 25
CD10 Monosan MONX10345 Citrate pH 6.7, 30 min 
100°C
1:20 ≥ 25
HGAL Sigma-Aldrich HPA002473 Citrate pH 6.0, 
pressure cooker
1:400 ≥ 30
IRTA1 prof. Falini, Perugia, Italy EDTA pH 9.0, 10 min 
100°C
1:10 ≥ 301
LMO2 Abcam ab 80046 EDTA pH 9.0, 15 min 
100°C
1:6000 ≥ 30
MNDA Kind gift from dr. Roncador, 
Madrid, Spain
EDTA pH 9.0, 15 min 
95°C
1:1 ≥ 15
1for IRTA1, a case was only considered positive if 30% or more of the cells showed moderate or strong 
expression.
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Supplementary Figure 5.1. Typical immunohistochemical staining pattern in follicular lymphoma (FL) 
and nodal marginal zone lymphoma (NMZL). An example of a typical case of FL (top) with expression of 
BCL6, CD10, HGAL, and LMO2, but not MNDA or IRTA1. In contrast, typical case of NMZL (bottom) showed 
the opposite pattern with expression of MNDA and IRTA1, but not BCL6, CD10, HGAL, or LMO2.
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Supplementary Figure 5.2. Examples of atypical immunohistochemistry. Atypical staining in nodal 
marginal zone lymphoma (NMZL) (A-E): showing variable but significant expression of BCL6 (A), strong 
expression of HGAL (B), weak nuclear staining for LMO2 (C), strong staining for MNDA (D) and no staining 
for CD10 (E). Atypical staining in follicular lymphoma (FL) (F-I): expression of MNDA (F) in a case of FL. 
FISH confirmed a translocation involving BCL2 with a break apart probe hybridizing to BCL2 (G), which 
showed multiple split signals. One case of FL showed interstitial staining with the IRTA1 antibody, which 
was interpreted as background staining rather than true positivity (H). With FISH, this case showed a BCL2 
translocation, with an additional green signal (I).
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ABSTRACT
Aims
Current immunohistochemical methods to study expression of multiple proteins in a 
single tissue section suffer from several limitations. In this study, we report on sequential 
immunohistochemistry (S-IHC); a novel, easy method that allows study of numerous proteins 
in a single tissue section, while requiring very limited optimization.
 
Methods and results
In S-IHC, a tissue section is stained for multiple antibodies, with intermediate scanning of the 
section and elution of chromogen and antibodies. Overlays are made of the digital images, 
allowing assessment of multiple proteins in the same tissue section. We used S-IHC to study 
nine nodular lymphocyte-predominant Hodgkin lymphomas (NLPHLs) and ten T-cell- and 
histiocyte-rich diffuse large B-cell lymphomas (T/HRBCLs) for expression of cyclin D1, CD20, 
and CD68. We observed cyclin D1 expression in single tumor cells in 44% of NLPHLs and 
60% of T/HRBCLs. Comparison of S-IHC with classical single immunohistochemical staining 
revealed discrepancies in 8 cases (42%), demonstrating the difficulty to differentiate tumor 
cells from histiocytes on morphological grounds, and stressing the additional value of S-IHC.
Conclusion
For research and diagnostic purposes, S-IHC is a promising technique that assesses expression 
of numerous proteins in single tissue sections with complete architectural information, 
allowing phenotypical characterization of single cells.
93
SEQUENTIAL IMMUNOHISTOCHEMISTRY
C
ha
pt
er
 6
INTRODUCTION
Immunohistochemistry, in which an antibody is used to show the presence of a specific protein 
in tissue, has transformed the practice of diagnostic pathology. Especially in hematopathology, 
immunohistochemistry is vital for reaching the right diagnosis. Usually, in the diagnostic 
setting, single immunohistochemical stains are performed, in which multiple sections are cut 
from a tissue block and each section is stained for a different protein. With this approach, each 
tissue section contains different cells. Although this is generally of no concern, it can cause 
difficulties in some situations, for example when assessing tumor cells that are difficult to 
distinguish from surrounding non-neoplastic cells. To solve this problem, double stains have 
been developed in which a single tissue section is stained for two or sometimes three proteins 
simultaneously. These double stains do have some disadvantages, however. First, they require 
extensive optimization, which is necessary for each new combination of antibodies. Secondly, 
only a limited number of antigens can be stained in a single tissue section because a limited 
number of systems for visualization (enzyme-chromogen combinations) are available. Also, if 
two antigens are located in close proximity to each other, one chromogen can interfere with or 
prevent binding of a second primary antibody or it can obscure the other chromogen, thereby 
complicating assessment. Finally, in general it is only possible to use one primary antibody 
derived from a specific species because of cross-reactivity.
 In this study, we report on a novel sequential immunohistochemistry (S-IHC) approach 
that does not come with the disadvantages described above. In S-IHC, a tissue section 
is immunohistochemically stained for a particular protein, visualized with a chromogen, 
counterstained with hematoxylin, and digitized by scanning microscopy, after which the stain 
and the antibodies are removed and another round of immunohistochemistry with scanning is 
performed (Figure 6.1). Overlays are then made of the scanned images. In this way, expression 
of multiple proteins can be visualised in single cells with complete architectural information.
 We applied the S-IHC technique to two types of lymphoma; nodular lymphocyte-
predominant Hodgkin lymphoma (NLPHL) and T-cell- and histiocyte-rich large B-cell 
lymphoma (T/HRBCL). NLPHL is a distinct type of Hodgkin lymphoma (HL), comprising 5-7 % 
of all HLs. Its diagnosis is based on morphological as well as immunohistochemical features.19 
Morphologically, the tumor has a nodular or nodular and diffuse architecture with scattered 
large tumor cells. These tumor cells, called lymphocyte-predominant (LP) cells, have folded 
or multilobulated nuclei and lie in a background of small lymphocytes and histiocytes. 
Immunohistochemically, LP cells have retained many but not all of the B cell-specific antigens 
(i.e. CD20, CD79a) and lack expression of CD15 and CD30, allowing distinction from classical HL. 
T/HRBCL is a subtype of diffuse large B-cell lymphoma that is also characterized histologically 
by scattered large neoplastic B-cells in a background of small lymphocytes and histiocytes.19 
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Figure 6.1. Overview of sequential immunohistochemistry. Tissue sections are cut and processed 
according to standard procedures (1) as described under Materials and methods. Subsequently, primary 
antibody (2) and secondary antibody (3) are added with intermediate washing steps. Then the staining 
is visualized and counterstained (4), followed by scanning of the stained section (5). Then, the dye and 
antibodies are eluted (6) after which another round of staining is performed (7).
It has a diffuse or vaguely nodular growth pattern and an immunohistochemical profile similar 
to NLPHL.
 Following coincidental detection of cyclin D1 expression in NLPHL, we used S-IHC to 
determine if cyclin D1 expression was indeed present in tumor cells or in histiocytes. Because 
S-IHC is a straightforward technique that can be easily introduced in any laboratory that has 
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facilities for immunohistochemistry and a basic slide scanning facility, we believe that this 
is a very promising tool for diagnostic pathology, especially with the coming of age of digital 
pathology.
MATERIALS AND METHODS
Patient selection
Ten patients with a diagnosis of T/HRBCL, and 9 patients with a diagnosis of NLPHL were 
selected from the databases of the Department of Pathology of the Radboud university medical 
center (Nijmegen, the Netherlands) and the Department of Pathology of the Rijnstate Hospital 
(Arnhem, the Netherlands). This study was performed according to local and national ethical 
guidelines and the Declaration of Helsinki.
Conventional immunohistochemistry
For conventional immunohistochemistry, 4 µm sections were cut from formalin-fixed paraffin-
embedded tissue and subsequently deparaffinized and rehydrated after which antigen retrieval 
was performed in sodium citrate (pH 6.0) for 10 minutes at 96°C in a PreTreatment module 
(Labvision, Klinipath, Duiven, the Netherlands). After blocking of endogenous peroxidase with 
3% hydrogen peroxide in methanol, sections were incubated for 1 h at room temperature (RT) 
in a humid chamber with the primary antibody in a 1:40 dilution (anti-cyclin D1, clone SP4, 
Neomarkers, Klinipath). Next, slides were incubated with the secondary antibody (PowerVision 
poly-HRP-anti Ms/Rb/Rt, Immunologic, Klinipath) for 30 minutes at RT and visualized with 
bright 3,3’-diaminobenzidine (DAB). Counterstaining was performed with hematoxylin. Tumor 
cells were identified based on cellular morphology and a case was considered positive if more 
than 10% of putative tumor cells were at least weakly positive for cyclin D1.
Sequential immunohistochemistry
For S-IHC, we used an adapted version of the protocol described by Kim et al.255 A schematic 
overview of our protocol is presented in Figure 6.2. From formalin-fixed, paraffin-embedded 
tissue, 4 µm sections were cut, dried, deparaffinized, and rehydrated before antigen retrieval in 
sodium citrate (pH 6.7) at 100°C for 30 min in a PreTreatment module (Labvision). Endogenous 
peroxidase was blocked with 3% hydrogen peroxide in methanol for 10 minutes after which 
sections were rinsed in PBS and the first primary antibody (anti-cyclin D1, clone SP4, dilution 
1:40) was applied for 1h at RT. Slides were then washed in PBS after which the secondary 
antibody was applied (PowerVision poly-HRP-anti MS/Rb/Rt) for 30 min at RT. Section were 
washed in PBS before visualization with Vector NovaRED (Vector laboratories, Burlingame, CA) 
according to the manufacturer’s instructions. Sections were counterstained with hematoxylin, 
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mounted in aqueous mounting medium, and scanned with the Dotslide virtual image system 
(Olympus, Japan) at a 200x magnification. 
 After scanning, the slides were decoverslipped and briefly rinsed in PBS. Destaining 
and stripping of antibodies was performed at 50 °C for 1 h in stripping buffer containing 2% 
SDS, 0.8% β-mercaptoethanol, and 62,5 mM Tris-HCl pH 7.50. After stripping, sections were 
rinsed in tap water for 15 min and briefly rinsed in 95% ethanol, demineralized water, and 
PBS after which the next round of staining was performed, starting with the second primary 
antibody (anti-CD20, clone L26, dilution 1:300 Dako, Glostrup, Denmark). After the second 
round of staining, scanning, and destaining/ stripping, the third primary antibody (anti-CD68, 
clone KP1, dilution 1:8000, Dako) was applied overnight at 4°C. The subsequent steps in the 
third round were similar to those in the first and second round. Normal tonsillar tissue was 
stained along with the samples to ensure specific staining.
 Images of the sections were made using Olympus software (DotSlide, OlyVIA). For 
each case, at least 100 tumor cells were assessed for cyclin D1 expression. For a cell to qualify 
as a tumor cell, it was required to have a large irregular nucleus, positivity for CD20 and no 
expression of CD68.
Figure 6.2. Schematic overview of the sequential immunohistochemistry protocol.
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FICTION
Fluorescence immunophenotyping and interphase cytogenetics as a tool for the investigation 
of neoplasms (FICTION) was performed as described before.256 Briefly, 4 µm sections were cut, 
deparaffinized, and rehydrated as described above. Antigen retrieval was performed in a pressure 
cooker in EDTA buffer (pH 9.0). After antigen retrieval, sections were incubated for 1 h at RT in a humid 
chamber with the primary antibody in a 1:75 dilution (CD20, clone L26, Dako). The slides were then 
washed in PBS and incubated for 30 minutes with a biotin-conjugated secondary antibody (Rabbit 
anti-mouse, dilution 1:50, Dako). Slides were again washed in PBS and incubated in a humid chamber 
for 30 minutes with a mixture of AlexaFluor 350 (goat-anti-rabbit, 1:50, Invitrogen, Carlsbad, CA), and 
Streptavidin conjugated with AlexaFluor 350 (1:50, Invitrogen). The slides were then dehydrated and 
air-dried after which the CCND1 split probe (Dako) was prepared according to the manufacturer’s 
instructions and applied to the slides, after which slides were covered and sealed with liquid rubber 
cement. The slides were then placed in a hybridizer (Dako), denatured for 5 minutes at 82°C, and 
hybridized overnight at 45°C. Slides were subsequently rinsed in preheated 2xSSC for 5 minutes at 
42°C and washed in preheated 0.3% NP40 for 3 minutes at 72°C. After several washing steps, the 
slides were then mounted in Vectashield mounting medium (Vector Laboratories). Results were 
assessed with a Leica DM 4000B microscope equipped with a Leica DFC 300 FX digital camera. 
Appropriate Leica software was used for further processing. Tumor cells were defined as isolated 
large cells that express CD20. If more than 10% of tumor cells showed a split signal, the case was 
considered to carry a translocation. For each case, at least 100 cells were studied.
RESULTS
S-IHC shows frequent cyclin D1 expression in tumor cells of NLPHL and T/HRBCL
In routine diagnostic practice, we incidentally observed expression of cyclin D1 in the tumor 
cells of a single case of NLPHL. Following this observation, 8 additional cases of NLPHL and 10 
cases of the related lymphoma T/HRBCL were studied for cyclin D1 expression. To determine if 
the cells studied were really tumor cells and not histiocytes, we used S-IHC in which sections 
are stained, scanned, destained, and then stained again with a different antibody. In addition to 
identification, this protocol also allows quantification of tumor cells. All cases were stained for 
cyclin D1, CD20, and CD68. Expression of these proteins was assessed in individual tumor cells, 
by evaluating the same cells in the scans of the different immunohistochemical stains (Figure 
6.3). Tumor cells were identified based on morphology, the presence of CD20 staining, and the 
absence of CD68 staining. In this way, significant cyclin D1 expression (staining in ≥10% of tumor 
cells) was observed in 4 out of 9 (44%) NLPHLs and 6 out of 10 (60%) T/HRBCLs (Table 6.1).
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Differences in cyclin D1 positivity between conventional IHC and S-IHC
Cyclin D1 expression was also assessed by conventional IHC by an expert haematopathologist 
(HvK) without knowledge of the S-IHC results. A case was considered positive if by estimation 
≥10% of tumor cells showed at least moderate cyclin D1 expression. A comparison between 
conventional IHC and S-IHC showed discrepancies in 8 out of 19 cases (42%, Table 6.1), with 
an overestimation of positive tumor cells in T/HRBCLs and an underestimation in NLPHLs, 
indicating that it is difficult to differentiate LP cells from histiocytes on morphological grounds 
in immunohistochemically stained sections.
Cyclin D1 expression in NLPHL and T/HRBCL cannot be attributed to a CCND1 translocation
We assessed if a translocation involving CCND1 could cause cyclin D1 overexpression in NLPHL or T/
HRBCL. This was studied with a combination of CCND1 FISH with a break-apart probe and fluorescent 
immunohistochemistry against CD20 to identify tumor cells. In all successfully investigated cases 
(n=17), no breaks involving CCND1 were detected. We did observe additional copies of chromosome 
11 in a subset of cases, but the current approach did not allow reliable quantification of this finding.
Table 6.1 Overview of results
Patient No. Diagnosis Cyclin D1 expression - 
S-IHC (tumor cell %)
Cyclin D1 expression 
– CIHC1
t(CCND1)
1 NLPHL 20 + -
2 NLPHL 0 + -
3 NLPHL 60 + -
4 NLPHL 6 + -
5 NLPHL 3 + NA
6 NLPHL 52 - -
7 NLPHL 7 - -
8 NLPHL 12 - -
9 NLPHL 2 - NA
10 T/HRBCL 2 - -
11 T/HRBCL 14 + -
12 T/HRBCL 59 + -
13 T/HRBCL 83 + -
14 T/HRBCL 0 + -
15 T/HRBCL 80 + -
16 T/HRBCL 21 + -
17 T/HRBCL 2 + -
18 T/HRBCL 30 + -
19 T/HRBCL 8 + -
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Figure 6.3. Sequential immunohistochemistry (S-IHC) in NLPHL and T/HRBCL. a-c: S-IHC for cyclin 
D1 (a), CD20 (b), and CD68 (c) in the same area in a case of NLPHL (case no. 4). Some of the larger cells 
express cyclin D1 (arrows), but are ultimately shown to be histiocytes because they lack CD20 but do 
express CD68. In contrast, another large cell (arrowhead) that does not express cyclin D1 turns out to be a 
tumor cell because of its expression of CD20 but not CD68. With conventional immunohistochemistry, this 
area could have falsely been interpreted as cyclin D1 expression in tumor cells. d-f: S-IHC for cyclin D1 (d), 
CD20 (e), and CD68 (f) in the same area of a case of T/HRBCL (case no. 13). The large cell (arrow) expresses 
cyclin D1 and is confirmed to be a tumor cell by its expression of CD20 but not CD68.
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DISCUSSION
In this study, we identified expression of cyclin D1 in tumor cells in 44% of NLPHLs and 60% of 
T/HRBCLs with S-IHC; an immunohistochemical protocol in which a single section is stained 
sequentially for multiple markers, allowing the assessment of the expression of multiple proteins in 
individual cells. Translocations involving CCND1, known to be associated with cyclin D1 expression 
in other lymphoid neoplasms, were excluded with FICTION.
 At present, double staining protocols are typically used to assess the expression of 
multiple proteins in a single tissue section. S-IHC protocols have been described by several groups, 
but have not been adopted broadly. In 2009, Glass and colleagues described a protocol with a 
stripping procedure using acidified potassium permanganate, which had been described earlier by 
Tramu et al.257, 258 In the same year, Pirici et al. compared several other antibody elution methods 
and concluded that an acidic Glycine/SDS solution with pH 2.0 was optimal.259 Madelung et al. 
described a method to detect up to four markers with a combination between sequential IHC and 
a traditional double staining protocol.260 Recently, Kim et al. reported a method using a Tris-SDS-
β-mercaptoethanol buffer (pH 7.5).255 In this study, we have used an adapted version of the latter 
protocol. An important difference between the protocol from Kim et al. and ours is the significant 
reduction in time we have introduced both for antibody incubations and the elution procedure, 
allowing three stains to be performed in two days. It is worth stressing that in our experience, a 
sufficiently sensitive chromogen was required. AEC, as used by Glass et al. and Pirici et al., did not 
provide adequate staining with all antibodies in our hands, whereas the NovaRED substrate did 
(data not shown).
 In comparison to traditional double or triple stains, S-IHC carries several advantages. 
First, it requires only very limited optimization. For this particular study, we simply used our usual 
protocol but with the scanning and destain/ stripping steps in between. No optimization of order or 
concentration of the used antibodies was necessary and almost all reagents used were identical to 
the usual protocol.
  Another advantage of S-IHC is that it allows the staining of a larger number of proteins 
than conventional multi-stain immunohistochemistry. In our laboratory, we have successfully 
used up to eight antibodies on a single section while retaining sufficient antigenicity and without 
significant tissue damage (data not shown). Because antibodies are removed between each round 
of staining, no problems arise from species cross-reactivity of the different antibodies. Also, S-IHC 
allows each stain to be assessed individually, and because hematoxylin is used as a counterstain, 
each stain can be assessed with complete architectural information. Other methods to visualize 
large numbers of proteins using fluorescence have the important drawback that appreciation of the 
tissue architecture is more difficult.
 We applied this technique first in haematopathology, since particularly in 
haematopathology, a diagnosis requires extensive typing of the lymphoid cells and therefore the 
assessment of multiple markers. Because in histological sections, tumor cells and benign reactive 
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cells are intermingled, it is not always easy to identify which cells are the tumor cells, especially in 
immunohistochemically stained slides. With S-IHC, individual cells can be stained for numerous 
markers, allowing evaluation of particular markers in tumor cells only. In this study, the strength 
of this approach is illustrated by the striking difference between the results from conventional IHC 
and S-IHC; only just over half of cases were classified correctly with conventional IHC compared to 
S-IHC.
 S-IHC also carries some disadvantages. Most importantly, it is labor-intensive and time-
consuming. We used an adapted, shorter version of the protocol described by Kim and colleagues, 
but even with this shorter protocol, the triple stain in this study required two days to be completed and 
a protocol with eight stains would require up to 4 days. This problem might be resolved with further 
automation of immunohistochemical procedures and the adoption of faster immunohistochemical 
techniques. Another potential drawback is the requirement of a slide scanning facility, which is 
currently not available in every laboratory.
 All in all, we feel that S-IHC could prove to be an important addition to the diagnostic 
arsenal in pathology. Especially with pathology becoming more digitized, and pathologists becoming 
used to making a diagnosis from a computer screen, this tool could acquire broad acceptance.
Michiel van den Brand1, Konnie M Hebeda1, Jeroen AWM van der Laak1,  
Patricia JTA Groenen1, J Han JM van Krieken1
1Department of Pathology, Radboud university medical center, Nijmegen, the Netherlands
Manuscript in preparation.
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ABSTRACT
Nodal marginal zone lymphoma is a rare type of low-grade B-cell non-Hodgkin lymphoma that 
can be difficult to differentiate from other low-grade B-cell lymphomas, especially follicular 
lymphoma. Recognition of follicular colonization, in which tumor cells infiltrate pre-existent 
germinal centers, is an important feature for distinguishing nodal marginal zone lymphoma 
from follicular lymphoma. In this study we used sequential immunohistochemistry for MNDA, 
BCL2, BCL6, and Ki67 on four cases of nodal marginal zone lymphoma to investigate follicular 
colonization. MNDA positive cells were defined as tumor cells. It was shown that these putative 
tumor cells change expression upon entry in the germinal center with higher expression of 
BCL6 and Ki67 and lower expression of BCL2 in a subset of cases. Although these results 
have implications for the morphological differential diagnosis between nodal marginal zone 
lymphoma and follicular lymphoma, careful assessment of BCL2 and Ki67 will still allow a 
distinction between true neoplastic follicles and follicular colonization in most cases. Our 
findings indicate that B-cell lymphomas have no fixed phenotypical portraits; expression of 
several markers and even a proliferative phenotype is dependent on the microenvironment in 
which the neoplastic cells are located.
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INTRODUCTION
Nodal marginal zone lymphoma (NMZL) is a rare type of small B-cell non-Hodgkin lymphoma. It 
accounts for 1.5-1.8% of B-cell lymphomas, although the incidence appears to be increasing.1-3 
At present, diagnostic criteria for NMZL are not well defined and a diagnosis of NMZL is often a 
diagnosis of exclusion.4, 5 This can cause problems in the differential diagnosis with other low-
grade B-cell lymphomas, especially with follicular lymphoma (FL). 
The histological features of NMZL are quite variable with a growth pattern at low power, which 
can be nodular, marginal zone, or diffuse.6, 7 At high power, cellular morphology is also variable, 
ranging from small cells to centrocytes to monocytoid cells. Plasma cell differentiation is a 
common feature, but is not always present. An important morphological feature of NMZLs 
with a nodular/ follicular or marginal zone growth pattern is follicular colonization and this 
feature also helps in distinguishing NMZL from FL. In follicular colonization, pre-existent 
germinal centers are being colonized by tumor cells. As these tumor cells frequently express 
BCL2, this can give the impression of BCL2-positive follicles at low power, similar to those 
seen in FL. However, high power will show BCL2-positive small colonizing lymphoma cells 
intermingled with BCL2 negative pre-existent germinal center cells, many of which will have 
large nuclei. Ki67 is also of aid in distinguishing neoplastic follicles from germinal centers 
with follicular colonization; neoplastic follicles of low-grade B-cell lymphomas show a low 
proliferative index, whereas pre-existent germinal centers show a very high proliferative index. 
Immunohistochemistry for germinal center markers (e.g. CD10, BCL6, LMO2, HGAL) can 
also be helpful, as these will be expected to highlight the pre-existent germinal center cells, 
but not the colonizing tumor cells. However, as the present study shows, plasticity in protein 
expression of tumor cells adds another layer of complexity in distinguishing neoplastic follicles 
from follicular colonization. 
It is a known phenomenon that the protein expression profile of the tumor cells of FL is dependent 
on the micro-anatomical compartment the cell is in; the tumor cells in the interfollicular space 
often show less or no expression of germinal center markers (like CD10) in comparison to 
the follicular component. In the present study, using sequential immunohistochemistry, we 
detected a similar phenomenon for NMZL in which the tumor cells gain expression of BCL6 
and Ki67 and show less expression of BCL2 upon follicular colonization. These findings indicate 
that lymphoma classification cannot be based on protein expression only.
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MATERIALS AND METHODS
Case selection
Four cases of NMZL with evident follicular colonization and strong MNDA positivity in the large 
majority of tumor cells were selected from the archive of the Department of Pathology of the 
Radboud university medical center, Nijmegen, the Netherlands. These were selected based on 
the availability of material and the fact that follicular colonization had been demonstrated with 
routine morphological and immunohistochemical analysis. Also, all cases were required to 
show extensive expression of MNDA by conventional immunohistochemistry, allowing analysis 
of MNDA-positive cells.
This study was reviewed and approved by the local medical ethical committee (reference 
number  2011/270).
Table 7.1 Primary antibodies for sequential immunohistochemistry
Antibody order Target Clone Dilution Manufacturer
1. CD20 L26 1:300 Thermo Scientific
2. BCL2 124 1:160 Dako
3. BCL6 LN22 1:40 Novocastra
4. Ki67 MIB1 1:200 Dako
5. MNDA 253A Undiluted Kind gift from dr. Roncador
Sequential immunohistochemistry
Sequential immunohistochemistry was performed as described previously.8 In short, 
4 µm sections were cut from formalin-fixed paraffin-embedded tissue and dried, deparaffinized, 
and rehydrated before antigen retrieval in sodium citrate (pH 6.7) at 100°C for 30 min. 
Endogenous peroxidase was blocked with 3% hydrogen peroxide in methanol for 10 minutes 
after which sections were rinsed in PBS and the primary antibody was applied for 1h at RT. 
Slides were then washed in PBS after which the secondary antibody was applied (PowerVision 
poly-HRP-anti MS/Rb/Rt) for 30 min at RT. Section were washed in PBS before visualization 
with Vector NovaRED (Vector laboratories, Burlingame, CA) according to the manufacturer’s 
instructions. After nuclear counterstaining with hematoxylin, sections were mounted in 
aqueous mounting medium, and scanned with the Dotslide virtual image system (Olympus, 
Japan) at a 200x magnification. After scanning, slides were decoverslipped and briefly rinsed in 
PBS. Destaining and stripping of antibodies was performed at 50 °C for 1 h in stripping buffer 
containing 2% SDS, 0.8% β-mercaptoethanol, and 62,5 mM Tris-HCl pH 7.50. After stripping, 
sections were rinsed in tap water for 15 min and briefly rinsed in 95% ethanol, demineralized 
water, and PBS after which the next round of staining was performed, starting with application 
of the primary antibody. Antibodies, clones and dilutions are indicated in table 7.1 in the order in 
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which they were applied. Before the final round of immunohistochemistry for MNDA, a second 
retrieval step was performed in EDTA pH 9.0 at 100°C for 15 minutes. 
Image analysis
From the digital images, representative snapshots were made containing both follicular and 
interfollicular areas. The same areas were recorded from the different immunohistochemical 
stains. Further image analysis was performed in Fiji/ImageJ software version 2.0.0.
The ImageJ macro that was used for further image analysis is available in the Online 
Supplement. After opening of all images, an alignment step was performed with bUnwarpJ9, 
achieving a finer alignment of all images to the BCL6 image. Next, the follicular and 
interfollicular areas were selected manually, followed by a color deconvolution step.10 Nuclear 
segmentation was performed in the hematoxylin image by applying a Gaussian blur, running 
an auto threshold step according to Li et al.11, 12, and applying a watershed. Areas with a size 
between 50 and 700 pixels were selected to measure the staining intensity of MNDA, BCL6, 
and Ki67. For measurement of BCL2 staining intensity, all areas were expanded by 2 pixels 
to include part of the cytoplasm. For each area in the follicular and interfollicular areas, the 
NovaRed staining signal was measured and exported. Although some areas contained multiple 
cells due to imperfect nuclear segmentation, most areas corresponded to a single nucleus. 
Box plots and scatter plots were generated with SPSS version 20. For the box plots, a cut-off 
score of 70 out of 256 was used. This cut-off was based on the histogram of MNDA which 
showed a clear bimodal distribution (data not shown).
RESULTS
A subset of nodal marginal zone lymphomas change protein expression upon follicular 
colonization
For this study we selected NMZLs with prominent MNDA expression. Cells that expressed 
MNDA were considered to represent tumor cells, allowing analysis of expression of BCL2, 
BCL6 and Ki67 in these MNDA-positive putative tumor cells in both the areas of follicular 
colonization and the interfollicular areas.
In two of the four cases tested (cases no. 1 and 3), a clear difference in phenotype was observed 
between MNDA-positive cells in the interfollicular areas in comparison to areas of follicular 
colonization (follicular areas) (Figure 7.1). In the areas of follicular colonization, the MNDA-
positive cells obtained expression of BCL6, but showed less expression of BCL2. In one case 
(case 3), increased expression of Ki67 was noted in the areas of follicular colonization.
Morphologically, in two other cases, no differences in expression of BCL6, BCL2, or Ki67 was 
evident between MNDA-positive cells in the interfollicular and follicular areas.
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For additional images, the reader is referred to the online supplement, which contains 
representative images of the different immunohistochemical stainings, and allows easy 
switching between the different images of a single case in a web browser.
Digital image analysis confirms different protein expression in different anatomical 
compartments
To substantiate the qualitative findings from assessment of immunohistochemistry, image 
analysis of representative snapshots was performed. This analysis allows the assessment 
of the signals of multiple immunohistochemical stainings for a single cell, in addition to the 
anatomical compartment the cell is in (interfollicular or follicular colonization). Box plots and 
scatter plots of the image analysis confirmed the increased expression of BCL6 in MNDA-
positive cells in areas of follicular colonization in the two cases described above and also 
showed a significant increase in a third case (case 2) (Figures 7.2-3, box plots for all cases are 
included in supplementary Figure 1).
The box plots for BCL2 in cases 1, 2, and 3 showed decreased of BCL2 in MNDA-positive cells 
in the areas of follicular colonization compared to the interfollicular areas (supplementary 
Figure 7.1). For Ki67, increased expression in areas of follicular colonization was noted in case 
3 only (Figure 7.2).
Figure 7.2. Comparison of follicular and interfollicular expression of BCL6, BCL2, and Ki67 in MNDA-
positive cells (case 3). These boxplots show the distribution of the average staining intensity per area 
of measurement (each area aimed to represent a single tumor cell) for BCL6, BCL2, and Ki67 in cells 
selected for MNDA positivity, thereby representing putative tumor cells. Comparison of interfollicular 
areas and areas of follicular colonization show that upon follicular colonization, the tumor cells show an 
increased staining intensity for BCL6 (A), a decreased staining intensity for BCL2 (B), and an increased 
staining intensity for Ki67 (C).
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Figure 7.1. Differential expression of BCL6, BCL2, and Ki67 in different lymph node compartments 
(case 3). In the image stained for MNDA (A), MNDA-positive putative tumor cells are seen both in the 
interfollicular area (left) and in areas of follicular colonization (right). With BCL6 (B), the interfollicular 
area shows very rare positive cells, whereas the follicular colonization area shows numerous positive 
cells, many of which show co-expression of MNDA and BCL6. BCL2 (C) shows stronger expression in 
the interfollicular area (left) compared to the area of follicular colonization (right) while Ki67 (D) shows 
stronger expression in the areas of follicular colonization, with also frequent Ki67-MNDA double positive 
cells. Insets represent a view at higher power of the area of follicular colonization.
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Figure 7.3. Scatter plots of MNDA versus BCL6, BCL2, and Ki67 (case 3). Each circle represents one 
area of measurement; most of these areas will represent a single tumor cell. Cells in areas of follicular 
colonization are indicated in blue, cells in interfollicular areas in green. These scatter plots show a higher 
BCL6 staining intensity in the follicular areas (A), with a subset of these cells also showing high MNDA 
staining intensity. In contrast, BCL2 staining intensity is lower in areas of follicular colonization (B), also in 
cells with high MNDA staining intensity. Ki67 staining intensity is higher in the follicular areas (C), both in 
areas with and without high MNDA staining.
DISCUSSION
Diagnostic criteria for NMZL have not been well defined and as a result, a diagnosis of NMZL is 
often made by exclusion. Also, differentiating NMZL from other lymphomas can be troublesome, 
especially from FL. Although most cases of FL and NMZL can be classified reliably, FLs lacking 
the characteristic BCL2 translocation and not showing the classical morphology can be difficult 
to distinguish from NMZL.4, 13 In these more difficult cases, assessment of the presence of 
follicular colonization is an important feature.
In follicular colonization, tumor cells colonize pre-existent germinal centers. This results in 
a mixed population consisting of: 1) the pre-existent germinal center cells which are negative 
for BCL2, positive for germinal center markers, and show high proliferative activity with Ki67; 
2) the colonizing lymphoma cells which are (in the large majority of cases) BCL2 positive, are 
expected not to express germinal center markers, and show low proliferative activity with Ki67.
However, to complicate matters further, our study shows that the colonizing cells can show an 
increased expression of BCL6 and Ki67 and a decreased expression of BCL2 upon entry into 
the germinal center, thereby increasing their resemblance to pre-existent germinal centers 
and making the distinction between a neoplastic follicle and a colonized germinal center more 
difficult. Gain of expression of BCL6 in follicular colonization has been shown before by double 
staining or IRTA1 and BCL614, but modulation of BCL2 and Ki67 has not been demonstrated 
before to the best of our knowledge.
To study the expression of multiple proteins in the same cells, we used sequential 
immunohistochemistry. In this technique, a tissue section is stained immunohistochemically 
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for a particular antigen and scanned to obtain a digital image.8 Then, the chromogen and the 
antibodies are removed to allow staining for another antigen, which is again scanned. In this 
way, multiple rounds of staining, scanning, and destaining can be performed, giving information 
of the expression of multiple proteins in exactly the same cells.
Next, we aligned the different images and performed image analysis. We aimed to measure 
individual cells and therefore we used a protocol for nuclear segmentation in the hematoxylin 
stain. The advantage of this approach is that information for each antigen is obtained for 
each area, allowing the generation of box plots and scatter plots for interpretation of results. 
Unfortunately, due to the nature of the tissue, nuclear segmentation has its imperfections. 
Most of the areas generated did represent individual nuclei, but some areas consisted of two 
or more nuclei overlapping. Also, larger areas of numerous nuclei overlapping were excluded 
because of their size. Although the imperfections in nuclear segmentation will have had some 
influence on our results, this influence will have been minor as the large majority of areas 
represented single nuclei.
The extent in the change of protein expression between the interfollicular compartment 
and areas of follicular colonization varied, being very prominent in one case (case 3), less 
prominent in two other cases (cases 1 and 2) and not clearly different in the final case (case 
4). To establish the frequency of changing protein expression upon follicular colonization in 
NMZL would require the study of more cases. Because NMZL is a rare lymphoma and we had 
to select for cases with prominent follicular colonization and MNDA expression in the large 
majority of tumor cells, we were only able to study four cases.
Although the findings from this study add complexity to differentiating follicular colonization 
from neoplastic follicles, we do believe that this differentiation remains possible. Assessment 
of BCL2 remains an important feature because although we observed a decreased staining 
intensity in areas of follicular colonization in three cases, the BCL2 positivity of the tumor cells 
remained recognizable. Also, the fact that one case showed increased Ki67 staining intensity 
might create confusion with pre-existent germinal center cells, but not with the tumor cells of 
a low-grade follicular lymphoma.
In conclusion, we used sequential immunohistochemistry to show changes in protein 
expression of BCL6, BCL2, and Ki67 in NMZL tumor cells, depending on the anatomical 
compartment the cells are in. These findings emphasize that B-cell lymphomas do not have 
fixed immunophenotypical portraits, but expression profiles that are dependent on the micro-
environment in which the lymphoma cells are located. Tables that indicate that characteristic 
immunophenotypes define lymphoma types need to be interpreted with care.
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Recurrent mutations in genes involved in 
nuclear factor kappa B signaling in nodal 
marginal zone lymphoma
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ABSTRACT
Aim
To investigate the spectrum of mutations in 20 genes involved in B-cell receptor and/or Toll-
like receptor signalling resulting in activation of nuclear factor kappa B (NF-kappaB) in 20 
nodal marginal zone lymphomas (NMZLs), 20 follicular lymphomas (FLs), and 11 cases of 
B-cell lymphoma, unclassifiable (BCL-u). 
Methods and results
NMZLs were diagnosed with strict criteria including expression of at least one putative 
marginal zone marker (MNDA and/or IRTA1). Cases that showed features of NMZL but did not 
fulfil all criteria were included as BCL-u. All FLs were required to have a BCL2 rearrangement.
Mutations were found in 9 NMZLs, with recurrent mutations in TNFAIP3 and CD79B. In FL, 
mutations were found in 12 cases, with recurrent mutations in TNFRSF14, TNFAIP3, and 
CARD11. In BCL-u, mutations were found in 5 cases with recurrent mutations in TNFRSF14. 
TNFRSF14 mutations were present in FL and BCL-u, but not in any of the NMZLs. In the group 
of BCL-u, TNFRSF14 mutations clustered with a FL immunophenotype. 
Conclusions
These results suggest that TNFRSF14 mutations point towards a diagnosis of FL and can 
be used in the sometimes difficult distinction between NMZL and FL, but to apply this in 
diagnostics would require confirmation in an independent cohort. In addition, the presence or 
absence of specific mutations in pathways converging on NF-kappaB could be important for 
decisions regarding targeted treatment.
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INTRODUCTION
Nodal marginal zone lymphoma (NMZL) is a rare type of low-grade B-cell non-Hodgkin 
lymphoma which is currently defined as a primary nodal B-cell neoplasm that resembles lymph 
node involvement by splenic or extranodal marginal zone lymphoma, but without evidence of 
splenic or extranodal disease.19 A diagnosis of NMZL is complicated by the fact that only little 
is known about its pathogenesis, which is reflected by a lack of routinely used positive markers 
for a diagnosis of NMZL. Therefore, NMZL is often a diagnosis of exclusion, resulting in a 
heterogeneous disease category. Particularly, the distinction between NMZL and follicular 
lymphoma (FL) can be problematic.242
Several novel immunohistochemical markers for NMZL have been reported, including IRTA1 
and MNDA.218-220 Addition of these markers to the usual diagnostic procedures could potentially 
result in a more reliable diagnosis of NMZL. Along these lines, we have recently described 
an immunohistochemical algorithm, including both established and novel markers, to help 
differentiate between NMZL and FL.261
The NF-kappaB pathway has an important role in B-cell functioning with signals from different 
receptors including the B-cell receptor (BCR), tumour necrosis factor receptor (TNFR), 
interleukin-1 receptor (IL1R), and Toll-like receptor (TLR) converging on NF-kappaB. In BCR 
signalling, binding of the BCR by antigen causes phosphorylation of CD79A and CD79B, which 
initiates a signalling cascade involving multiple proteins including Bruton’s tyrosine kinase 
(BTK) and protein kinase C beta (PKCB). This results in phosphorylation of CARD1179, 80, which 
then associates with BCL10 which in turn binds MALT1.81-86 The CARD11-BCL10-MALT1-
complex then interacts with TRAF2 and TRAF6 which induces inhibitor of kappa-B kinase 
(IKK) complex activation.81 The IKK complex phosphorylates NF-kappaB inhibitors (NFKBIs) 
causing them to be degraded by the proteasome, thereby exposing nuclear localization signals 
on NF-kappaB dimers resulting in their sustained nuclear localization and binding of DNA for 
transcriptional regulation. The IL1R and TLRs signal via receptor-bound MYD88, IRAK, and 
TRAF6, also resulting in IKK complex activation. Stimulation of the TNFR causes IKK complex 
activation via yet another pathway involving the proteins RIP1, TAK1, and TAB2. In addition 
to canonical NF-kappaB signaling, a non-canonical pathway exists in which signaling from 
the lymphotoxin B receptor, B-cell activating factor receptor (BAFFR), and CD40 activate NF-
kappaB.
Mutations in genes involved in NF-kappaB signalling have been reported in many subtypes of 
lymphoma,103 including extranodal and splenic marginal zone lymphomas.114, 115, 262 As NMZL 
resembles its extranodal counterparts, this suggests that the NF-kappaB pathway could 
also be activated in NMZL. Indeed, enrichment of expression of genes involved in NF-kappaB 
signalling has been shown in NMZL.223 The inhibitor of NF-kappaB signalling TNFAIP3 has 
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been suggested as a tumour suppressor gene in extranodal marginal zone lymphomas108, 263, 
264 and TNFAIP3 mutations have also been detected in a small series of NMZL (in 3 out of 9 
cases).113 
In the study presented here, we investigated 20 strictly defined NMZLs for the presence of 
mutations in genes involved in B-cell receptor (BCR) and/or Toll-like receptor (TLR) signalling 
resulting in activation of NF-kappaB. We compared these to 20 FLs and a group of 11 
unclassifiable B-cell lymphomas (BCL-u). The latter group had been diagnosed as possible 
NMZL in routine diagnostics, but could not fulfil the strict criteria for NMZL used in this study. 
Knowledge of the presence of NF-kappaB activating mutations in NMZL is of potential benefit 
for diagnosis and prognostication. In addition, it carries great promise for targeted treatment. 
Given the importance of BCR/TLR/NF-kappaB signalling in many subtypes of lymphoma, 
an increasing array of drugs is being developed which target specific components of these 
pathways. Knowledge of the spectrum of mutations occurring in a specific lymphoma has the 
potential to predict to which drugs this lymphoma will respond.
MATERIALS AND METHODS
Patient selection
Thirty one cases of possible NMZL and 20 cases of FL diagnosed between 2003 and 2014 were 
collected from the archive of the Department of Pathology at the Radboud university medical 
center (Nijmegen, the Netherlands). 
This study was reviewed and approved by the local ethical committee (reference number 
2011/270).
Clinically, for a diagnosis of NMZL, patients were required to present with nodal disease 
without extranodal involvement other than the bone marrow. Also, a clinical presentation with 
Waldenström macroglobulinaemia was an exclusion criterion. Morphological criteria for NMZL 
were used as previously reported.261
For immunohistochemistry, all lymphomas were stained with an extensive panel of germinal 
centre markers (CD10, BCL6, LMO2, and HGAL) and putative marginal zone markers (MNDA 
and IRTA1). As was recently described, we used these markers to classify the tumour according 
to an algorithm into one of three categories: 1) NMZL, for lymphomas expressing less than 2 
germinal centre markers and either MNDA or IRTA1; 2) FL, for lymphomas expressing all 4 
germinal centre markers or expressing 2 or 3 germinal centre markers in the absence of 
MNDA and IRTA1; 3) low-grade B-cell lymphoma (BCL), unclassifiable, for lymphomas not 
fitting into one of the two categories described above.261 To be included as NMZL in this study, 
an algorithm result of ‘NMZL’ was required.
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Finally, the presence of a BCL2 translocation was excluded in all NMZLs by fluorescent in-
situ hybridisation (FISH) with a split-probe approach. FISH experiments were performed as 
described previously with a similar protocol with split probes against BCL2 (DAKO Y5407, 
DAKO, Glostrup, Denmark) or BCL6 (DAKO Y5408).261
From the 31 cases of possible NMZL that were selected from the archive, 20 could be included 
as NMZL in the study after application of the strict criteria indicated above. The other 11 cases 
fulfilled the clinical, morphological, and cytogenetic criteria for NMZL, but were not classified 
as ‘NMZL’ by the immunohistochemical algorithm. These cases were included in the study as 
‘B-cell lymphoma, unclassifiable’ (BCL-u). Clinical features of patients with NMZL, FL, and 
BCL-u are indicated in table 1.
Table 8.1 Patient characteristics
NMZL (n=20) BCL-u (n=11) FL (n=20)
Male:Female 12:8 6:5 12:8
Median age (years) 64 56 59
Tumour localisation (n)
- Nodal
- Extranodal
20 (100%)
0 (0%)
11 (100%)
0 (0%)
19 (95%)
1 (5%) (parotid gland)
Ann Arbor stage (n)
- Stage I
- Stage II
- Stage III
- Stage IV
- unknown
6 (30%)
2 (10%)
3 (15%)
6 (30%)
3 (15%)
2 (18%)
3 (27%)
2 (18%)
2 (18%)
2 (18%)
1 (5%)
3 (15%)
3 (15%)
11 (55%)
2 (10%)
B symptoms (n) 1/14 (7%) 1/10 (10%) 2/18 (11%)
Bone marrow involvement (n) 7/15 (47%) 1/10 (10%) 10/16 (63%)
Concurrent diffuse large B-cell 
lymphoma at diagnosis
1 (5%) 1 (9%) 0 (0%)
Transformation during follow-up 2/16 (13%) 0/10 (0%) 7/19 (37%)
Grade
- Grade 1-2
- Grade 3A
- Grade 3B
NA NA 14 (70%)
5 (25%)
1 (5%)
BCL-u: B-cell lymphoma, unclassifiable; FL: follicular lymphoma; NA: not applicable; NMZL: nodal 
marginal zone lymphoma.
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Next generation sequencing
A custom Ion AmpliSeq panel (Life Technologies, Bleiswijk, the Netherlands) was used, which 
consisted of 410 primer combinations, covering the entire coding sequence or specific regions 
of interest of 20 genes involved in TLR/BCR/NF-kappaB signalling (Supplementary Table 1), 
achieving a theoretical coverage of 94.4% of the defined targets (Supplementary Table 2).
Amplicon libraries were generated in 2 pools with 20 ng of DNA input per pool according to 
the manufacturer’s instructions (Life Technologies). Sequencing was performed on an Ion 
Personal Genome Machine 200 (Life Technologies) using one Ion 318 chip per four DNA samples. 
Supplementary figure 1 shows the percentage of amplicons reaching different depths of coverage.
Sequences were analysed with the SeqNext software package (JSI Medical Systems, 
Kippenheim, Germany). Variants were called if the absolute number of variant reads was 25 
of higher, if the ratio of forward vs. reverse read directions did not exceed 30%/70%, and if the 
variant constituted at least 10% of the reads. Intronic mutations, mutations in untranslated 
regions and silent mutations were filtered out by adaptation of the software settings. Variants 
were called by the software, but variants that were also present in reactive lymph nodes were 
considered as single nucleotide polymorphisms or artefacts and were excluded. For missense 
mutations, in silico pathogenicity predictions were performed using PolyPhen 2.0  (http://
genetics.bwh.harvard.edu/pph2/), Align GVGD, and SIFT, using the Alamut software package 
(Version 2.1, Interactive Biosoftware, Rouen, France). Variants that were predicted not to be 
pathogenic by all prediction programs were considered benign and excluded. Mutations were 
confirmed by conventional Sanger chain-terminating sequencing in duplicate.
Statistical analysis
Data were analysed using IBM SPSS Statistics version 20 (Armonk, NY). Pearson’s Chi square 
test was used for comparison of categorical variables. Survival analysis was performed using 
Kaplan-Meier statistics with log-rank tests. Overall survival was defined as the time from 
date of diagnosis until the time of last follow-up or death. Event-free survival was defined as 
the time from date of diagnosis until the time of last follow-up or an adverse event (disease 
progression, relapse, second tumour, death from any cause). Two-tailed p values of 0.05 or 
lower were considered statistically significant.
RESULTS
Recurrent mutations in genes involved in BCR/TLR/NF-kappaB signalling
In NMZL, 9 of 20 cases (45%) displayed mutations in one or more of the genes tested, and 
in FL 12 out of 20 cases (60%) showed mutations, but the genes involved were different. 
In NMZL, mutations were most frequently observed in TNFAIP3 (in 6 cases, 30%) and 
CD79B (in 2 cases, 10%) (Figure 8.1A, Table 8.2). In single cases, mutations were observed 
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in CARD11, MYD88, and TNIP2. In FL, mutations in TNFRSF14 were most frequent (in 5 
cases, 25%), followed by TNFAIP3 (in 3 cases, 15%), and CARD11 (in 3 cases, 15%) (Figure 
8.1B, Table 8.3). Mutations in CD79B, MAP3K3, and MAP3K7 were detected in single cases. 
In the group of BCL-u, mutations in TNFRSF14 were most frequent, being present in 4 out of 11 
cases (36%) (Figure 8.1C, Table 8.4). Single mutations were observed in TNFAIP3, TRAF3, and TRAF7 
in this group. In all but one case, mutations in TNFAIP3 and TNFRSF14 were mutually exclusive.
 Mutations in TNFAIP3 or TNFRSF14 did not significantly correlate with disease stage, 
the presence of B-symptoms, overall survival or progression-free survival (data not shown).
TNFRSF14 mutations cluster with diagnosis
When using strict criteria for NMZL as was done in this study, TNFRSF14 mutations were not 
observed in any of the NMZLs. In contrast, TNFRSF14 was the most frequently mutated gene 
in both the group of FL and the group of BCL-u, being present in 25% and 36% respectively. 
Clinicopathological differences between NMZL and BCL-u
To investigate additional differences between the groups of NMZL and BCL-u, we compared 
the clinicopathological features of these two groups. NMZLs showed a trend towards more 
frequent bone marrow involvement with bone marrow involvement in 8 out of 15 (53%) patients 
with NMZL, but only 1 out of 10 (10%) patients with BCL-u (p = 0.054). 
Rearrangements involving BCL6 were observed in 4 out of 11 (36%) cases of BCL-u, but in only 
1 out of 19 (5%) NMZLs (p = 0.028, Figure 1). No clear differences were observed in disease 
stage, the presence of B-symptoms, or rate of transformation (Table 1). Overall and event-free 
survival were also similar between the two groups (Figure 8.2).
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Figure 8.1. Mutations detected in nodal marginal zone lymphoma (NMZL) (a), follicular lymphoma (FL) 
(b), and B-cell lymphoma, unclassifiable (BCL-u) (c). For a diagnosis of NMZL, both the morphological 
features and the immunohistochemical algorithm result supported this diagnosis. If the morphological 
features were consistent with NMZL, but the immunohistochemical algorithm did not support this 
diagnosis, the case was classified as BCL-u. All cases included as FL carried a BCL2 rearrangement. 
Mutations are indicated in red. The result from the immunohistochemical algorithm is indicated in the row 
labelled “algorithm” with a result consistent with FL as “F” and a result of BCL-u as “U”. For all cases 
included as NMZL in this figure, the immunohistochemical algorithm showed a result consistent with 
NMZL. The final row of Fig 1A and 1C shows the presence of a BCL6 rearrangement in red, which was 
studied by FISH.
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Table 8.2: Mutations affecting nf-kappab pathway genes in nodal marginal zone lymphoma
Gene Sample 
no.
Nucleotide change Exon Allelic 
frequency
Pathogenicity description
TNFAIP3 1002 c.2062G>T p.(Glu688*) 8 10% Known tumour 
suppressor gene, 
truncating (nonsense) or 
frameshift mutations  
pathogenic
1007 c.346C>T p.(Gln116*) 3 33% As above
1013 c.301_302delinsATGAGGACA 
p.(Gly101Metfs*41)
3 23% As above
c.338_341del p.(Trp113Serfs*9) 7 15% As above
1018 c.426G>A p.(Trp142*) 3 21% As above
c.1035C>G p.(Tyr345*) 7 27% As above
1031 c.296_315del p.(Gly99Alafs*34) 3 14% As above
1053 c.751dup p.(Tyr252Leufs*2) 5 10% As above
c.826_827dup p.(Asn277Leufs*11) 6 18% As above
CARD11 1031 c.1078A>G p.(Met360Val) 8 33% Known oncogene, 
missense mutation in 
coiled coil domain  
likely pathogenic
CD79B 1032 c.586_588del p.(Tyr196del) 5 31% Known oncogene, 
deletion and missense 
mutation in ITAM domain 
which is needed for 
signal transduction  
likely pathogenic
1050 c.586T>G p.(Tyr196Asp) 5 46% As above
MYD88 1052 c.794T>C p.(Leu265Pro) 5 11% Oncogene/ tumour 
suppressor gene not 
known, missense 
mutation in hotspot, 3/3 
prediction programs 
predict deleterious 
mutation  likely 
pathogenic
GVGD: Class C65
SIFT: Deleterious (score 
0.01)
PolyPhen2: Probably 
damaging (score 1.000)
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TNIP2 1052 c.787C>T p.(Arg263Trp) 4 49% Oncogene/ tumour 
suppressor gene not 
known, missense 
mutation in hotspot, 3/3 
prediction programs 
predict deleterious 
mutation  likely 
pathogenic
GVGD: Class C65
SIFT: Deleterious (score 
0)
PolyPhen2: Probably 
damaging (score 1.000)
aNumbering according to NM_001270508.1/ENST00000612899 (TNFAIP3); NM_003820.2/ 
ENST00000355716 (TNFRSF14); NM_0032415.5/ ENST00000396964 (CARD11); NM_000626.2/ 
ENST00000006750 (CD79B); NM_002468.4/ ENST00000396334 (MYD88); NM_024309.3/ ENST00000315423 
(TNIP2); NM_003300.3/ ENST00000560371 (TRAF3); NM_032271.2/ ENST00000326181 (TRAF7). 
bGVGD: Grantham Variation Grantham Deviation, risk classes are C0, C15, C25, C35, C45, C55 and C65 
with higher classes indicating a higher risk of a damaging mutation; SIFT: Sorts Intolerant From Tolerant, 
scores ranging from 0 to 1, a score of 0.05 or less is predicted to be damaging; PP2: PolyPhen-2, scores 
ranging from 0 to 1, with higher scores being predicted to be more damaging.
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Table 8.3 Mutations affecting nf-kappab pathway genes in follicular lymphoma
Gene Sample 
no.
Mutationa Exon Allelic 
frequency
Pathogenicity 
descriptionb
TNFAIP3 2024 c.477T>A p.(Tyr159*) 3 77% Known tumour 
suppressor gene, 
truncating (nonsense) or 
frameshift mutations  
pathogenic
2003 c.2090_2091del p.(Arg697Ilefs*54) 9 23% As above
2048 c.190_191delinsGA p.(Ile64Asp) 2 54% Missense mutation, 3/3 
prediction programs 
predict deleterious effect 
 likely pathogenic
GVGD: Class C45
SIFT: Deleterious (score 0)
PolyPhen-2: probably 
damaging (score 0.999)
c.101A>G p.(Asn34Ser) 2 56% Missense mutation, 0/3 
prediction programs 
predict deleterious 
mutation  probably not 
pathogenic
GVGD: Class C0
SIFT: Tolerated (score 
0.22)
PolyPhen-2: benign 
(score 0.004)
TNFRSF14 2002 c.36G>A p.(Trp12*) 1 30% Known tumour 
suppressor gene, 
truncating (nonsense) or 
frameshift mutations  
pathogenic
2009 c.423C>G p.(Tyr141*) 4 43% As above
2003 c.357_358del p.(Cys119Trpfs*114) 4 19% As above
c.71T>A p.(Val24Glu) 2 18% Missense mutation, 1/3 
prediction programs 
predict deleterious effect 
 possibly pathogenic
GVGD: Class C0
SIFT: Tolerated (score 
0.13)
PolyPhen-2: probably 
damaging (score 0.999)
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c.103T>C p.(Tyr35His) 2 18% Missense mutation, 
0/3 prediction programs 
predict deleterious 
effect  probably not 
pathogenic
GVGD: Class C0
SIFT: Tolerated (score 
0.54)
PolyPhen-2: benign 
(score 0.369)
2012 c.552G>C p.(Lys184Asn) 6 47% Missense mutation
1/3 prediction programs 
predict deleterious effect 
  possibly pathogenic
GVGD: Class C0
SIFT: Tolerated (score 
0.34)
PolyPhen-2: possibly 
damaging (score 0.588)
2013 c.334T>C p.(Ser112Pro) 4 24% Missense mutation
1/3 prediction programs 
predict deleterious effect 
  possibly pathogenic
GVGD: Class C0
SIFT: Tolerated (score 0.1)
PolyPhen-2: probably 
damaging (score 0.997)
CARD11 2010 c.644A>T p.(Lys215Met) 5 39% Known oncogene, 
missense mutation in 
coiled coil domain  
likely pathogenic 
2018 c.746A>C p.(Gln249Pro) 6 43% As above
2049 c.752T>C p.(Leu251Pro) 6 37% As above
CD79B 2013 c.617_618del p.(Thr206Ilefs*2) 6 28% Known oncogene, 
deletion and missense 
mutation in the ITAM 
domain which is needed 
for signal transduction  
likely pathogenic
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MAP3K3 2014 c.1616T>G p.(Phe539Cys) 16 12% Oncogene/ tumour 
suppressor gene not 
known, missense 
mutation, 2/3 prediction 
programs scores predict 
deleterious mutation  
possibly pathogenic
GVGD: Class C0
SIFT: Deleterious (score 
0)
PolyPhen2: probably 
damaging (score 1.000)
MAP3K7 2001 c.681A>T p.(Lys227Asn) 7 57% Oncogene/ tumour 
suppressor gene not 
known, missense 
mutation, 2/3 prediction 
programs scores predict 
deleterious mutation  
possibly pathogenic
GVGD: Class C0
SIFT: Deleterious (score 
0)
PolyPhen2: probably 
damaging (score 0.962)
aNumbering according to NM_001270508.1/ENST00000612899 (TNFAIP3); NM_003820.2/ ENST00000355716 
(TNFRSF14); NM_0032415.5/ ENST00000396964 (CARD11); NM_000626.2/ ENST00000006750 (CD79B); 
NM_203351.1/ ENST00000361357 (MAP3K3); NM_145331.1/ ENST00000369329 (MAP3K7).
bGVGD: Grantham Variation Grantham Deviation, risk classes are C0, C15, C25, C35, C45, C55 and C65 
with higher classes indicating a higher risk of a damaging mutation; SIFT: Sorts Intolerant From Tolerant, 
scores ranging from 0 to 1, a score of 0.05 or less is predicted to be damaging; PP2: PolyPhen-2, scores 
ranging from 0 to 1, with higher scores being predicted to be more damaging.
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Table 8.4 Mutations affecting nf-kappab pathway genes in b-cell lymphoma, unclassifiable
Gene Sample 
no.
Nucleotide change Exon Allelic 
frequency
Pathogenicity 
descriptionb
TNFAIP3 1064 c.2107_2108del p.(Asp703Cysfs*48) 9 36% Known tumour 
suppressor gene, 
truncating (nonsense) or 
frameshift mutations  
pathogenic
TNFRSF14 1028 c.283C>T p.(Gln95*) 3 20% Known tumour 
suppressor gene, 
truncating (nonsense) or 
frameshift mutations  
pathogenic
1023 c.852A>G p.(*284Trpext*78) 8 65% As above
1058 c.477_487del p.(Asp159Glufs*71) 5 53% As above
1020 c.288C>G p.(Cys96Trp) 3 29% Missense mutation 
3/3 prediction programs 
predict deleterious effect 
  likely pathogenic 
GVGD: Class C65 
SIFT: Deleterious (score 0) 
PP2: Probably damaging 
(score 1.000)
TRAF3 1023 c.598G>T p.(Val200Leu) 6 36% Tumour suppressor 
gene, 1/3 prediction 
programs predict 
possible deleterious 
effect  possibly 
pathogenic 
GVGD:  Class C0 
SIFT: Tolerated (score 
0.21) 
PolyPhen2: Possibly 
damaging (score 0.808)
TRAF7 1058 c.352C>A p.(Pro118Thr) 6 51% Oncogene/ tumour 
suppressor gene not 
known, 1/3 prediction 
programs predict 
possible deleterious 
effect  possibly 
pathogenic 
GVGD: Class C0 
SIFT: Tolerated (score 
0.08) 
PolyPhen2: Possibly 
damaging (score 0.651)
aNumbering according to NM_001270508.1/ENST00000612899 (TNFAIP3); NM_003820.2/ ENST00000355716 
(TNFRSF14); NM_003300.3/ ENST00000560371 (TRAF3); NM_032271.2/ ENST00000326181 (TRAF7). 
bGVGD: Grantham Variation Grantham Deviation, risk classes are C0, C15, C25, C35, C45, C55 and C65 
with higher classes indicating a higher risk of a damaging mutation; SIFT: Sorts Intolerant From Tolerant, 
scores ranging from 0 to 1, a score of 0.05 or less is predicted to be damaging; PP2: PolyPhen-2, scores 
ranging from 0 to 1, with higher scores being predicted to be more damaging
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Figure 8.2. Kaplan-Meier curves for progression-free (a) and overall (b) survival in patients with NMZL 
(solid line) vs. BCL-u (dotted line).
DISCUSSION
NF-kappaB transcription factors have an important role in multiple cellular processes including 
cell survival, maturation, response to stress, and immune responses. Not surprisingly, NF-
kappaB signalling has a role in oncogenesis; many solid tumours as well as haematological 
malignancies show activated NF-kappaB,265 making it an interesting treatment target. 
Indeed, therapeutic agents that target BCR/TLR/NF-kappaB signalling (including bortezomib, 
carfilzomib, lenalidomide, ibrutinib, and idelalisib) are increasingly becoming available. To 
select patients that will benefit from targeted treatment, it will be important to have information 
on mutations in these pathways. This has been most extensively studied in diffuse large B-cell 
lymphoma (DLBCL), in which ibrutinib was shown to be more effective in patients with the 
activated B-cell like (ABC-like) subtype of DLBCL in comparison to the germinal center 
B-cell-like (GC) subtype.266 This can be explained by the frequent presence of mutations that 
activate BCR signaling in ABC DLBCL, including mutations in CD79A/B, CARD11 and MYD88. 
Interestingly, mutations in MYD88 in the absence of CD79A/B mutations predicted resistance to 
ibrutinib which can be understood by the fact that MYD88 activates NF-kappaB independent of 
BTK.266 However, tumors with MYD88 mutations in combination with mutations in CD79A/B did 
respond to ibrutinib, which cannot be readily explained by known signaling pathways. 
In this study, we focused on mutations in genes involved in NF-kappaB signalling in NMZL, the 
rationale coming from the fact that an NF-kappaB signature has been shown in NMZL,223 and 
that other MZLs are also characterised by lesions in genes involved in NF-kappaB signalling.103 
Importantly, for a case to be included as NMZL, it had to fulfil strict criteria including 
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immunohistochemical expression of at least one putative marginal zone marker (MNDA and/
or IRTA1). For comparison, we studied 20 cases of typical FL, all with a BCL2 rearrangement. 
Finally, we included 11 unclassifiable cases that had been diagnosed as possible NMZL in 
routine diagnostics, but could not fulfil the strict criteria used for NMZL in this study.
Overall, we found fewer mutations in NMZLs compared to FLs, and the patterns were different. 
Mutations in TNFAIP3 were the most frequent abnormality detected in NMZLs. TNFAIP3 
mutations have been reported previously in lymphomas including MZLs,108, 113, 114, 267, 268 FL,123 
and DLBCL.269 Under normal circumstances, TNFAIP3 functions as an inhibitor of NF-kappaB 
signalling at multiple levels. Loss of function mutations cause increased activation of NF-
kappaB resulting in reduced apoptosis and cell proliferation.269, 270 In FL, TNFAIP3 mutations 
have been reported in association with transformation.123
TNFRSF14 was the most frequently mutated gene in both FL and BCL-u. TNFRSF14 is a 
member of the TNF receptor superfamily and triggering of TNFRSF14 has been suggested to 
render B-cells more susceptible to FAS-induced apoptosis.127, 128 In line with this, TNFRSF14 
can act as a tumour suppressor in a mechanism where mutations cause loss-of-function and 
evasion of T-cell mediated immune surveillance. Mutations in TNFRSF14 have been reported 
in 18-46% of FLs in previous studies and in 22% of diffuse large B-cell lymphomas.124, 125, 127 We 
report a lower percentage of mutated cases (in 16%) which can be explained by the fact that, in 
contrast to earlier reports, we did not study copy number changes. 
Mutations in TNFRSF14 were found frequently in FL, but not in any of the NMZLs when strict 
criteria for the latter diagnosis were used. These results suggest that TNFRSF14 mutations 
are not a feature of NMZL and that the presence of these mutations can be of diagnostic help to 
rule out a diagnosis of NMZL. Furthermore, the fact that TNFRSF14 mutations were a frequent 
event in the difficult category of BCL-u is promising, because these lymphomas are difficult 
to distinguish from FL. All but one case of BCL-u with a TNFRSF14 mutation showed a FL 
immunophenotype, suggesting that TNFRSF14 mutations point towards a diagnosis of FL. This 
is of potential diagnostic use in lymphomas in which differentiation between NMZL and FL is 
difficult, but the numbers are small and these results should be confirmed in an independent 
cohort before their use in diagnostics.
Rearrangements of BCL6 were only found in a single case of NMZL, but in 4 out of 11 cases of 
BCL-u. Although the numbers are small, this suggests that BCL6 rearrangements are rare in 
strictly defined NMZL.
Interestingly, the association between the absence of BCL2 translocations in FL and deletions of 
the chromosomal region containing TNFRSF14 (1p36) has been reported in patients who typical 
present with low stage inguinal disease with morphologically diffuse FL.271 A direct comparison 
is difficult however, because in the current study, we looked at mutations rather than deletions 
of TNFRSF14, which were also frequently detected in FLs with a BCL2 translocation.
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In NMZL and BCL-u, single mutations were detected in CARD11, MYD88, TNIP2, TRAF3, and 
TRAF7.  MYD88 is of particular interest, as the L265P mutation in MYD88 has been described 
in the large majority of lymphoplasmacytic lymphomas (LPL). The single NMZL in our series 
with a MYD88 mutation showed no plasmacytic differentiation. Also, the patient did not present 
with a clinical syndrome of hyperviscosity, fitting Waldenström macroglobulinaemia. We 
therefore believe it is justified to classify this lymphoma as a NMZL with a MYD88 mutation. 
However, the distinction between LPL and NMZL with a MYD88 mutation remains difficult as 
was emphasized during the 2014 meeting of the European Association for Haematopathology/ 
Society for Hematopathology meeting in which rare cases of NMZL with a MYD88 mutation 
were recognized.272
In this study, we used a targeted approach following on from the hypothesis that reported 
mutations in genes involved in NF-kappaB signalling could also have a role in NMZL. This 
targeted approach allowed a good coverage of the genes tested, but limits our results to this 
gene set only. It is likely that other mutations are also important in NMZL pathogenesis and 
accordingly, a recent study that combined whole exome sequencing, deep sequencing of tumour-
related genes, high resolution SNP array, and RNAseq, detected frequent abnormalities in 
JAK/STAT, NOTCH, NF-kappaB, and Toll-like receptor signalling, including frequent mutations 
in MLL2, PTPRD, and NOTCH2.273 In this study, among other genes, recurrent mutations were 
also detected in TNFAIP3, TNFRSF14, MYD88, BCL10, REL, CARD11, TRAF3, and BIRC3. This 
highlights the fact that multiple pathways are deregulated in NMZL, further complicating the 
prediction of responses to different targeted treatments.
While the number of different signalling pathways that can be deregulated in lymphomas and 
the heterogeneity of mutations described already pose a challenge for therapy prediction, 
this is further complicated by other factors influencing response to specific targeted therapy, 
including the epigenome and the tumour microenvironment. For the NF-kappaB pathway for 
example, activation can be caused by mutations, paracrine signalling, and Epstein-Barr virus 
infection and it is possible that patients could benefit from therapy targeting the NF-kappaB 
pathway, regardless of the exact mechanism. Therefore, ultimately, it might be necessary to 
move towards functional assays rather than mutation detection.
In conclusion, we detected frequent but heterogeneous mutations in genes related to BCR/
TLR/NF-kappaB signalling in both NMZL and FL. The strong correlation between TNFRSF14 
mutations and a FL immunophenotype is of potential diagnostic use, but confirmation in an 
independent cohort is warranted. In addition, with the increase of drugs that target pathways 
that converge on NF-kappaB, thorough knowledge on the mutational status of a lymphoma will 
be helpful to guide targeted treatment decisions.
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A central theme of this thesis is to develop methods to make a more reliable diagnosis of 
NMZL. A precise diagnosis is necessary for treatment and prognosis, but also for forming 
homogeneous study groups for research.  In the first part of the general discussion, the key 
findings of this thesis will be discussed in relation to the literature, thereby summarizing the 
current approach to the diagnosis and differential diagnosis of NMZL. In the second part, we 
will adopt a more broad approach and discuss the classification of indolent B-cell lymphomas 
and remaining problems in classification with possible solutions.
TOWARDS A MORE PRECISE DIAGNOSIS OF NMZL
Morphology
In chapter 3, the morphological features of indolent B-cell lymphomas without a BCL2 
rearrangement were studied and it was concluded that these show strong resemblance to the 
morphological features of NMZL. The following morphological features were recognized: 
Effaced architecture of the lymph node by a small B-cell proliferation with a follicular, marginal 
zone, or diffuse growth pattern. 
 1.  Centrocyte-like or ‘CLL-like’ small cell morphology with intermingled centroblasts. 
 2.  An immunophenotype  of a mature B-cell (CD20 and CD79a positive) with BCL2 
positivity and lacking expression of cyclin D1 and CD5. 
 3.  The cases with a follicular/ nodular growth pattern showed follicular colonization; 
the presence of both neoplastic and reactive cells in a follicle.
The first three morphological features are not very specific and also very well compatible with 
a diagnosis of FL. It is the fourth feature of follicular colonization that was most crucial in 
differentiating lymphomas with and without BCL2 rearrangements from each other. Follicular 
colonization is the process in which neoplastic lymphoma cells from outside the secondary 
lymphoid follicle infiltrate the germinal center and intermingle which the pre-existing non-
neoplastic cells. 
On casual inspection, follicular colonization can impart an appearance which strongly 
resembles FL. FL is characterized by a nodular proliferation of B-cells with the presence of 
follicles which show BCL2 expression in the large majority of cases. In follicular colonization, 
the remaining follicular architecture causes a nodular/ follicular pattern. In addition, the 
neoplastic cells are BCL2 positive and because they are present in the follicles this suggests 
the presence of BCL2 positive follicles. Also, the remaining germinal center cells will retain 
BCL6 and/ or CD10 which will also suggest a FL. The key to recognize follicular colonization is 
to look for features of a non-neoplastic germinal center in the background. The features that 
are most helpful include:
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 1.  The presence of BCL2 negative non-neoplastic cells intermingled with BCL2 
positive tumor cells. To recognize this often requires assessment of the BCL2 
staining at high power, although at low power the follicles will already appear 
somewhat heterogeneous.
 2.  The presence of foci with high Ki67 staining. Normal germinal centers show very 
high Ki67 staining, reflecting their strong proliferative activity. In contrast, indolent 
B-cell lymphomas show Ki67 in a low percentage of neoplastic cells. The presence 
of nodular foci with high Ki67 staining therefore suggests the presence of remnants 
of non-neoplastic germinal centers.
In chapter 7 another layer of complexity is added to the subject of follicular colonization. In this 
chapter, we show that NMZL tumor cells can change their protein expression in different micro-
anatomical compartments. More specifically, in a subset of NMZLs, tumor cells that enter the 
germinal centers adopt the germinal center immunoprofile by acquiring BCL6 expression and 
lowering expression of BCL2. This increases the resemblance to a normal germinal center 
and to FL and makes the recognition of follicular colonization even more difficult. The features 
describe above of BCL2 negative cells and foci of high proliferative activity will still help in 
the differential diagnosis. Another feature that might help is that CD10 expression in the pre-
existent germinal center cells was lost in the lymphomas that showed follicular colonization 
with gain of BCL6. However, it must be emphasized that the number of cases studied was very 
small and additional lymphomas should be studied to establish the extent of this problem for 
daily practice. Also, the loss of CD10 expression on pre-existent germinal center cells does not 
appear to be universal as a larger series on NMZLs with prominent follicular colonization did 
not report loss of CD10.199
Immunohistochemistry
Immunohistochemistry plays a very important role in accurate lymphoma classification. 
For many types of indolent B-cell lymphomas, routine immunohistochemical stainings are 
available that allow recognition of these entities. Unfortunately, for marginal zone lymphomas 
and for lymphoplasmacytic lymphoma, no specific immunohistochemical markers are used 
in routine diagnostic practice.  However, putative marginal zone markers have been reported 
and in chapter 5, we have tested the combined value of multiple germinal center markers 
(CD10, BCL6, LMO2, and HGAL) and putative marginal zone markers (MNDA and IRTA1) in the 
distinction between NMZL and FL. This resulted in the formation of an algorithm that helps 
to distinguish between NMZL and FL. It should be emphasized that this algorithm forms an 
addition to, rather than a substitution for the classical features that help in the distinction 
between NMZL and FL.
 NMZLs were selected based on morphological criteria as discussed above. To 
minimize selection bias, we did not consider expression of germinal center markers as an 
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exclusion criterion for NMZL. As expected, the group of ‘NMZLs’ was rather heterogeneous 
with a significant subset of cases showing a staining pattern of ‘FL’ or  ‘B-cell lymphoma, 
unclassifiable’. Accordingly, addition of the immunohistochemical algorithm to standard 
diagnostic procedures would result in a smaller, but potentially more homogeneous group of 
NMZLs.
 For routine diagnostic practice, it would be helpful to use marginal zone markers for 
a diagnosis of NMZL, and MNDA and IRTA1 appear to be good candidates. From our studies, 
MNDA appears to be most useful as it is positive in a significantly larger subset of NMZLs 
than IRTA1 (70% vs. 21%). Also, the MNDA stain results in a sharp and strong nuclear staining 
facilitating easy interpretation. IRTA1 was more difficult to interpret due to weaker staining and 
background staining. However, in contrast to our study, the earlier report on IRTA1 showed 
positivity in 73% of NMZLs.220 The origin of this large difference is unclear but could be due to 
differences in tissue processing, the batch of antibodies used, or the diagnostic criteria used. 
 An important point to consider is that the algorithm was developed from and 
primarily tested on FLs with a BCL2 rearrangement. However, in diagnostic practice, the BCL2 
rearrangement can be easily studied and the differential diagnosis will be between NMZLs and 
FLs without a BCL2 rearrangement. To compare FL without a BCL2 rearrangement with NMZL 
is problematic because it is very difficult to be certain of either diagnosis. We therefore decided 
to compare NMZL with FLs with a BCL2 translocation to have at least one homogeneous group 
for comparison. The downside of this approach is that the results might not translate fully to the 
actual diagnostic problem. We have partially addressed this problem by testing a small number 
of FLs (n=6) without a BCL2 translocation with a typical morphology of FL which all stained as 
‘FL’ in the algorithm, but the study of larger numbers is required for firm conclusions.
Molecular genetics
Chapter 8 describes mutations in genes involved in BCR/TLR/NF-kappaB signaling in 45% of 
NMZLs. Mutations in TNFAIP3 and CD79B were most frequently observed. These mutations 
are expected to induce activation of the NF-kappaB pathway, thereby contributing to tumor 
progression. Detection of these mutations cannot be used to recognize NMZLs as they are also 
present in other types of indolent B-cell lymphomas, most notably in extranodal MZLs and 
FL.113, 123 In FLs we also found mutations in TNFAIP3 and CD79B, but mutations in TNFRSF14 
were more frequent and present in a quarter of cases. Interestingly, TNFRSF14 mutations 
were not found in a group of strictly defined NMZLs, indicating that detection of TNFRSF14 
mutations could be helpful in the differential diagnosis between NMZL and FL. However, to 
use TNFRSF14 mutation status in diagnostic practice would require the study of more patients 
for confirmation.
In this study, we used a multiplex PCR protocol followed by next generation sequencing (NGS) 
for mutation detection on a panel of genes. In comparison to traditional PCR and Sanger 
sequencing, this has the advantage that a large number of amplicons can be amplified and 
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sequenced simultaneously.  Also, NGS allows a high coverage of the genes of interest. A 
disadvantage of NGS using gene panels instead of exome or whole genome NGS, is that it only 
studies a limited number of the genes. This is relevant for our study, because we had to select 
genes of interest from the literature to include in the gene panel. This also means that it is not 
possible to find novel genes of interest with this approach. Nevertheless, we used the targeted 
approach because for most of the NMZLs in the study only formalin-fixed paraffin-embedded 
tissue was available and because normal tissue for comparison was not generally available.
Integrated diagnosis of NMZL
A diagnosis of lymphoma requires integration of information in the different domains (clinical, 
morphological, immunohistochemical, molecular) and a diagnosis of NMZL is no exception. 
The power of an integrated diagnosis is also evident from the studies described in this thesis. 
In chapter 8, we used an integrated approach combining the morphological approach from 
chapter 3 and the immunohistochemical algorithm from chapter 5. Three groups were created:
 1.  NMZL. These lymphomas fulfilled the morphological criteria for NMZL as described 
in chapter 3 and also had an algorithm result of “NMZL”.
 2.  B-cell lymphoma, unclassifiable (BCL-u). These lymphomas fulfilled the 
morphological criteria for NMZL but showed an algorithm result of “FL” or “B-cell 
lymphoma, unclassifiable”.
 3.  FL. These lymphomas were indolent B-cell lymphomas with the morphology of FL 
and a BCL2 rearrangement.
Mutation analyses were subsequently performed in these three groups and an interesting 
pattern emerged: TNFRSF14 mutations were found in the FL group and in the BCL-u group 
but not in any of the lymphomas in the NMZL group. This suggests that the distinction made by 
morphology and immunohistochemistry also has some relevance on the molecular level and 
forms a good illustration of the power of an integrated approach.
From the above, several recommendations for diagnostic practice can be made:
 1.  Before making a diagnosis of FL, follicular colonization has to be considered. Ki67 
and BCL2 are important immunohistochemical markers to help recognize follicular 
colonization.
 2.  The threshold should be low for performing BCL2 rearrangement studies for 
confirmation of a diagnosis of FL.
 3.  In the differential diagnosis between NMZL and FL without a BCL2 translocation, 
use of positive markers for NMZL like MNDA or IRTA1 is advisable in addition 
to germinal center markers. However, the fact that these are not available 
commercially forms an important impediment for their use in diagnostic practice.
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 4.   Lymphomas in the spectrum between NMZL and FL that express both germinal 
center markers and marginal zone markers or that express none of these markers 
should be classified as B-cell lymphoma, unclassifiable.
 5.  Mutation analysis of TNFRSF14 should be considered as an additional criterion in 
the distinction between NMZL and FL.
 For the WHO classification of lymphoid neoplasms, inclusion of a category of ‘indolent nodal 
B-cell lymphoma, unclassifiable’ should be considered. This will prevent contamination of the 
categories of FL and NMZL. However, before such a category is adopted, positive markers for 
NMZL should be available for routine use because otherwise the distinction between NMZL 
and ‘indolent nodal B-cell lymphoma, unclassifiable’ will be virtually impossible.
BREAKING OUT OF CIRCULAR REASONING
An important problem in studies into disease classification is circular reasoning. If one is to 
study the properties that define a particular disease, it is necessary to use a set of properties to 
form a study group. These properties will then turn out to be the properties of that disease in a 
perfect circular argument. Although this pitfall is obvious, it is sometimes difficult to avoid. This 
is well illustrated by studies into the separation of NMZL from FL using immunohistochemistry. 
Expression of germinal center markers is often reported to be absent or very rare in NMZL and 
frequent in FL. But looking more closely at some of these studies, expression of germinal 
center markers was used as an exclusion criterion for NMZL and in addition, expression of 
other germinal center markers which were tested in the study resulted in reclassification of 
NMZL to FL.193 
In an attempt to avoid circular reasoning we adopted a less biased approach by starting from 
morphological and cytogenetic criteria to study the immunohistochemical features of NMZL 
versus FL. Not surprisingly, the results were quite heterogeneous, especially in the NMZL 
group, and we found frequent germinal center marker expression in ‘NMZLs’. It is controversial 
to consider low-grade B-cell lymphomas with germinal center marker expression to be NMZLs 
and for practical purposes it is also much more convenient to consider all lymphomas with 
germinal center marker expression to be FL rather than NMZL. However, to simply consider 
them to be FLs is also problematic because the morphological features in our series pointed 
toward a diagnosis of NMZL. Ultimately, rather than arguing if these lymphomas are NMZLs or 
FLs, the best way to proceed might be to study larger groups of these lymphomas in different 
ways to allow refinement of our classification.
One way to study the borderland between FL and NMZL without circular reasoning could be 
to adopt a totally unbiased approach which focuses on the collection of a large set of features 
of a large series of indolent B-cell lymphomas without making a diagnosis. Analysis of these 
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features in the different diagnostic domains (clinical presentation, morphology, protein 
expression, molecular analysis of gene mutations and copy number alterations) can then be 
used to make subgroups using cluster analysis. It would then be very interesting to see if 
specific clusters arise or rather a spectrum of disease is present.
NODAL MARGINAL ZONE LYMPHOMA – HOW MANY ENTITIES?
In current diagnostic practice, NMZL is mainly a diagnosis of exclusion. Not surprisingly 
therefore, the group of NMZLs in our studies showed heterogeneous features in the clinical, 
morphological, and molecular domains. Given this heterogeneity, it can be questioned whether 
‘NMZL’ actually represents a single entity, multiple entities, or rather a spectrum of disease. 
At present, this question is difficult to answer, but the results from this thesis raise some 
more specific questions. First, it would be interesting to compare larger groups of ‘NMZLs’ 
with expression of putative marginal zone markers (MNDA and/ or IRTA1) to ‘NMZLs’ lacking 
expression of these markers (i.e. ‘B-cell lymphomas, unclassifiable’) to see the differences 
in clinical features at presentation, prognosis, and treatment response. Second, it would 
be interesting to determine the relationship between different categories of ‘NMZL’ and the 
relationship to normal B-cells (How often does plasmacytic differentiation occur? Does the 
BCR show evidence of hypermutation? Is there stereotypy in the BCRs?). It has been shown 
for CLL/SLL and MCL that lymphomas with hypermutated BCRs show a better prognosis than 
unmutated BCRs and it would be interesting to determine if this also holds true for lymphomas 
in the NMZL spectrum.
To get an idea of the variation in the NMZL spectrum, the unbiased approach discussed above 
would be very informative to help in determine which entities actually are present within the 
diagnosis of NMZL.
GRAY AREAS IN LYMPHOMA CLASSIFICATION
The ideal disease classification would consist of sharply defined and non-overlapping entities 
that encompass the entire spectrum of disease. In addition, these entities would have to be as 
meaningful as possible for the patient with respect to refinement of treatment and prognosis. 
Unfortunately, this classification utopia has not been achieved yet and it is not likely to be 
achieved in the near future due to several reasons.
 First and most importantly, biology has many gray areas and lymphomas resembling 
these gray areas are very difficult to classify. For aggressive lymphomas, these gray areas are 
mentioned explicitly in the WHO classification of 2008 with separate categories for lymphomas 
in the spectrum between Burkitt lymphoma and DLBCL and in the spectrum between classical 
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Hodgkin lymphoma and DLBCL.19 However, many more gray areas exist, one of which is the 
gray area between FL and NMZL. For pathologists it is difficult to classify lymphomas with 
features intermediate between different entities and subjectivity and interobserver variability 
can be expected.
Indeed, significant interobserver variability has been reported in lymphoma diagnosis with 
discordance rates from 6 up to 27% for expert central review.274-276 The increase of small samples 
for diagnosis could increase interobserver variability and in one study it was suggested that FL 
and NMZL are particularly difficult to diagnose on small samples.277 
If there is disagreement whether a particular case represents NMZL or FL without a BCL2 
rearrangement, it will be very difficult to tell who is right, as there is no true gold standard for 
NMZL diagnosis. The putative marginal zone markers MNDA and IRTA1 might be a first step 
towards a positive diagnosis of NMZL, but a better insight into the pathogenesis of NMZL is 
expected to provide a stronger improvement in the accuracy of NMZL diagnosis. Paradoxically, 
to select patients to study the pathogenesis of NMZL requires the formation of a homogenous 
study population which requires the use of positive markers for NMZL diagnosis.
TARGETED TREATMENT OF B-CELL LYMPHOMA
With the development of techniques for large-scale sequencing, knowledge of the molecular 
alterations that underlie lymphomas has increased enormously. At the same time, more 
and more drugs are being developed that target deregulated pathways in lymphomas. B-cell 
receptor (BCR) signaling is one of the major targets of these novel drugs, with ibrutinib and 
idelalisib being prominent new drugs that target these pathways. Additional mechanisms 
that are being exploited for targeted therapy include inhibition of BCL2, inhibition of BCL6, 
epigenetic therapy, and proteasomal inhibition (Figure 9.1).  
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Figure 9.1 Deregulated pathways in B-cell lymphoma with targeted treatments.
BCR signaling inhibitors
Binding of its ligand to the BCR results in a signaling cascade that ultimately results in NF-
kappaB activation (Figure 9.2). Bruton’s tyrosine kinase (BTK) forms an intermediate step in 
this signaling cascade. Ibrutinib binds covalently to BTK at cysteine 481, thereby preventing 
phosphorylation and blocking of downstream signaling.278, 279 In the United States, ibrutinib has 
been approved by the Food and Drug Administration (FDA) for treatment of patients with CLL 
and recurrent MCL. In Europe, the European Medicines Agency (EMA) has approved its use in 
patients with CLL, recurrent MCL, and Waldenström macroglobulinemia. In addition, efficacy 
of ibrutinib has been shown in DLBCL, mainly in the activated B-cell-like (ABC) subtype.266, 
280 However, not all patients show a response to ibrutinib and both primary and secondary 
mechanisms of resistance have been identified.280
 In a small number of patients with MCL and in MCL cell lines, resistance to ibrutinib 
was associated with PI3K-AKT activation.281, 282 In resistant cell lines, ibrutinib did decrease BTK 
phosphorylation, but this did not result in decreased survival. The lack of an effect of ibrutinib 
can be explained by persistent activation of the BCR pathway through PI3K-AKT signaling. In 
a similar fashion, MCLs with activation of the alternative NF-kappaB pathway show resistance 
to ibrutinib which blocks the classical NF-kappaB pathway.283 Genetic mechanisms underlying 
activation of the alternative NF-kappaB pathway include mutations in TRAF2 and TRAF3, both 
encoding for inhibitors of alternative NF-kappaB signaling. 
 In DLBCL, ibrutinib is more effective in patients with the ABC-like subtype of DLBCL 
in comparison to the germinal center B-cell-like (GC) subtype.266 This can be explained by 
the frequent presence of mutations that activate BCR signaling in ABC DLBCL, including 
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mutations in CD79A/B, CARD11 and MYD88. Interestingly, mutations in MYD88 in the absence 
of CD79A/B mutations predicted resistance to ibrutinib which can be understood by the fact that 
MYD88 activates NF-kappaB independent of BTK.266 However, tumors with MYD88 mutations 
in combination with mutations in CD79A/B did respond to ibrutinib, which cannot be readily 
explained by known signaling pathways.
 In contrast to DLBCL, in lymphoplasmacytic lymphoma (LPL) MYD88 mutations 
predict response rather than resistance to ibrutinib, which is in line with experiments showing 
BTK phosphorylation after mutant MYD88 overexpression in LPL.284 MYD88 L265P mutations are 
present in the large majority (>90%) of lymphoplasmacytic lymphomas119, 228, 285, and patients 
with MYD88 mutated LPL show a major response in 91% versus only 29% in patients with 
MYD88 wildtype LPL.286 Mutations in CXCR4 are also associated with a decreased response to 
ibrutinib in LPL with a major response rate of 91% vs. 62% for patients with LPL without and 
with CXCR4 mutations. This might be caused by activation of AKT signaling by CXCR4 mutations 
in which the mechanism might be similar to that in MCL as discussed above.287, 288 CXCR4 is a 
G-protein coupled chemokine receptor with a role in lymphocyte homing and migration. CXCR4 
mutations of WHIM-like type are present in 30% of LPLs. WHIM-like describes the presence 
of nonsense and frameshift mutations that are also present in the germline of patients with 
Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome.
In CLL, an unmutated BCR appears to be related to a better response to ibrutinib with one 
study showing response rates of 33% vs. 77% for mutated vs. unmutated CLL.289 This could 
be due to a larger dependence on BCR signaling in BCR unmutated CLL.280 CLL patients with 
deletion of 17p and/or TP53 mutations showed a good response to ibrutinib. Interestingly, 
CLL patients with a mutated BCR, without 17p loss or TP53 mutations, respond very well on 
conventional chemoimmunotherapy.290
Secondary resistance to ibrutinib occurs as well. In both CLL and MCL, C481S mutations in 
BTK have been detected after ibrutinib therapy which where not present before therapy.291, 292 
This mutation is located at the active site of BTK and causes a strong decrease in the affinity 
for ibrutinib for BTK. In addition, mutations in PLCG2 have been detected after treatment with 
ibrutinib.292 These are gain-of-function mutations which activate BCR signaling downstream 
of BTK.293
Other novel drugs in targeting B-cell receptor signaling are directed against PI3K or SYK. 
Idelalisib and duvelisib are inhibitors of PI3K that target specific isoforms of the p110 subunit 
of PI3K. Idelalisib targets the delta isoform and duvelisib targets both the delta and gamma 
isoform. Idelalisib has been shown to be effective in patients with relapsed CLL294 and indolent 
non-Hodgkin lymphoma (NHL), including FL, MZL, and LPL.295, 296 In MCL, idelalisib was also 
effective but the majority of patients showed only a short response duration.297 Resistance 
mechanisms for idelalisib have not been studied as well as for ibrutinib, but higher expression 
of other PI3K isoforms has been suggested as a mechanism from in vitro studies.298 In addition, 
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activation of other oncogenic pathways such as MYC have been hypothesized as a resistance 
mechanism for idelalisib resistance.299 Idelalisib has been approved by the FDA for treatment of 
patients with relapsed CLL in combination with rituximab and for patients with relapsed FL and 
SLL. In Europe, idelalisib is authorized in combination with rituximab for use in patients with 
refractory FL and patients with refractory CLL or CLL with 17p deletion or TP53 mutation in 
patients who are too frail for standard chemotherapy. Currently, the EMA has started a review 
of idelalisib because of reported serious adverse events, mainly due to infections. 
Duvelisib has been studied in indolent NHL and CLL in which overall response rates of 65% and 
55% were found, respectively.300, 301 
SYK inhibitors fostamatinib and entospletinib have been studied in small groups of patients with 
lymphoma, but response rates have been moderate at best with significant toxicity, especially 
in a study into the combination of entospletinib with idelalisib.302-305
Figure 9.2 Activation of B-cell receptor (BCR) signaling induces NF-kappaB activation via SYK, BTK, and 
PKCB.  In addition, BCR signaling activates the PI3K pathway. Interleukin 1 receptor (IL1R) and Toll-like 
receptor (TLR) signaling also induces NF-kappaB activation. Deregulated pathways in B-cell lymphoma 
with targeted treatments. In lymphoplasmacytic lymphoma, mutated MYD88 causes BTK activation.
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BCL2 inhibitors
Venetoclax is a BH3 mimetic drug that mimics the effect of physiological antagonists of BCL2. 
It is less active against BCL-xL, which causes less frequent thrombocytopenia in comparison 
to its predecessor navitoclax.306, 307 Venetoclax has been shown to be effective in relapsed or 
refractory CLL, in which a response was observed in 79% of patients with a complete response 
in 20%.308 In a study of multiple types of NHL, venetoclax monotherapy showed response in 15% 
of patients with DLBCL and 34% of patients with FL, with responses in DLBCL being only short-
lived.309 Therefore, venetoclax might be better used in combination with other drugs which is 
also suggested by the first studies into combination treatment including venetoclax.310 
Another method to inhibit BCL2 is by using DNA interference with liposome-encapsulated 
oligonucleotides that hybridize to the BCL2 gene.311 Using this approach, responses have been 
observed in small groups of patients with FL and DLBCL.312
BCL6 inhibitors
Studies into BCL6 inhibitors are currently limited to in vitro and mice studies. These studies 
show a strong response of tumors to BCL6 inhibition in vitro and in vivo, but oncogene addiction 
to BCL2 was observed in response to BCL6 inhibition, indicating that BCL6 inhibitors could be 
particularly useful in combination with BCL2 inhibitors.313-315 In addition to drugs specifically 
targeting BCL6, histone deacetylase (HDAC) inhibitors also counteract the effects of BCL6.316
Epigenetic therapy
In hemato-oncology, HDAC inhibitors are mainly used for the treatment of patients with T-cell 
lymphoma, but limited studies have also been performed in B-cell lymphomas. Phase II studies 
with the HDAC inhibitor vorinostat in patients with relapsed or refractory FL, MZL, or MCL 
showed a modest response in patients with FL and MZL, but not MCL.317, 318 In a follow-up study 
with vorinostat-rituximab combination treatment in patients with mostly FL, a similar effect 
was seen with a response in half of patients.319 In addition to HDAC inhibitors, EZH2 inhibitors 
are being studied in phase I trials of non-Hodgkin lymphomas.305
Proteasome inhibitors
Inhibition of the proteasome in hematological as well as solid tumors induces a wide range of 
effects including anti-proliferative and pro-apoptotic effects in vitro.320 Although the ubiquitin-
proteasome system also has key functions in normal cells, proteasome activity has been shown 
to be higher in hematological malignancies, forming a basis for in vivo use of proteasome 
inhibitors in these tumors.321, 322 Bortezomib was the first proteasome inhibitor approved for 
clinical use and is currently approved by the FDA and EMA for use in multiple myeloma (MM) 
and MCL. Carfilzomib was developed after bortezomib. In contrast to bortezomib, it binds 
irreversibly to the proteasome. In addition, it may cause less frequent peripheral neuropathy, 
one of the major side effects of bortezomib.323 Carfilzomib is approved by both the FDA and 
146
CHAPTER 9
EMA for use in MM. Currently, novel compounds that can be used orally or that have less 
side-effects are being tested. In addition, inhibitors of the immunoproteasome are under 
development. Immunoproteasomes are predominantly present in hematopoietic cells and 
immunoproteasome inhibition is therefore a potentially more targeted method of proteasome 
inhibition.320 Furthermore, compounds that inhibit components of the ubiquitin-proteasome 
system other than the proteasome are being developed.320
 Although initially thought to be mainly due to NF-kappaB pathway inhibition, the effect 
of proteasome inhibitors is manifold and includes inhibition of ERK signaling, upregulation 
of pro-apoptotic proteins, downregulation of anti-apoptotic proteins, anti-angiogenic effects, 
inhibition of DNA repair, disruption of tumor-microenvironment interactions and stabilization 
of p21, p27 and p53.324
Prediction of effective targeted treatment
With the increase of novel targeted treatments, the pressing question is which patient should 
receive which treatment. To select patients for treatment, the diagnosis still forms a starting 
point to select patients, but refinements are already being added. Particularly in DLBCL, more 
and more clinical trials are aiming particularly at the germinal center-like or activated B-cell-
like type of DLBCL. An important next step is to use results from molecular diagnostics for 
treatment selection, which is now being adopted for alterations of MYC in DLBCL. It is expected 
that the use of molecular diagnostics for treatment prediction will increase significantly as 
more and more mechanisms for resistance and sensitivity become known. The mutations that 
predict response or resistance to ibrutinib are well studied in DLBCL and need to be evaluated 
in the other lymphoma entities.266 It can also be expected that complexity will increase as more 
molecular events relevant for prediction of therapy response will be detected and more drugs 
developed. This also means that large clinical trials will become more difficult as each patient 
will have a different lymphoma with a different genetic background and novel approaches to 
clinical studies should be introduced.
 Another question that needs to be answered in the near future is whether targeted 
mutation detection will suffice for treatment prediction. Mutations in non-coding regions, 
epigenetic alterations, and the micro-environment could all have an impact on the response 
to a particular treatment. In line with this, it might be necessary in the future to add functional 
studies to guide treatment decisions.
NEW APPROACHES TO B-CELL LYMPHOMA CLASSIFICATION
The current WHO method of lymphoma classification starts from the assumption that a 
limited set of entities are present that encompass the entire spectrum of disease. Indeed, in 
diagnostic practice, the large majority of lymphomas fit well into one of the defined entities. 
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At the same time, significant heterogeneity exists within entities. For example in CLL, tumors 
with unmutated IGH variable regions confer a worse prognosis in comparison to those with 
mutated IGH variable regions. Interestingly, it is now also recognized that patients with MCLs 
with a mutated IGH variable region do better than those with unmutated MCLs and perhaps 
a common phenomenon is emerging where patients with small cell B-cell lymphomas with 
mutated IGH do better.325 Also in the category of NMZL significant heterogeneity is present 
which is clearly illustrated by the results in this thesis.
 In addition to heterogeneity within entities, some lymphomas are difficult to classify 
as a specific type of lymphoma, which was one of the main starting points of this thesis. It could 
be argued that rather than bending the lymphoma to fit into one of the entities, we should adopt 
a more flexible approach to disease classification. Especially in the spectrum between FL and 
NMZL, forced disease classification appears to be hampering rather than facilitating a clear 
message to the clinician. A more flexible approach of classification could focus on features 
of the lymphoma rather than the diagnostic category. For example, a diagnosis of a ‘mature 
small cell B-cell lymphoma with a mutated BCR and cyclin D1 translocation’ already offers 
more in terms of prognosis than a diagnosis of ‘mantle cell lymphoma’. It would then be very 
interesting to see which features predict prognosis and therapy response across the spectrum 
of small B-cell lymphomas. Ultimately, with further refinement of diagnostic procedures, each 
patient could indeed have a unique diagnosis in which a comprehensive analysis of important 
features of the patient and the tumor predict prognosis and treatment response.
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SUMMARY
Accurate lymphoma classification is essential to guide patient management, to determine 
prognosis, and to facilitate research. In the current World Health Organization (WHO) 
classification, lymphomas are defined as entities with disease characteristics in the clinical, 
morphological, immunophenotypic, and genetic domains. Although many lymphomas 
can be classified reliably using this system, gray areas still remain. Nodal marginal zone 
lymphoma (NMZL) is one of the lymphomas that is difficult to classify, because no specific 
immunophenotypic or genetic features are known, making it essentially a diagnosis of 
exclusion. In particular, the distinction between NMZL and follicular lymphoma (FL) is often 
problematic. In this thesis, differences between NMZL and FL in the different domains of the 
WHO classification are studied with the ultimate goal to better distinguish between NMZL and 
FL.
Chapter 2 reviewed the literature on NMZL at the start of this thesis. Striking heterogeneity 
was observed in in the morphology, immunophenotype, and genetic features of NMZL.
Chapter 3 built the hypothesis that a subset of low-grade B-cell lymphomas diagnosed as FL 
actually has features of NMZL. In thirty-three low-grade B-cell lymphomas without a BCL2 
rearrangement, highly recurrent morphological features were noted which were strongly 
overlapping with the morphological features of NMZL. This raised the hypothesis that a 
subset of low-grade B-cell lymphomas with a follicular growth pattern but without a BCL2 
translocation actually represents NMZL. 
In chapter 4, the clinical features of fifty-six patients with NMZL in comparison to forty-six patients 
with follicular lymphoma (FL) were assessed. Patients with NMZL and FL had a largely similar 
clinical presentation, but patients with FL had a higher disease stage at presentation, more 
frequent abdominal lymphadenopathy and bone marrow involvement, and showed more common 
transformation into diffuse large B-cell lymphoma (DLBCL) during the course of disease. Overall 
survival and event-free survival were similar for patients with NMZL and FL, but factors associated 
with worse prognosis differed between the two groups. Transformation into diffuse large B-cell 
lymphoma was associated with a significantly poorer outcome in both groups, but the phenotypes 
were different: DLBCL arising in FL was mainly of germinal center B-cell phenotype whereas 
DLBCL arising in NMZL was mainly of non-germinal center B-cell phenotype.
Chapter 5 compared established and novel immunohistochemical markers for the 
differentiation between NMZL and FL, including MNDA and IRTA1 which are potential 
‘marginal zone markers’. This resulted in the construction of an algorithm combining the 
immunohistochemical results for CD10, BCL6, LMO2, HGAL, MNDA, and IRTA1. Importantly, 
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this algorithm included a category of low-grade B-cell lymphoma, unclassifiable, preventing 
contamination of the FL and NMZL categories.
Chapter 6 described the method of sequential immunohistochemistry, which allows the 
immunohistochemical staining of a single histological slide with multiple antibodies. Using 
overlays of digital images of the different stained slides, expression of multiple proteins in 
single cells can be assessed. This method was used in chapter 7 to study differences in protein 
expression in NMZL in different micro-anatomical compartments. Tumor cells were defined 
as MNDA-positive cells and it was shown that these putative tumor cells change expression 
upon entry into the germinal center with upregulation of BCL6 and Ki67 and downregulation of 
BCL2 in a subset of cases. Although this complicates the assessment of follicular colonization 
further, careful assessment of BCL2 and Ki67 will still allow a distinction between true 
neoplastic follicles and follicular colonization in most cases.
In chapter 8, a panel of genes involved in B-cell receptor and/or Toll-like receptor signalling 
resulting in activation of nuclear factor kappa B (NF-kappaB) was studied in 20 NMZLs, 20 
FLs, and 11 cases of B-cell lymphoma, unclassifiable (BCL-u). NMZLs were strictly defined 
and had to fulfil the morphological criteria as established in chapter 3 and had to have a result 
of ‘NMZL’ in the algorithm as established in chapter 5. BCL-u showed the morphological 
features of NMZL, but a different result from the algorithm. FLs were all required to have a 
BCL2 rearrangement.
Mutations were found in 9 NMZLs, with recurrent mutations in TNFAIP3 and CD79B. In FL, 
mutations were found in 12 cases, with recurrent mutations in TNFRSF14, TNFAIP3, and CARD11. 
In BCL-u, mutations were found in 5 cases with recurrent mutations in TNFRSF14. TNFRSF14 
mutations were present in FL and BCL-u, but not in any of the NMZLs. In the group of BCL-u, 
TNFRSF14 mutations clustered with a FL immunophenotype. These results suggest that 
TNFRSF14 mutations point towards a diagnosis of FL and can be used in the sometimes difficult 
distinction between NMZL and FL. In addition, the presence or absence of specific mutations in 
pathways converging on NF-kappaB could be important for decisions regarding targeted treatment.
Despite advances in our understanding of NMZL, many questions remain. Future studies into 
NMZL should recognize the difficulty of the diagnosis and preferably should include marginal 
zone markers in their protocols. An unbiased approach, using diagnostic features rather than 
a diagnosis as a starting point, might provide more insight into the boundaries between NMZL 
and FL and the heterogeneity within the group of NMZLs. Extensive molecular analyses are 
likely to have an important role in further studies, both for disease classification and prediction 
of treatment response. Finally, if marginal zone markers can be implemented more broadly, 
inclusion of a category of B-cell lymphoma, unclassifiable in the WHO classification should be 
considered to prevent contamination of the NMZL group.
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Lymfocyten zijn cellen van het immuunsysteem die centraal staan in de verworven afweer. 
Wanneer het lichaam in aanraking komt met ziekteverwekkers zoals virussen of bacteriën 
zorgt het verworven immuunsysteem voor een specifieke reactie gericht tegen onderdelen van 
het virus of de bacterie. Daarbij worden geheugencellen gevormd die zorgen voor een snelle en 
sterke reactie bij herhaalde met deze specifieke ziekteverwekker. B-lymfocyten (ook B-cellen 
genoemd) zorgen hierbij voor de humorale afweer waarbij antilichamen tegen ziekteverwekkers 
worden gevormd. Antilichamen zijn moleculen die gericht zijn tegen specifieke andere 
moleculen. Het molecuul waar het antilichaam tegen gericht is wordt antigeen genoemd. 
De binding tussen een antilichaam en zijn antigeen is zeer specifiek, vergelijkbaar met een 
sleutel en een slot. Doordat er zeer veel verschillende ziekteverwekkers zijn moet het lichaam 
in staat zijn zeer veel verschillende antilichamen te produceren. Omdat iedere B-cel slechts 
in staat is om één type antilichaam te produceren tegen één bepaald antigeen zijn er zeer 
veel verschillende B-cellen nodig. Het lichaam vormt dan ook een zeer groot repertoire van 
verschillende B-cellen die gereed staan voor het geval het antigeen waartegen ze gericht zijn 
zich aandient. Voor het vormen van dit grote repertoire van B-cellen worden verschillende 
genen met elkaar gecombineerd waarbij er ook stukjes gen kunnen worden toegevoegd of 
weggenomen. Hierdoor ontstaan een repertoire dat wordt geschat op meer dan een biljoen 
(1000 miljard) verschillende mogelijkheden. Op het moment dat het antigen waartegen 
een B-cel gericht is zich daadwerkelijk aandient wordt de B-cel geactiveerd en volgt de 
kiemcentrumreactie. Doel van de kiemcentrumreactie is het maken van antilichamen die nog 
beter binden aan het antigeen. Om dit te bereiken worden willekeurige mutaties aangebracht 
in het gen dat codeert voor het antilichaam en worden juist die cellen geselecteerd waarin 
mutaties zitten die leiden tot een antilichaam met een hogere affiniteit voor het antigeen. 
Na de kiemcentrumreactie gaat een deel van de B-cellen over in plasmacellen die grote 
hoeveelheden antilichamen produceren. Deze antilichamen neutraliseren de ziekteverwekker. 
Een ander deel wordt geheugencel.
B-cel lymfomen zijn kwaadaardige woekeringen van B-cellen. B-cel lymfomen worden 
geclassificeerd volgens het systeem van de Wereldgezondheidsorganisatie (Engels: World 
Health Organization, WHO). In deze classificatie zijn de verschillende vormen van B-cel lymfoom 
gedefinieerd als ‘entiteiten’. Een entiteit is een combinatie van kenmerken in verschillende 
domeinen (klinische presentatie, microscopisch beeld, eiwitexpressie, genetische afwijkingen) 
die samen de diagnose bepalen. De kenmerken die doorslaggevend zijn voor de diagnose 
verschillen per entiteit. Doel van de WHO classificatie is betekenisvolle entiteiten te definiëren, 
waardoor een specifieke diagnose relevant is voor de patiënt; deze bepaalt namelijk de 
behandeling en de prognose. Een ideale classificatie zou bestaan uit scherp afgegrensde 
categorieën die niet overlappen en die samen het gehele spectrum van ziekte beslaan. Echter, 
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hoewel veel vormen van B-cel lymfoom goed te diagnosticeren zijn is de huidige classificatie 
niet perfect en zijn er lymfoomtypen die lastig te classificeren zijn.
Het nodaal marginale zone lymfoom (NMZL) is een van de lymfoomtypes dat lastig te 
classificeren is. De naam is afgeleid van de marginale zone, een structuur in lymfoïde organen 
waarvan de cellen sterke overeenkomsten hebben met cellen van marginale zone lymfoom. 
NMZL is een weinig agressieve (indolente), chronische vorm van B-cellymfoom. Naast NMZL 
bestaan er ook varianten van marginale zone lymfoom die ontstaan in slijmvliezen en huid 
(mucosa-geassocieerd lymfoïd weefsel lymfoom – MALT lymfoom) en in de milt (splenaal 
marginale zone lymfoom – SMZL). In de huidige WHO classificatie is NMZL gedefinieerd als 
een lymfoom dat eruit ziet als MALT lymfoom of SMZL, maar zonder dat daarbij sprake is van 
lymfoom in de milt of huid/ slijmvliezen. De kenmerken van NMZL die vervolgens beschreven 
worden zijn niet specifiek waardoor NMZL vaak een diagnose bij uitsluiting is. Hierdoor is het 
onderscheid met andere soorten van lymfoom soms lastig. Met name de differentiaaldiagnose 
tussen NMZL en folliculair lymfoom (FL) is vaak problematisch. Dit proefschrift onderzoekt de 
kenmerken van NMZL met nadruk op het onderscheid met FL
Hoofdstuk 2 bevat een systematische revisie van de literatuur over NMZL. Wat hieruit duidelijk 
naar voren kwam is de significante heterogeniteit die bestaat binnen de groep van NMZL met 
betrekking tot klinische presentatie, morfologie, eiwitexpressie en genetische afwijkingen. 
Deze heterogeniteit lijkt in elk geval deels een weerspiegeling van de onduidelijke diagnostische 
criteria.
Hoofdstuk 3 gaat over het microscopisch beeld van NMZL en FL. Uitgangspunt is een groep 
van indolente B-cellymfomen die geen BCL2 translocatie bevatten. Een BCL2 translocatie is 
een genetische afwijking die voorkomt in 90% van de gevallen van FL, maar niet in NMZL. 
In de praktijk is dan ook juist het maken van onderscheid tussen NMZL en FL zonder BCL2 
translocatie het probleem. 
In deze groep van indolente B-cellymfomen zonder BCL2 translocatie werd het microscopisch 
beeld systematisch onderzocht waaruit bleek dat de morfologische kenmerken sterk overeen 
kwamen met die van NMZL. Folliculaire kolonisatie was hierbij het belangrijkste criterium. 
Folliculaire kolonisatie is het fenomeen waarbij lymfoomcellen een kiemcentrum binnendringen 
(‘koloniseren’) en wordt frequent gezien bij NMZL. Folliculaire kolonisatie kan bij vluchtige 
beoordeling sterk lijken op het morfologisch beeld van FL, maar doordat resterende cellen van 
het kiemcentrum andere eiwitten tot expressie brengen dan de infiltrerende lymfoomcellen kan 
toch het onderscheid gemaakt worden. NMZL cellen zijn in de overgrote meerderheid van de 
gevallen positief voor het eiwit BCL2, terwijl de resterende cellen van het kiemcentrum negatief 
zijn. Daarnaast tonen de resterende cellen van het kiemcentrum zeer sterke delingsactiviteit 
en is dit veel minder in de lymfoomcellen. Delingsactiviteit kan zichtbaar gemaakt worden met 
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een kleuring voor het eiwit Ki67. Door de kleuringen voor BCL2 en Ki67 nauwkeurig en op hoge 
vergroting te beoordelen kan folliculaire kolonisatie worden herkend. Ondanks het feit dat veel 
lymfomen in de onderzoeksgroep als FL waren gediagnosticeerd werd bij herbeoordeling in 
het kader van deze studie frequent folliculaire kolonisatie gezien, wijzend op een diagnose van 
NMZL.
Hoofdstuk 4 vergelijkt de klinische presentatie van NMZL en FL. Deze bleek grotendeels 
vergelijkbaar, maar patiënten met FL presenteerden zich vaker in een hoger stadium met 
vaker vergrote lymfklieren in de buik en met vaker uitbreiding van lymfoom in het beenmerg. 
Ook was bij patiënten met FL vaker sprake van progressie naar een agressieve vorm van 
lymfoom (diffuus grootcellig B-cel lymfoom – DLBCL) tijdens het ziektebeloop. De overleving 
was vergelijkbaar voor patiënten met NMZL en FL, maar de factoren die geassocieerd waren 
met overleving verschilden wel tussen de twee groepen. Progressie naar DLBCL werd bij zowel 
NMZL als FL gezien en was bij beide geassocieerd met een slechtere prognose, maar het 
subtype van DLBCL was wel verschillend tussen de groepen; bij FL was dit met name het 
‘kiemcentrum’ subtype en bij NMZL met name het ‘non-kiemcentrum’ subtype.
In hoofdstuk 5 worden meerdere immunohistochemische kleuringen vergeleken voor hun 
waarde bij het differentiëren tussen NMZL en FL. Bij immuunhistochemie wordt gebruik 
gemaakt van antilichamen om specifieke eiwitten in weefsels aan te tonen. Voor deze studie 
werden kleuringen gebruikt tegen de eiwitten CD10, BCL6, LMO2 en HGAL die normaal tot 
expressie komen in het kiemcentrum en kleuringen gericht tegen MNDA en IRTA1 waarvan 
eerdere studies suggereren dat dit ‘marginale zone markers’ zijn. Inderdaad werden de 
kiemcentrum markers voornamelijk aangetroffen in FL en MNDA en IRTA1 in NMZL. Echter, 
geen van de markers was perfect voor het onderscheid tussen FL en NMZL en om die reden 
werd een algoritme opgesteld dat een lymfoom op basis van de resultaten van de verschillende 
immunohistochemische kleuringen indeelt in één van drie categorieën: 1) FL, 2) NMZL of 3) 
B-cel lymfoom, niet nader te classificeren. Deze laatste categorie weerspiegelt de praktijk 
waarin het soms niet goed mogelijk is onderscheid te maken tussen FL en NMZL en voorkomt 
ook vervuiling van de andere twee categorieën met lymfomen die er eigenlijk niet goed in 
passen. Bij gebruik van dit algoritme moet worden benadrukt dat het een aanvulling is op de 
standaarddiagnostiek in plaats van een vervanging hiervan.
Hoofdstuk 6 beschrijft een methode waarbij een enkele weefselcoupe met meerdere 
immunohistochemische kleuringen sequentieel kan worden gekleurd (sequentiële 
immuunhistochemie). Van iedere kleuring worden digitale opnames gemaakt die vervolgens over 
elkaar kunnen worden gelegd. Hierdoor is het mogelijk van steeds dezelfde cellen de expressie 
te bepalen van een groot aantal eiwitten. Tussen de kleuringen door wordt de voorgaande 
kleuring steeds uitgewist met een oplossing die zowel de kleuring als de antilichamen 
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verwijderd. Bij het opzetten van deze techniek werd deze toegepast op nodulair lymfocyten-
predominant Hodgkin lymfoom (NLPHL). Met behulp van sequentiële immuunhistochemie 
werd aangetoond dat in een deel van de gevallen van NLPHL het eiwit cycline D1 tot expressie 
wordt gebracht. Cycline D1 is een eiwit dat een rol speelt bij het ontstaan van kanker doordat 
het celdeling stimuleert.
In hoofdstuk 7 wordt de techniek van sequentiële immuunhistochemie uit hoofdstuk 6 toegepast 
op NMZL. Hierbij werden tumorcellen herkend met een MNDA kleuring en vervolgens werd van 
deze vermoedelijke tumorcellen de expressie van BCL6, BCL2 en Ki67 bepaald in verschillende 
compartimenten van de lymfklier. Hierbij werden in een deel van de geteste lymfomen 
verschillen gezien tussen tumorcellen in de ruimte tussen de kiemcentra en tumorcellen in 
kiemcentra (i.e. gebieden van folliculaire kolonisatie). De tumorcellen in het kiemcentrum 
toonden expressie van BCL6, toegenomen expressie van Ki67 en afgenomen expressie van 
BCL2. Doordat BCL6 expressie normaal gesproken juist een kenmerk is van FL maakt dit het 
onderscheid tussen NMZL en FL nog lastiger. Wel zal door zorgvuldige beoordeling van BCL2 
en Ki67 ook in deze gevallen folliculaire kolonisatie herkend kunnen worden.
In hoofdstuk 8 werd gezocht naar mutaties in genen betrokken bij signaleringsroutes die 
resulteren in NF-kappaB activatie. NF-kappaB eiwitten spelen een rol bij talrijke processen 
in de cel waaronder celproliferatie en -overleving. Deze eiwitten spelen een belangrijke rol 
in normale B-cellen, maar verstoring van deze signaleringsroute komt ook frequent voor in 
B-cellymfomen. Doordat NF-kappaB verstoring vaak wordt gezien bij andere vormen van 
marginale zone lymfoom was de hypothese dat dit ook het geval is bij NMZL. Met moderne 
DNA analyse (next-generation sequencing) werd gekeken naar mutaties in 20 genen in 
20 gevallen van NMZL, 20 gevallen van FL en 11 gevallen van B-cellymfoom, niet nader te 
classificeren. Voor een diagnose van NMZL in deze laatste studie moest zowel sprake zijn 
van de morfologische kenmerken beschreven in hoofdstuk 3 als een algoritme resultaat van 
‘NMZL’ zoals beschreven in hoofdstuk 5. Gevallen van B-cel lymfoom, niet nader te classificeren 
hadden wel de morfologie, maar niet het algoritme resultaat van NMZL.
 In 9 gevallen van NMZL werden mutaties gevonden met herhaaldelijke mutaties in de 
genen TNFAIP3 en CD79B. In 12 gevallen van FL werden mutaties gevonden, het meest frequent 
in de genen TNFRSF14, TNFAIP3 en CARD11. In 5 gevallen van B-cel lymfoom, niet nader te 
classificeren werden mutaties gevonden, waarbij alleen in TNFRSF14 mutaties werden gezien 
in meerdere gevallen. Opvallend was dat TNFRSF14 mutaties niet werden gezien in NMZL, 
maar wel in de andere twee groepen. Hoewel onderzoek van grotere groepen noodzakelijk is ter 
bevestiging, zou TNFRSF14 mogelijk gebruikt kunnen worden bij het maken van onderscheid 
tussen NMZL en FL. Daarnaast is het zo dat mutaties zoals boven beschreven mogelijk kunnen 
voorspellen of een tumor wel of niet goed zal reageren op nieuwe, doelgerichte medicatie.
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Ondanks vooruitgang in ons begrip van NMZL zijn nog veel vragen onopgelost. In toekomstige 
studies zou meer aandacht moeten zijn voor de lastige diagnose die NMZL vaak is en zouden 
idealiter ook marginale zone markers gebruikt moeten worden in het studieprotocol. Een 
andere benadering met minder bias zou kunnen bestaan uit het scoren van kenmerken van het 
lymfoom in plaats van te focussen op de diagnose. Cluster analyse van deze kenmerken zou 
dan kunnen leiden tot beter inzicht in het spectrum van ziekte binnen de categorie van NMZL. 
Bij verdere studies is daarbij een belangrijke rol te verwachten van uitgebreide moleculair 
studies, zowel voor ziekteclassificatie als voor het voorspellen van therapierespons. Tot slot, 
indien het lukt om het gebruik van marginale zone markers breder te implementeren, zou 
het opnemen van een categorie van “indolent B-cellymfoom, niet nader te classificeren” in de 
WHO classificatie moeten worden overwogen om contaminatie van de categorie van NMZL te 
voorkomen.
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